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About the EMCDDA
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 
is one of the European Union’s decentralised agencies. Established in 1993 
and based in Lisbon, it is the central source of comprehensive information 
on drugs and drug addiction in Europe.
The EMCDDA collects, analyses and disseminates factual, objective, 
reliable and comparable information on drugs and drug addiction. In 
doing so, it provides its audiences with an evidence-based picture of the 
drug phenomenon at European level.
The Centre’s publications are a prime source of information for a wide 
range of audiences including policymakers and their advisers; professionals 
and researchers working in the field of drugs; and, more broadly, the 
media and general public.
The annual report presents the EMCDDA’s yearly overview of the drug 
phenomenon in the EU and is an essential reference book for those seeking 
the latest findings on drugs in Europe.
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How to obtain EU publications
Free publications:
•	 via	EU	Bookshop	(http://bookshop.europa.eu);
•	 	at	the	European	Union’s	representations	or	delegations.	You	can	obtain	their	contact	details		
on	the	Internet	(http://ec.europa.eu)	or	by	sending	a	fax	to	+352	2929-42758.
Priced publications:
•	 via	EU	Bookshop	(http://bookshop.europa.eu).
Priced subscriptions (e.g. annual series of the Official Journal of the European Union  
and reports of cases before the Court of Justice of the European Union):
•	 	via	one	of	the	sales	agents	of	the	Publications	Office	of	the	European	Union		
(http://publications.europa.eu/others/agents/index_en.htm).
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5This year marks the 50th anniversary of the signing at 
the United Nations of the Single Convention on narcotic 
drugs, a cornerstone of the international drug control 
system. In presenting our annual assessment of the state 
of the European drug problem, it is hard not to be struck 
by how much this phenomenon has evolved over the 
last half-century. The complex drug problems we face 
today in Europe are shaped by many factors and do 
not exist in either social or geographical isolation. Our 
report recognises this fact as well as the need to take 
into account broader cultural developments and global 
trends, as both can have profound implications for the 
patterns of drug use and the associated harms that we 
face. The current economic difficulties experienced by 
many European countries are a part of the backdrop to 
our reporting; one that already is making itself felt as 
budgets for services become harder to find. Advances 
in information technology have transformed almost 
all aspects of our modern lives, and it is therefore not 
surprising that we now see an impact on the drug 
phenomenon. We see this concretely not only in the way 
that drugs are marketed and sold, but also in the arrival 
of new opportunities for prevention and treatment. The 
more joined-up world we live in is increasingly exploited 
by organised crime, which sees drugs as just one type 
of illicit commodity among others. Here again a global 
perspective is important, as the implications of drug use in 
Europe do not stop at our borders. Just one example of this 
is the way that the results of EU efforts to support social 
development in neighbouring countries are put at risk by 
changes in drug trafficking routes, which undermine the 
growth of fragile democratic institutions and feed corrupt 
practices.
It is important to acknowledge that this report is a 
collaborative achievement, and we express here our 
appreciation of all those who have contributed to its 
production. In particular, this report is only possible 
because of the hard work and dedication of our partners 
in the Reitox network of national focal points and the 
experts across Europe who have contributed to its 
analysis. We are also indebted to other European and 
international agencies for the analysis they have provided. 
Our job, however, is not simply to collate the information 
provided by others. Our task is to provide a scientifically 
sound and independent analysis of the European drug 
problem. To do this, we need to interpret often-imperfect 
data. The EMCDDA’s approach to analysis is both multi-
indicator and cautious. Conclusions derived from one 
data set must be tested against other information sources; 
and we make no apologies for our conservatism in the 
interpretation made where information is poor. That said, 
the quality, quantity and comparability of information 
available on the drug situation in Europe continues to 
grow. This in itself represents a real achievement, and 
testifies to the value of cooperation and coordinated 
actions within the European Union.
Finally, this annual report should not be read on its own, 
but as one part of our comprehensive annual reporting 
package. The data on which our analysis is based and 
extensive methodological notes can be found in the 
accompanying statistical bulletin. In more issue-focused 
publications linked to this year’s report, we also explore in 
detail: the cost and funding of drug treatment, guidelines 
on the delivery of care, the cannabis market and overall 
mortality attributable to drug use. Country-specific 
information is available in detailed national reports and 
online country overviews. Our reporting is designed to be 
accessible to the general reader, strategically focused to 
serve our policy audience and sufficiently detailed to meet 
the needs of researchers, students and scientists. Whatever 
your perspective, we hope that our work will increase your 
understanding of the European drug situation. This is our 
mission, but moreover we believe that such understanding 
is a critical requirement to the development of effective 
drug policies and responses.
João Goulão
Chairman, EMCDDA Management Board
Wolfgang Götz
Director, EMCDDA
Foreword
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9This annual report is based on information provided to 
the EMCDDA by the EU Member States, the candidate 
countries Croatia and Turkey, and Norway. The statistical 
data reported here relate to the year 2009 (or the last year 
available). Graphics and tables in this report may reflect a 
subset of EU countries; the selection may be made on the 
basis of those countries from which data are available for 
the period of interest, or to highlight certain trends.
Analysis of trends is based only on those countries 
providing sufficient data to describe changes over the 
period specified. Figures for 2008 may substitute for 
missing 2009 values in trend analysis of drug market 
data; for the analysis of other trends, missing data may be 
interpolated.
Background information and a number of caveats that 
should be borne in mind when reading the annual report 
are presented below.
Drug supply and availability data
Systematic and routine information to describe illicit drug 
markets and trafficking is still limited. Production estimates 
of heroin, cocaine and cannabis are obtained from 
cultivation estimates based on fieldwork (sampling on the 
ground) and aerial or satellite surveys. These estimates 
have some important limitations, linked for instance 
with variations in yield figures or with the difficulty of 
monitoring crops such as cannabis, which may be grown 
indoors or are not restricted to certain geographical areas.
Drug seizures are often considered as an indirect indicator 
of the supply, trafficking routes and availability of drugs. 
They are a more direct indicator of drug law enforcement 
activities (e.g. priorities, resources, strategies), while also 
reflecting both reporting practices and the vulnerability of 
traffickers. Data on purity or potency and retail prices of 
illicit drugs may also be analysed in order to understand 
retail drug markets. Retail prices of drugs reported to the 
EMCDDA reflect the price to the user. Trends in price are 
adjusted for inflation at national level. Reports on purity 
or potency, from most countries, are based on a sample of 
all drugs seized, and it is generally not possible to relate 
the reported data to a specific level of the drug market. 
For purity or potency and retail prices, analyses are based 
on the reported mean or mode or, in their absence, the 
median. The availability of price and purity data may be 
limited in some countries and there may be questions of 
reliability and comparability.
The EMCDDA collects national data on drug seizures, 
purity and retail prices in Europe. Other data on drug 
supply comes from information systems and analyses of 
the United Nations Office on Drugs and Crimes (UNODC), 
complemented by additional information from Europol. 
Information on drug precursors is obtained from the 
European Commission, which collects data on seizures of 
these substances in the EU, and the International Narcotics 
Board (INCB), which is involved in international initiatives 
to prevent the diversion of precursor chemicals used in the 
manufacture of illicit drugs.
The data and estimates presented in this report are the 
best approximations available, but must be interpreted 
with caution, as many parts of the world still lack 
sophisticated information systems related to drug supply.
Prevalence of drug use as measured by general population 
surveys
Drug use in the general or school population can be 
measured through representative surveys, which provide 
estimates of the proportion of individuals that report 
having used specific drugs over defined periods of time. 
Surveys also provide useful contextual information on 
patterns of use, sociodemographic characteristics of users 
and perceptions of risks and availability.
Introductory note
Accessing the annual report and its data 
sources on the Internet
The annual report is available for downloading in 
22 languages on the EMCDDA website. The electronic 
version contains links to all online sources cited in the 
annual report.
The following resources are available only on the Internet.
The 2011 statistical bulletin presents the source tables on 
which the statistical analysis in the annual report is based. 
It also provides further detail on the methodology used and 
about 100 additional statistical graphs.
The national reports of the Reitox focal points give a 
detailed description and analysis of the drugs problem in 
each country.
Country overviews provide a top-level, graphical summary 
of key aspects of the drug situation for each country.
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The EMCDDA, in close collaboration with national 
experts, has developed a set of core items for use in adult 
surveys (the ‘European Model Questionnaire’, EMQ). 
This protocol has now been implemented in most EU 
Member States. However, there are still differences in 
the methodology used and year of data collection, and 
this means that small differences, in particular between 
countries, should be interpreted with caution.
Surveys are expensive to conduct and few European 
countries collect information each year, although many 
collect it at intervals of two to four years. In this report, 
data are presented based on the most recent survey 
available in each country, which in most cases is between 
2006 and 2009. Prevalence data for the United Kingdom 
refer to England and Wales, unless otherwise stated, 
although separate data for Scotland and Northern Ireland 
are also available.
Of the three standard time frames used for reporting 
survey data, lifetime prevalence (use of a drug at any 
point in one’s life) is the broadest. This measure does not 
reflect the current drug use situation among adults, but can 
be helpful to understand patterns of use and incidence. 
For adults, the EMCDDA’s standard age ranges are 
15–64 years (all adults) and 15–34 years (young adults). 
Countries using different upper or lower age limits include: 
Denmark (16), Germany (18), Hungary (18), Malta (18), 
Sweden (16) and the United Kingdom (16–59). The focus 
is on the last year and last month time frames (use during 
the last 12 months or last 30 days before the survey; for 
more information, see the EMCDDA website). For school 
students, lifetime and last year prevalence are often 
similar, as illicit drug use before age 15 is rare.
The European school survey project on alcohol and other 
drugs (ESPAD) uses standardised methods and instruments 
to measure drug and alcohol use among representative 
samples of school students who turn 16 during the 
calendar year. In 2007, data were collected in 35 
countries, including 25 EU Member States, Croatia and 
Norway. The results of the fifth round, conducted in 2011 
with participation of 23 out of the 27 Member States 
together with Croatia and Norway, will be published 
in 2012.
The ‘Health behaviour in school-aged children’ (HBSC) 
survey is a WHO collaborative study which investigates 
children’s health and health behaviour, and has included 
questions about cannabis use among 15-year-old students 
since 2001. The third round of this survey with questions 
about cannabis use was conducted in 2009–10 with 
the participation of 23 out of the 27 EU Member States 
together with Croatia and Norway.
Treatment demand
In reports on treatment demand, ‘new clients’ refers to 
those who have entered treatment during the calendar 
year for the first time in their lives and ‘all clients’ refers 
to all those entering treatment during the calendar year. 
Clients in continuous treatment at the start of the year 
in question are not included in the data. Where the 
proportion of treatment demands for a primary drug is 
given, the denominator is the number of cases for which 
the primary drug is known.
Interventions
Information on the availability and provision of various 
interventions in Europe is generally based on the informed 
judgment of national experts, collected through structured 
questionnaires. However, for some indicators, quantitative 
monitoring data are also available.
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The drug situation in perspective
In many respects, this year’s report is one of contrasts. On 
the one hand, drug use appears to be relatively stable in 
Europe. Prevalence levels overall remain high by historical 
standards, but they are not rising. And in some important 
areas, such as cannabis use by young people, there are 
positive signs. On the other hand, there are worrying 
indications of developments in the synthetic drugs market 
and, more generally, in the way drug consumers now use 
a wider set of substances. Polydrug use, including the 
combination of illicit drugs with alcohol, and sometimes, 
medicines and non-controlled substances, has become 
the dominant pattern of drug use in Europe. This reality 
presents a challenge to both European drug policies 
and responses. A comprehensive policy framework for 
addressing psychoactive substance use is still lacking in 
most Member States, and treatment services are having 
to adapt their practice to meet the needs of clients whose 
problems span multiple substances. Similarly, targeting 
and assessing the impact of measures to reduce drug 
supply requires consideration to be given to the overall 
market for psychoactive substances. Without this wider 
perspective, gains made in relation to one drug may result 
in a displacement of use to other products. This report 
contains many examples of how the European illicit drug 
market is dynamic, innovative and quick to adapt to both 
opportunities and control measures.
The European model under review
Europe has, by global standards, a well-developed, 
mature and arguably relatively effective approach 
to responding to illicit drug use. At EU level, this is 
articulated through the current EU drug strategy and 
its action plan, which represents a unique example of 
long-term cooperation and knowledge exchange at 
transnational level. The achievements of the latest EU 
drug strategy are currently under review. Most Member 
States now have relatively consistent and well-developed 
drug strategies that, to a large extent, reflect a common 
model. Despite these positive developments and an overall 
increase in service provision for those with drug problems, 
pronounced differences still exist between countries, 
particularly in respect to investments made in demand 
reduction interventions. Addressing these discrepancies 
will be an important challenge for future EU policies in this 
area.
The European model can be characterised as 
pragmatically balancing drug supply reduction and 
demand reduction objectives, as well as acknowledging 
the importance of both human rights and community 
safety. This approach permits both concerted action and 
cooperation in law enforcement and border control efforts 
to limit drug supply, as illustrated by current programmes 
targeting heroin importation routes from Afghanistan, 
cocaine trafficking via the Atlantic and West Africa and 
synthetic drug production. It also permits innovative 
developments in the area of treatment and harm reduction, 
one example of which is heroin-assisted treatment, which 
is of growing interest to a number of European countries 
and is the subject of a new EMCDDA review.
Risk of localised HIV epidemics among drug injectors may 
be growing
Following reductions in the overall spread of HIV in 
the European Union, the focus on HIV prevention as 
a primary public health objective for drug policy has 
become less evident. However, this year’s analysis raises 
the worrying prospect that the potential risk for new 
localised HIV epidemics may be growing. The economic 
downturn affecting many European countries may be 
increasing the vulnerability of communities while, at the 
same time, limiting the ability of Member States to provide 
adequate responses. The historical evidence is clear: if the 
conditions exist, drug-related HIV infections can spread 
rapidly within vulnerable communities. Furthermore, 
the gains made in the European Union in reducing the 
drug-related spread of HIV have not been seen in many 
of our neighbouring countries, where transmission of the 
virus, related to both injecting drug use and unsafe sex, 
continues to be a major public health problem. Recently, 
political and economic developments have increased 
migration from these affected regions towards EU Member 
Commentary
Seeing the big picture: drug use in Europe today
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States, which can put further pressure on already stretched 
services.
A particular concern, therefore, is that the conditions 
now exist in a number of EU Member States, including 
those that have not previously experienced significant 
drug-related HIV epidemics, which now make them 
potentially vulnerable to future problems. Greece, 
historically a low-prevalence country, reported a local 
HIV outbreak among injectors in 2011, and the situation 
in a number of eastern Member States is also worrying, 
as illustrated by rising rates of infection in Bulgaria. The 
picture is also looking less positive in some countries that 
had made progress in addressing drug-related HIV/AIDS 
epidemics, with gains made in recent years in tackling 
new infections in Estonia and Lithuania, for example, now 
looking increasingly fragile, as both these countries report 
recent increases in infections.
Opioids trends: the need to understand market dynamics
Internationally, and particularly in North America, there 
has been increasing concern about the availability and 
misuse of prescription opioids, mainly painkillers. The 
extent of this phenomenon in Europe is difficult to access 
from the data currently available. Moreover, direct 
comparisons between the European Union and other 
parts of the world are difficult to make, due in large part 
to the considerable differences that exist in prescribing 
patterns and regulations. Currently, illicit synthetic opioid 
use in Europe appears mainly to involve the consumption 
of substitution drugs diverted from drug treatment. In 
addition, some countries in northern and central Europe 
are now reporting the use of fentanyl, which is likely 
manufactured illicitly outside the European Union. The 
appearance of this drug is of particular concern and, 
overall, given the situation elsewhere, a good argument 
exists for improving our capacity to monitor trends in the 
misuse of psychoactive products intended to be used only 
for therapeutic purposes.
As synthetic opioids are used illicitly mainly in place of 
heroin, information on their use can provide insights into 
the overall heroin market. Currently, an important question 
in this area is the extent to which supply reduction 
measures are now impacting on the availability of heroin 
on the streets of Europe. The possibility that supply 
reduction measures are reducing the heroin availability 
in Europe is supported by indications that some, but not 
all, EU countries experienced a heroin drought in late 
2010, and that this may also have effected some non-EU 
countries, such as Russia and Switzerland. An alternative 
explanation put forward to explain this apparent shortage 
referred to a recent outbreak of poppy blight in some 
parts of Afghanistan. However, on closer inspection, this 
association is probably tenuous, although other events 
in Afghanistan and some significant successes resulting 
from cooperation between Turkish and EU police forces 
may have played a role. Any short-term supply problems, 
however, have to be viewed in the context of the 
long-term, relatively stable heroin market in Europe.
Despite the importance of information on heroin 
availability to understanding the dynamics of the illicit 
drug market Europe, it is worth noting how difficult it is 
currently to comment on this issue with authority. More 
sophisticated attempts are now being made to better 
achieve this based on analysis of both production and 
use data. However, for a number of technical reasons, 
considerable caution is still merited when drawing 
conclusions on this sensitive topic. Good indicators of 
market availability in Europe are largely lacking, for 
example. Estimates of opium production in Afghanistan 
are frequently taken at face value, despite the fact that 
such calculations are in many ways methodologically 
challenging. Also, suggestions of opium production in 
other countries in Asia are rarely considered. Moreover, 
models of heroin flows often include the existence of 
‘stocks’ of stored opium or heroin — although there is 
limited empirical evidence to support this assumption. 
Elucidating the relationship between opium production 
and heroin availability is further complicated by 
the existence of different trafficking routes into, and 
sub-markets within, the European Union, and by the 
significant time lag that is believed to exist between the 
harvest of opium in Afghanistan and its appearance as 
heroin on the streets of Europe.
Are overdose deaths just the tip of the iceberg?
The typical fatal overdose victim in Europe is a man 
in his mid to late thirties, with a long history of opioid 
problems. Attendance in drug treatment, particularly 
substitution treatment, is known to reduce the risk of 
overdose. However, despite a dramatic increase in 
treatment availability over the years, the number of 
users dying of drug overdose in Europe has remained 
stable. Reducing overdose fatalities therefore represents 
a major challenge for drug services across Europe. Some 
innovative programmes are currently under evaluation and 
development in this area, often targeting those events that 
are known to be particularly risky for opioid users, such 
as leaving prison or dropping out of treatment. While this 
work is important, it will only address part of the problem. 
Studies suggest that overdose deaths may represent 
somewhere between a third and two thirds of the overall 
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mortality among problem drug users. Other major causes 
of death among drug users include AIDS, suicide and 
trauma. The implications of this finding are discussed in 
detail in a publication accompanying this report, and 
strongly point to the high level of excess mortality in this 
population and the role that services can play in reducing 
the human costs of long-term drug problems.
Has the cocaine bubble burst?
Over the last decade, cocaine has established itself as 
the most commonly used stimulant drug in Europe, even 
though high levels of use are only found in a restricted 
set of countries. Commentators have noted that part of 
the appeal of this substance is its image, with cocaine 
use often portrayed as being part of an affluent and 
fashionable lifestyle. The reality of regular cocaine use is 
different, however. The positive image may be increasingly 
challenged by the growing recognition of cocaine-related 
problems, which are manifest in increased hospital 
emergencies, deaths and treatment demands related 
to this drug. The financial cost associated with regular 
cocaine consumption may make it a less attractive option 
in countries in which austerity is now the order of the day. 
New data raise the question as to whether the popularity 
of this drug has now peaked. Recent surveys show some 
decline in use in the countries with the highest prevalence 
levels, although the picture elsewhere is less clear. Supply 
data is also equivocal. The amount of cocaine seized 
has fallen considerably since 2006, and overall both the 
price and the purity of the drug have also decreased. 
However, in contrast to volume, the number of seizures 
has continued to rise, and there is evidence that traffickers 
are continuing to adapt their practices in response to 
interdiction efforts; and as they do so, there is the risk of 
a diffusion in use into new areas.
MDMA on the rebound
In recent years, the European ecstasy market went through 
a period in which the availability of tablets containing 
MDMA became increasingly rare. Commonly, ‘ecstasy’ 
tablets sold on the illicit market contained other drugs, 
often a piperazine, with the result that some of those 
buying what they believed to be an illicit drug were in 
fact buying a non-controlled substance. The scarcity of 
MDMA in ecstasy tablets appears to have been related to 
a shortage of the main precursor, PMK, possibly reflecting 
the success of interdiction efforts. However, the most 
recent data point to increasing MDMA availability, with 
some reports noting the existence of very high dosage 
tablets and high purity powders.
Current MDMA production methods now appear 
to be based on either safrole or, increasingly, on 
imported chemicals, such as PMK-glycidate and 
alpha-phenylacetoacetonitrile, that are structurally similar, 
Commentary: Seeing the big picture — drug use in Europe today 
At a glance — estimates of drug use in Europe
The estimates presented here relate to the adult population 
(15–64 years old) and are based on the most recent data 
available (surveys conducted between 2001 and 2009/10, 
mainly 2004–08). For the complete set of data and 
information on the methodology see the accompanying 
statistical bulletin.
Cannabis
Lifetime prevalence: about 78 million 
(23.2 % of European adults)
Last year use: about 22.5 million European adults (6.7 %) 
or one in three lifetime users
Last month use: about 12 million (3.6 %)
Country variation in last year use: 
overall range 0.4 % to 14.3 %
Cocaine
Lifetime prevalence: about 14.5 million 
(4.3 % of European adults)
Last year use: about 4 million European adults (1.2 %) or 
one in three lifetime users
Last month use: about 1.5 million (0.5 %)
Country variation in last year use: 
overall range 0.0 % to 2.7 %
Ecstasy
Lifetime prevalence: about 11 million 
(3.2 % of European adults)
Last year use: about 2.5 million (0.7 %) or 
a fifth of lifetime users
Country variation in last year use: 
overall range 0.1 % to 1.6 %
Amphetamines
Lifetime prevalence: about 12.5 million 
(3.8 % of European adults)
Last year use: 1.5–2 million (0.5 %) or 
up to a sixth of lifetime users
Country variation in last year use: 
overall range 0.0 % to 1.1 %
Opioids
Problem opioid users: estimated at between 
1.3 and 1.4 million Europeans
About 700 000 opioid users received substitution 
treatment in 2009
Principal drug in more than 50 % of all drug treatment 
requests
Drug-induced deaths: about 7 600, with opioids being 
found in around three quarters
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though not identical, to the controlled precursors hitherto 
used. A parallel exists here with developments in the 
‘legal highs’ area, where non-controlled products replace 
controlled ones. These chemicals are selected with two 
aims in mind: the new substance should not be subject 
to current controls, and it should be easily converted 
into a precursor necessary for MDMA synthesis. This 
illustrates again the considerable adaptability shown by 
synthetic drug producers. A related phenomenon has been 
observed in the amphetamine market, where precursors 
have been chemically ‘masked’ to avoid existing border 
and sales control mechanisms. As producers become 
more technically sophisticated and seek out new ways 
to circumvent interdiction efforts and regulations, the 
possibility to modify and reconvert substances represents 
another challenge to current drug control approaches.
New psychoactive substances: getting our response right
The rapid emergence of many new non-controlled 
psychoactive substances represents a growing challenge 
for current models of drug control.
In 2010, a record 41 new substances were reported to 
the European early-warning mechanism, and preliminarily 
data for 2011 show no sign of decline. This reflects 
both the continuing introduction of new substances 
and products into the marketplace and the increasing 
use of proactive measures to identify new substances. 
The Internet is one of the main marketplaces for these 
substances, and preliminary results from the latest 
EMCDDA online survey (July 2011) show that the number 
of online shops selling psychoactive products continues 
to increase. Sales practices in this area also appear to 
have become more sophisticated, with more evidence 
of measures taken to restrict access and protect the 
identity of buyers and sellers. Moreover, reports have 
come to light of illicit drug sales being conducted using 
restricted websites. It is unclear to what extent this kind of 
development will represent a significant future threat, but 
given the speed at which changes have occurred in this 
area, there is a need to remain vigilant.
Improving our capacity for detecting new drugs
The legal mechanism that supports the European 
early-warning system is currently under review. The 
European Commission has conducted an assessment noting 
both the strengths of the existing system and the need 
to increase Europe’s capacity to respond to the pace of 
developments in this area. Although Europe has been at 
the forefront of detecting new psychoactive substances, 
the global dimensions of this problem were made clear 
in discussions at a technical symposium hosted by the 
EMCDDA in 2011. International experts confirmed that 
products containing new psychoactive substances are 
now available in many parts of the world, including the 
Americas, the Middle East, Oceania and parts of Asia, 
and that identifying an ever-increasing range of substances 
in a rapidly changing market is a common problem. The 
expert consensus emerging from this meeting was that 
the challenges presented by new drugs will require more 
proactive monitoring of the market and sharing of forensic 
information as well as improved identification of the health 
problems arising from the use of these substances.
Predicting the future: new products and interplay between 
markets
Most new psychoactive substances reported to the 
early-warning system have been either stimulants or 
synthetic cannabinoids, largely reflecting the market for 
illicit drugs in Europe. It is likely that new substances of 
these types will continue to enter the market. In addition, 
producers appear to be exploring other substances with 
a psychoactive action that may be attractive to consumers. 
A large and accessible research literature exists that can 
be exploited for this purpose, and there is concern that 
the results of pharmaceutical research may be harnessed 
to provide more of the new psychoactive substances 
appearing in the future.
Much of the policy focus in this area has been on 
the legal status of new substances; however, it is also 
important to see them in the context of the overall drug 
market. As an example, users report that as well as 
Internet sales, mephedrone (see Chapter 8) was also 
sold through the same illicit supply networks as used for 
drugs such as ecstasy and cocaine. In addition, and as 
mentioned earlier, non-controlled psychoactive substances 
may be tableted as ecstasy and sold on the illicit market. 
Conversely, the controlled drug PMMA has recently been 
identified in some products advertised as ‘legal highs’. 
Taken as a whole, developments in this area are worrying 
as they are suggestive of a growing interplay between the 
‘legal highs’ and illicit drug markets.
Cannabis: policy dilemmas
Cannabis remains Europe’s most popular illicit drug, 
but it is also the one on which public attitudes are most 
divergent. This is reflected in the recent Eurobarometer 
study of youth attitudes to drug use, which found that 
views on cannabis prohibition were more mixed than 
for other drugs. Globally, no clear direction in the 
development of cannabis policies is evident. Interesting 
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examples of policy development here include the USA 
and the Netherlands. In the USA, there has been a move 
towards liberalising the availability of herbal cannabis 
for medical purposes in some states. In the Netherlands, 
policymakers now appear to be taking an increasingly 
robust stance against domestic cannabis production and 
the operational rules applied to ‘coffee shop’ sales.
The extent to which policy changes influence cannabis 
use is a much-debated question. In data presented in 
this report, no direct association can be seen between 
measures of the recent use of this drug and changes 
made to either increase or decrease penalties for use, 
suggesting that more complex processes are at work. 
A general observation may be made that, over the last 
decade, European cannabis policies have tended to direct 
law enforcement efforts towards offences connected with 
trafficking and supply rather than the use of the drug. 
One reason for this is to avoid the possible negative 
consequences of bringing large numbers of young people 
into contact with the criminal justice system, especially if 
their cannabis use is experimental. However, figures show 
that the number of offences related to cannabis use in 
Europe continues to rise, against a background of stable 
or even declining prevalence. This highlights a possible 
disconnect between policy objectives and practice. 
Explaining this observation is difficult, but one possibility 
is that the data reflect a net-widening effect, in which the 
adoption of more administrative sanctions for use results 
in an increased likelihood that they will be applied in 
practice.
Domestic cannabis production: a growing problem
Europe remains the biggest global market for cannabis 
resin. Historically, Morocco has been the main producer 
country of resin consumed in Europe. Recent reports, 
however, suggest that cannabis resin is increasingly 
imported from other countries, including Afghanistan 
and Lebanon. This is supported by recent UNODC 
field surveys, which reported large-scale cannabis resin 
production in Afghanistan. Herbal cannabis imported 
into the European Union comes mainly from neighbouring 
countries in the Balkan region, and to a lesser extent 
from some African and Asian countries. Most EU Member 
States now report domestic cultivation of cannabis, 
a phenomenon that appears to be increasing. This is 
mirrored in the existence of ‘grow shops’, which specialise 
in equipment for cannabis cultivation. Domestic cultivation 
can be small scale, but it may also consist of major 
production sites run by organised crime gangs. A knock-on 
effect of this is that some countries are now reporting 
increases in violence and other crimes associated with 
large production sites. Developments in the European 
cannabis market are reviewed in detail in a forthcoming 
EMCDDA ‘Insight’.
Guidelines, standards and the sharing of effective 
practices
Given the complex and fast-moving nature of 
contemporary drug problems, it is important to ensure 
that research findings and the knowledge gained from 
successful service development are shared as widely as 
possible. To this end, a number of European initiatives 
have been launched to identify and help promote the 
sharing of good practice. In 2011, in collaboration 
with the EMCDDA, the European Commission held 
a conference on identifying minimum quality standards 
and benchmarks for demand reduction programmes. 
The EMCDDA has also been expanding its web-based 
resources for disseminating evidence-based practices. It 
should be noted though, that the availability of evidence 
does not automatically ensure that it will be translated 
into practice. An example of this can be found in the 
area of drug prevention, where despite an increasingly 
robust evidence base for their effectiveness, selected 
and environmental strategies are often among the least 
commonly found interventions. However, a starting 
point for the adoption of good practices must be an 
understanding of what approaches have been shown 
to deliver benefit. And, as information to guide policy 
choices accumulates and becomes more readily available, 
investing in approaches not supported by good evidence 
will become harder to justify.
Commentary: Seeing the big picture — drug use in Europe today 
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Introduction
With the current EU drug strategy coming to an end 
in 2012, this chapter takes a look at the development 
of the EU drug policy approach over the past 20 years. 
Strategies recently adopted by some non-EU countries are 
examined for signs of convergence with or differences to 
the European approach. Within Europe, the most recently 
adopted national drug strategies are also briefly reviewed.
An overview of studies on public expenditure by EU 
Member States, presented here, highlights the different 
ways in which the topic has been approached, and the 
need for improved and harmonised data collection in 
this area. Also reviewed in this chapter are the changes 
in penalties for drug possession that have taken place 
in European countries in the last 10 years, and the latest 
developments in drug-related research.
EU and international policy developments
Road to the new EU drug policy initiatives
The new drug policy framework being developed by 
the European Commission will be one of the first drug 
policy documents adopted under the Lisbon Treaty (see 
EMCDDA, 2010a). Preparatory work includes a final 
external evaluation of the 2005–12 EU drug strategy. 
This evaluation will draw on interviews with stakeholders 
from the Member States, third countries and international 
organisations and on the analysis of policy documents and 
trend reports. The European Commission’s Civil Society 
Forum on Drugs will contribute with a position paper. 
In addition, members from different political groups of 
the European Parliament have organised meetings and 
hearings to discuss current and future EU drug policy. 
These various discussions and contributions, together 
with the evaluation, will contribute to the development 
of a comprehensive EU drugs policy for the period 
after 2012.
Two decades of EU drug policy
Since the early 1990s, the European Union has adopted 
eight drug strategies or action plans (see Figure 1), and 
the shift in content of successive documents reflects the 
development of the European approach to drugs. Actions 
aimed at reducing both the supply of drugs and the 
demand for drugs were included in the first two European 
drug plans. The concept of an integrated approach, linking 
both of these elements, first appeared in the 1995–99 plan. 
The strategy adopted in 2000 defined the EU approach 
as both integrated and balanced, attributing similar 
policy weights to demand reduction and supply reduction 
interventions. This shift in approach is reflected in the titles 
of these EU policy documents, where ‘plans to combat 
drugs’ were succeeded by the more neutrally denoted 
‘drugs strategies’ and ‘action plans’. In terms of content, one 
of the most obvious changes during the last two decades 
has been the introduction of harm-reduction objectives in 
the demand reduction area of EU drug policy documents.
Policy assessment and evaluation were not mentioned in 
the first two European plans, as the priority in the early 
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(1) The OAS is a regional organisation bringing together all 35 independent states of the Americas, where it is the main forum for intergovernmental 
cooperation.
1990s was to create a reliable European information 
system on drugs. Implementation assessment was 
introduced in the 1995 plan, but it was not until the 
2000–04 drug strategy that evaluation was consolidated 
as an integral part of the EU approach to drugs. Since 
then, all EU drug strategies and action plans have been 
evaluated, and the results used to guide subsequent policy 
documents. The new EU drug policy framework will follow 
this principle and, for the first time, will be based on an 
external evaluation of the previous strategy.
International perspective
Outside the European Union, a number of national or 
regional strategies were recently published, notably 
by Australia, Russia, the USA and the Organisation 
of American States (OAS) (1). Examining the content 
of these policy documents reveals the extent to which 
characteristics of the EU approach are shared with other 
countries.
The 2010 US drug control strategy is presented as a new 
direction in drug policy, where drug use is seen mainly 
as a public health issue, and where demand for drugs is 
recognised as the prime cause of the drugs problem in the 
country. The strategy emphasises prevention, treatment 
and recovery from addiction, and calls for the integration 
of addiction treatment into mainstream medicine, as with 
other chronic disorders. The US strategy is echoed in the 
OAS’s Hemispheric Drug Strategy, where drug addiction 
is described as a chronic relapsing disease that should be 
treated as such. The first Russian drug strategy (2010–20) 
builds on a recognition of the scale of the drugs problem, 
characterised by the growth in illicit drug use and its 
contribution to the spread of infectious diseases. The 
OAS, Russian and US strategies emphasise the importance 
of a balanced approach. The Australian drug strategy 
(2010–15) has the broadest scope of the four policy 
documents, covering all psychoactive substances capable 
of causing addiction and health problems: alcohol, 
tobacco and illicit and other drugs. Minimising harm is the 
overarching approach of this strategy.
An evidence-based approach to demand reduction, 
coupled with outcome evaluation, characterises the OAS, 
Australian and US strategies. Countries adopting the 
Hemispheric Drug Strategy are committed to subjecting 
their national policies and interventions to periodic, 
independent evaluation, the results of which will guide the 
allocation of resources. The 106 items of the US strategy 
are to be reviewed and updated annually, in order to 
fulfil the aims of the strategy, which include a 15 % 
reduction in the prevalence of drug use among 12- to 
17-year-olds and a 10 % reduction among young adults 
by 2015. The Australian strategy’s performance will be 
assessed according to three criteria: disruption of illegal 
drug supply, drug use and associated harm. The Russian 
strategy gives emphasis to better monitoring and data 
collection tools, but explicitly rejects opioid substitution 
treatment, an intervention that is seen as a key evidence-
based approach in the EU strategy. It is also notable 
that mass media campaigns are components of both the 
Russian and US strategies, despite little evidence of their 
effectiveness.
Overall, there appears to be some convergence in drug 
strategies internationally. While the first Russian drug 
strategy, though recognising the problem and emphasising 
monitoring, adopts an ideological stance not shared by 
the other strategies, both the USA and OAS appear to be 
Table 1: Recently adopted national drug policy documents 
Country Name of policy document Time span Main focus Notes
Czech Republic Strategy 2010–18 Illicit drugs Complemented by a 2010–12 action plan 
Denmark Action plan 2010 on Illicit drugs
Italy Action plan 2010–13 Illicit drugs Complemented by a projects plan 2010
Latvia Programme 2011–17 Illicit drugs
Lithuania Programme 2010–16 Illicit drugs Complemented by annual action plans
Luxembourg Strategy and action plan 2010–14 Illicit drugs The strategy also considers alcohol, tobacco, medicines 
and addictive behaviours
Poland Programme 2011–16 Illicit drugs
Portugal Action plan 2009–12 Illicit drugs Second action plan under the 2005–12 strategic plan 
Romania Action plan 2010–12 Illicit drugs Second action plan under the 2005–12 strategy 
United Kingdom Strategy 2010 on Illicit drugs Replaces the 2008–18 strategy adopted by the previous 
government
Turkey Action plan 2010–12 Illicit drugs, alcohol, 
tobacco
Second action plan under the 2006–12 national strategy
Sources: Reitox national focal points.
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(2) A new strategy was presented to parliament in 2011 in the format of a ‘drug letter’.
drawing closer to the EU model. The Australian approach, 
while encompassing many of the elements of EU policy, 
differs in the broad scope of substances it addresses.
National drug strategies
A central element of Europe’s drug policy model is the 
adoption of national drug strategies and action plans, and 
these now exist in almost all of the 30 countries monitored 
by the EMCDDA. In most of these countries, the latest 
drug policy document is less than three years old. These 
documents describe the drug situation and the government’s 
goals and objectives in this area, specifying actions and 
the parties that are responsible for their implementation. 
Criteria to measure the success of each action are often 
presented and, increasingly, a final evaluation of the 
strategy or action plan will be carried out.
New developments
Eleven countries have recently adopted new national drug 
strategies or action plans (Table 1), with time spans ranging 
from three to nine years. Of these, three (Portugal, Romania, 
Turkey) have their drug policy documents in synchrony with 
the current EU drug strategy (2005–12). Although alcohol 
and tobacco are sometimes mentioned, the main focus of 
most drug policy documents is on illicit drugs, and many 
countries have separate national alcohol and tobacco 
action plans. One of the few exceptions, a combined drugs 
and alcohol strategy to be adopted in Ireland, has been 
delayed due to parliamentary elections in early 2011.
A delay in the adoption of a new drug policy document, 
following a change of government, was also reported by 
the Netherlands (2), while the newly elected Hungarian 
government mentioned its intention to replace the 
drugs strategy that was adopted the year before by its 
predecessor. Four other countries (Germany, Estonia, 
Slovenia, Sweden) reported that they were in the process 
of developing and adopting new drug policy documents in 
2011, while Norway extended its action plan (2007–10) 
to 2012.
Public expenditure
In Europe, public expenditure on all aspects of the drug 
phenomenon has been under scrutiny during the last 
decade (EMCDDA, 2008c). This section explores the 
available comprehensive estimates of national drug-
related public expenditure in Europe. It looks for insights 
into two key questions on public expenditure. First, what 
proportion of gross domestic product (GDP) do countries 
spend on the drug problem and second, how are these 
funds divided among the different fields of activity, 
particularly the division between supply reduction and 
demand reduction interventions.
The amount and quality of information available on 
drug-related public expenditure varies greatly between 
countries. The available studies cover different years, 
use a range of methodologies and refer to countries 
with different public sector structures. Differences in 
methods of accounting drug-related expenditures greatly 
limit the scope for national comparisons. Some of the 
funds allocated by government for expenditure on tasks 
related to drugs are identified as such in national budgets 
(‘labelled’). Frequently, however, the bulk of drug-related 
expenditure is not identified (‘unlabelled’), and must be 
estimated by modelling approaches.
Drug policy developments
Rebalancing drug policy objectives towards promoting 
recovery has been a recent development in the United 
Kingdom, with successive drug policy documents focusing 
on treatment outcomes and the social reintegration of drug 
users (1), and on making the goal of recovery a key element 
of drug policy (2). Earlier policies were primarily aimed at 
increasing the number of people accessing drug treatment, 
notably opioid substitution treatment, whereas some of 
the new ones have a stronger focus on service quality. 
How these new directions in policy will translate into 
changes in drug treatment and social reintegration services 
remains to be seen. And there is the question of whether 
it points to deeper changes in drug policy in the future. A 
review of the evidence base around recovery found that 
several decisive factors for achieving a drug-free life and 
becoming an active member of the community lie outside 
the scope of drug policy, and are related to individual 
characteristics and broader social policies (Best et al., 
2010). Changing these, especially if it requires additional 
financial resources, may be difficult for governments at a 
time when they are cutting public expenditure.
Portugal’s current drug policy is more than 10 years old, 
but it has gained increased attention in recent years, first 
from drug policy analysts and advocacy groups, but now 
also from governments in Europe and elsewhere. Central to 
the Portuguese policy is the decriminalisation of drug use 
and the role of ‘commissions for dissuasion of drug abuse’ 
(CDT), managed under the Ministry of Health (EMCDDA, 
2011b). These bodies assess the situation of drug users 
and have the power to provide support or impose 
sanctions. While no other country has yet adopted this 
model, a committee set up by the Norwegian government 
has recently suggested the development of similar 
interdisciplinary tribunals in that country.
(1) 2008 UK strategy.
(2) 2008 Scottish and 2010 UK strategies.
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In the last decade, at least 12 countries have attempted 
to arrive at comprehensive estimates of drug-related 
expenditure (Table 2). These countries reported public 
expenditure on the drug problem ranging from 0.04 % of 
GDP to 0.48 % of GDP.
As seen in other areas of social policy, as countries 
become wealthier, the proportion of GDP spent by 
government on activities related to drugs increases (OECD, 
2006; Prieto, 2010). In Belgium, the Czech Republic, 
Germany, Luxembourg, the Netherlands, Sweden and the 
United Kingdom, it is estimated that at least 0.1 % of GDP 
was devoted to drug-related problems; in France, Latvia 
(labelled expenditure only), Hungary and Slovakia, it 
accounted for between 0.1 % and 0.04 % of GDP. Taking 
into account that different methods were used and that the 
degree of completeness varies, these values do not differ 
greatly from estimations for the USA (0.42 %) (Reuter, 
2006) and Australia (0.41 % of GDP) (Moore, 2008).
Public expenditure studies also attempt to estimate 
the allocation of funds for different types of drug-
related issues. However, caution is required in making 
comparisons between countries, as they may not apply 
the same classification of expenditure. Among the 
12 countries presenting complete estimations, supply 
reduction activities — ‘law enforcement’ or ‘public order 
and safety’ — accounted for between 48 % and 92 % 
of the total. Expenditure for justice, police, customs and 
prisons were the items most frequently reported.
The way countries categorise demand reduction 
expenditures varies markedly in Europe. Expenditure on 
Table 2: Estimates of drug-related public expenditure
Country Year Allocation of drug-related public 
expenditure (%)
Proportion 
of GDP (%) (1)
Level of government
Demand reduction Supply reduction 
Belgium 2004 43.4 56.2 0.10 Federal, regional, provincial and municipal authorities
Czech Republic (2) 2006 8.2 91.8 0.20 Central, regional and local government and social security
France 2005 51.6 48.4 0.07 Central government
Germany 2006 35.0 65.0 0.22–0.26 Federal, state, local authorities and social insurance
Hungary 2007 25.0 75.0 0.04 Central government
Latvia (2) 2008 40.9 51.3 0.04 Central government and one local programme
Luxembourg 2009 43.0 57.0 0.10 Central government and social security
Netherlands 2003 25.0 75.0 0.46 Central and local government
Slovakia 2006 30.0 70.0 0.05 Central government and social security
Finland 2008 45.0 55.0 0.07 Central and local government 
Sweden 2002 25.0 75.0 0.28 Unidentified public sectors (only the agencies involved)
United Kingdom 2005/06 41.3 58.7 0.48 Central and regional government
(1) Due to differences between countries in methodology, data quality and completeness, values for drug-related public expenditure as a proportion of gross domestic product 
(GDP) are indicative only, and should not be taken to represent the full extent of national public expenditure on the drug problem.
(2) Labelled expenditure only.
NB: See Table PPP-10 in the 2011 statistical bulletin for a full list of sources.
Sources: Reitox national reports, Eurostat.
Recession: the impact on interventions in the 
drugs area
The economic recession that hit Europe in 2008 has 
severely affected EU Member States. Its impact on public 
accounts may be long-lived, and requires policies aimed at 
reducing government deficits and debt in most countries. The 
European Commission (2011) predicts that, in 2011, for the 
first time in a decade, public expenditure (excluding interest 
payments) in the European Union will fall in real terms.
Data on budgetary allocations to interventions related to 
drugs were collected by the Reitox national focal points 
in order to have a first insight into the impact of austerity 
measures on drug policy. Of the 19 countries providing 
information, 15 reported reductions in funds available for 
some areas of drug policy since 2008. The size of the cuts 
varied considerably, however, with reported reductions 
ranging from 2 % to 44 %, depending on country and 
policy area.
Fiscal austerity appears to have affected different sectors 
of drug policy differently. For labelled expenditure, the 
areas most severely affected were research, prevention, 
social reintegration and organisational activities. Most 
countries appear to have avoided cutting their budgets 
for treatment, though some report reorganisation of 
services or cuts in provision. Reductions in funding for 
drug-related programmes in prisons or law enforcement 
activities were also reported. Information about 
unlabelled expenditure, which accounts for the lion’s 
share of drug-related public expenditure, is unavailable 
for most of the countries. Consequently, austerity 
measures affecting sectors such as law enforcement, 
justice or some areas of treatment provision might be 
under-reported.
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(3) A detailed analysis of the effects of decriminalisation in Portugal was published recently (Hughes and Stevens, 2010).
treatment or health accounts for about 40 % or more of 
the total reported for Belgium, France and Luxembourg. 
Spending on harm reduction was identified by five 
countries, ranging from 0.1 % to 28.8 % of estimated drug-
related expenditure. Seven countries provided data on 
expenditure related to prevention, with estimates ranging 
from 1 % to 12 % of the total expenditure on drugs issues.
A number of European countries are already using 
data on public expenditure as a tool for planning and 
evaluating the implementation of drug policies, while 
others, such as Portugal and Slovakia, report plans 
to do so. Developing a clear and complete picture of 
national drug-related public expenditure in Europe, 
however, remains a challenge. Currently, there is no 
consensus on how to estimate specific types of drug-
related expenditures. In order to improve accuracy and 
comparability across countries, a comprehensive mapping 
of the public bodies funding drug policy will be necessary, 
as well as the harmonisation of concepts and definitions.
National legislation
Personal possession of drugs: 10 years of penalty changes 
in Europe
In the last 10 years, 15 European countries have made 
changes to their penalties for possession of small amounts 
of drugs. The 1988 UN Convention against illicit traffic 
of drugs, Article 3(2), requires each state to establish 
possession of drugs for personal use as a criminal offence, 
subject to its constitutional principles and the basic 
concepts of its legal system. In Europe, this has been 
implemented in different ways. Possession for personal 
use of any illicit drug may be a criminal offence, a non-
criminal offence, or non-criminal sanctions may apply 
to cannabis, while possession of other drugs remains 
a criminal offence.
Three broad types of penalty changes can be identified 
in the last 10 years: those changing the legal status of 
the offence (criminal or non-criminal); those changing 
categories of drugs, when the category determines the 
penalty; and those changing the size of the maximum 
penalty available. Most of the countries that have altered 
their penalties for possession have used a combination of 
these types of change, complicating any concise analysis.
Changing the legal status of the offence is perhaps the 
most significant step for legislators, and this has happened 
in Portugal, Luxembourg and Belgium. In Portugal, the law 
from July 2001 decriminalised possession of all drugs for 
personal use. This reduced the maximum punishment for 
possession of small amounts of drugs from three months’ 
imprisonment to an administrative fine given by the 
new ‘commissions for dissuasion of drug abuse’, which 
prioritised health solutions over punitive sanctions (3). 
In Luxembourg, in May 2001, personal possession of 
cannabis was newly established as a separate offence 
with a lesser punishment, incurring only a fine for the 
first offence, without aggravating circumstances. At the 
same time, maximum penalties for personal possession 
of all drugs other than cannabis were reduced from three 
years in prison to six months. A similar change took 
place in May 2003 in Belgium. The possession of a small 
amount of cannabis for personal use, without aggravating 
circumstances, was previously punishable by up to five 
years in prison, but it now attracts the lowest prosecution 
priority, leading to a police fine.
Moves towards ‘decriminalisation’ were also made in 
Estonia and Slovenia. In Estonia, before September 
2002, a second administrative offence of drug possession 
within 12 months of the first was a criminal offence 
punishable by up to three years’ imprisonment. The new 
Penal Code deleted this, so a second offence is, like the 
first, considered a misdemeanour punishable by fine or 
administrative detention for up to 30 days. In Slovenia, 
the Misdemeanours Act from January 2005 removed 
prison penalties for all misdemeanours, one of which 
is possession of drugs for personal use. In this way, the 
maximum penalty was reduced from 30 days in prison, or 
five days for a small quantity, to a fine.
Without changing the legal status of the offence, six 
countries made changes to the way different drugs are 
categorised, with the category determining the penalty. 
In Romania, the law of 2004 divided substances into 
high-risk and risk categories. The penalty for high-
risk substances continued to be two to five years’ 
imprisonment, while substances in the risk category are 
now subject to a lower penalty of six months’ to two 
years’ imprisonment. In Bulgaria, the 2006 Criminal Code 
introduced specific penalties for offences not related to 
distribution, namely one to six years’ imprisonment for 
high-risk drugs (down from 10 to 15 years) and up to 
five years for risk drugs (down from three to six years); 
it also specified that minor offences could be punished 
with a fine. In the Czech Republic, from January 2010 the 
new Penal Code applied a lower maximum punishment 
for cannabis (one year in prison) than for other drugs 
(unchanged at two years) for personal possession of 
a quantity ‘greater than small’. Conversely, at the end of 
2006, Italy removed the sentencing distinctions between 
illicit drugs, while increasing the maximum duration of 
administrative sanctions, such as withdrawal of driving 
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(4) See the box ‘Priorities for future research: EMCDDA Scientific Committee recommendations’.
licence, to one year for any illicit drug. In the United 
Kingdom, cannabis was reclassified from Class B to Class 
C in 2004, lowering maximum penalties for personal 
possession from five to two years’ imprisonment, and 
national police guidelines were issued not to arrest but to 
give an informal warning, if there were no aggravating 
circumstances. In January 2009, cannabis was 
reclassified from Class C to Class B, raising maximum 
penalties to five years’ imprisonment once again. Revised 
national police guidelines continued to advise an informal 
warning for a first offence.
A third group of countries changed the penalties for 
personal possession without addressing legal status 
or relative harm. Penalties for personal possession for 
all drugs were simply changed in four countries, and 
effectively also in Slovakia by redefining the offence. 
In Finland, in 2001, an amendment to the Penal Code 
reduced the maximum penalty for a minor narcotics 
offence from two years in prison to six months, allowing 
the prosecutor to deal with the majority of cases with 
a fine. In Greece, in 2003, the maximum penalty for use 
or possession of small amounts for own use by a non-
dependent user was reduced from five years to one year 
in prison. This offence will not be entered in the criminal 
record if there is no reoffending during a five-year period. 
In Denmark, a guideline for prosecutors in May 2004 set 
out that the normal response for minor drug possession 
offences should be a fine, not a warning. In 2007, this was 
established in the law. In France, a 2007 law widened 
the range of possible judicial options to include a ‘drug 
awareness course’ aimed at occasional drug users and 
juveniles. The cost of the course is to be paid by the 
offender. In 2005, a change of the Slovak Criminal Code 
widened the definition of ‘possession for personal use’ from 
one to three doses of any illicit substance, while leaving 
the maximum punishment unchanged. Two new penalties 
can also be given to those offenders: monitored home 
imprisonment for up to one year, or community service 
of 40 to 300 hours. The change also introduced a new 
offence of ‘possession of a larger amount for personal use’, 
defined as up to 10 doses, punishable by up to five years 
in prison. Previously, this would have been a trafficking 
offence punishable by two to eight years in prison.
Motives for change are complex and vary between 
countries. For example, laws have been changed to 
access addicts (Portugal), to simplify punishment (Belgium, 
Finland, United Kingdom in 2004), to harmonise 
misdemeanour penalties (Estonia, Slovenia) and to 
indicate levels of harm (Bulgaria, Czech Republic, France, 
Italy, Luxembourg, Romania, United Kingdom in 2009).
In terms of an overall European trend in penalties for 
personal possession of drugs, it could be said that 
penalties were reduced in the first half of the decade, 
but increased in the second half. Yet it is more significant 
that, although the majority of countries have retained 
the possibility of prison as a sanction (Figure 2), no 
country has introduced criminal penalties or increased 
prison sentences over the 10-year period. In this respect, 
there are signs of convergence in Europe towards lower 
penalties for personal possession of drugs.
Drug-related research
Strengthening EU research capacity
Strengthening research capacity in the drugs field has 
been on the European agenda in recent years. In 2010, 
the first Council annual exchange on drug-related research 
took place, with the European Commission presenting 
an overview of Commission-funded research projects, 
and highlighting the added value of such initiatives. The 
EMCDDA presented an overview of mechanisms and 
topics of drug-related research in Member States and its 
Scientific Committee’s recommendations on future research 
priorities (4).
Europe’s main vehicle for funding research is FP7, 
the seventh framework programme for research and 
technological development, which will run until 2013. 
Under FP7’s ‘Cooperation’ programme, there are calls 
Figure 2: Penalties in laws: possibility of imprisonment for 
possession of drugs for personal use (minor offences)
for any drug
for drugs other than
cannabis
Imprisonment not possible
Imprisonment possible:
NB: For more information, see the European legal database on drugs (ELDD).
Sources: Reitox national focal points and ELDD.
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(5) Calls are published in the Official Journal of the European Union inviting researchers to submit project proposals for specific areas of the framework 
programme.
(6) See the box ‘ALICE RAP’.
for proposals that are of particular relevance to drug 
research (5). These include calls on ‘Addictive and/
or compulsive behaviour in children and adolescents’, 
‘Understanding of unintended consequences of global 
illicit-drug control measures’ and ALICE RAP (6).
The European Commission is also funding other drug-
related studies through the ‘Drugs prevention and 
information’ programme, the ‘Prevention of and fight 
against crime’ programme, the ‘Criminal justice’ 
programme and the ‘Public health’ programme. Projects 
such as the ‘Study on the development of an EU framework 
for minimum quality standards and benchmarks in drug 
demand reduction’, ‘New methodological tools for policy 
and programme evaluation’ and ‘Further analysis of the 
EU illicit drugs market and responses’ will bring important 
insights on the different challenges facing Member States 
in this field and contribute to the implementation of the 
current EU strategy and action plan on drugs.
As requested by the 2009 Council conclusions, the 
EMCDDA, in close cooperation with the European 
Commission, is disseminating information and the main 
findings of these projects on its research thematic web area.
Research information from Member States
Europe currently has no inventory of drug-related research 
conducted at the national level. All EU Member States 
carry out research into the drug problem and a proportion 
of these studies are captured and used in the Reitox 
national reports. Although citations from these reports 
refer only to a selection of studies and may not include 
all the relevant publications in the country, it is possible to 
identify some trends in the number and types of research 
topics cited. Between 2008 and 2010, the annual number 
of studies cited in the Reitox national reports increased 
from 370 to 750. Studies on responses to drug use formed 
the largest category (34 % of all citations in the 2008–10 
national reports), followed by studies on prevalence, 
incidence and patterns of drug use (29 %) and studies 
on consequences of drug use (23 %). Studies on 
methodologies and on mechanisms and effects of drugs 
were only rarely mentioned.
Priorities for future research: EMCDDA Scientific 
Committee recommendations
As a contribution to the ongoing debate on European 
priorities on research in the drugs field, the Scientific 
Committee drew up a set of recommendations covering five 
key areas.
Interventions: the focus should be on the effectiveness of 
treatment interventions, the impact of early interventions 
and the impact on affected family members.
Policy analysis: more research is needed on how national 
and European policies are shaped, decided upon and 
implemented, but also on their evaluation, including 
comparisons of outcomes in different countries.
Illicit drug supply: more attention needs to be paid to the 
improvement of indicators to study the dynamics of the 
market.
Epidemiological research: a series of longitudinal cohort 
studies is recommended in order to help understand the 
long-term course of differing patterns of substance use, and 
improved methods for estimating the size of the drug-using 
population are still required.
Basic research on aetiology and course of drug use: 
research in this area has the potential to improve both 
diagnostics and therapeutic outcomes.
ALICE RAP
The European Commission’s seventh research framework 
programme is funding a major research initiative on 
addiction under its ‘Cooperation’ programme. The 
challenges that contemporary European society faces 
from drugs and other addictions are being analysed under 
the ‘Addictions and lifestyles in contemporary Europe — 
reframing addictions project’ (ALICE RAP), which brings 
together researchers from 25 countries. The project’s 
budget of EUR 10 million will be used to fund research into 
all aspects of addiction, under the headings ownership of 
addiction, counting addiction, determinants of addiction, 
business of addiction, governance of addiction and 
addicting the young.
For more information, see the ALICE RAP website.
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Introduction
This chapter presents an overview of the responses to drug 
problems in Europe, highlighting trends, developments 
and quality issues. Prevention measures are reviewed 
followed by interventions in the areas of treatment, social 
reintegration and harm reduction. All these measures are 
part of a comprehensive drug demand reduction system 
and are increasingly coordinated and integrated.
The section on drug law enforcement reviews the most 
recent data on drug law offences and explores the part 
played by undercover operations in disrupting the supply 
of illicit drugs. The chapter ends with a review of the 
available data on drug users in prisons and the existing 
responses in this particular setting.
Prevention
Drug prevention can be divided into different levels 
or strategies, which range from targeting society as a 
whole (environmental prevention) to focusing on at-risk 
individuals (indicated prevention). The main challenges 
for prevention policies are to match these different levels 
of prevention to the degree of vulnerability of the target 
groups (Derzon, 2007) and to ensure that interventions 
are evidence-based and sufficient in coverage. Most 
prevention activities focus on substance use in general; 
only a limited number of programmes focus on specific 
substances, for example alcohol, tobacco or cannabis.
Environmental strategies
Environmental prevention strategies aim at altering the 
cultural, social, physical and economic environments in 
which people make their choices about drug use. These 
strategies typically include measures such as smoking 
bans, alcohol pricing and the development of health 
promoting schools. Evidence shows that environmental 
prevention measures operating at societal level and 
targeting the social climate in schools and communities 
can be effective in altering normative beliefs and, 
consequently, substance use (Fletcher et al., 2008).
With the recent introduction of a total ban on smoking 
in enclosed public spaces in Spain, almost all European 
countries now have some form of tobacco ban in place. 
Environmental strategies targeting alcohol are less common 
in Europe, though most Nordic countries report an increase 
in the implementation of responsible serving strategies (7), 
which have demonstrated effectiveness in local studies 
(Gripenberg et al., 2007).
In most European countries, there has been an increase 
in the implementation of school drug policies (8), and 
over a third of countries report that drug prevention 
is integrated into school curricula, for example via 
‘health’ or ‘civic education’ programmes. Four countries 
(Luxembourg, Netherlands, Austria, United Kingdom) 
report the implementation of ‘whole school’ prevention 
programmes (9), an approach that has been positively 
evaluated in terms of reducing substance use (Fletcher et 
al., 2008), and has additional benefits such as improving 
school atmosphere and enhancing social inclusion.
Universal prevention
Universal prevention addresses entire populations, 
predominantly at school and community levels. It aims 
to deter or delay the onset of drug use and drug-related 
problems by providing young people with the necessary 
competences to avoid initiation into substance use. When 
implementing universal prevention approaches, evidence 
shows that paying attention to cultural, normative and 
social context improves the chances that programmes will 
be accepted and successful (Allen et al., 2007).
Europe-wide expert ratings indicate a small shift in school-
based prevention, from approaches that have not been 
shown to be effective, such as information provision alone, 
information days and drug testing in schools, towards 
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(7) Responsible serving strategies aim to prevent alcohol sales to intoxicated and underage individuals, through a combination of server training and 
policy interventions.
(8) A school drug policy establishes the norms and regulations about substance use in the school setting and provides guidance on how to proceed 
when rules are broken.
(9) Whole school approaches aim at providing protective school environments and positive school climates.
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(10) See SFP, FRED, Preventure, EU-DAP and GBG on the ‘Best practice’ portal.
more promising approaches, such as manual-based life-
skills programmes and interventions specifically for boys. 
Countries also report that several of the more effective 
universal prevention interventions are being transferred 
from one country to another (10). However, despite the 
availability of positively evaluated prevention methods, a 
number of interventions that are not supported by scientific 
evidence, such as expert and police visits to schools, are 
being increasingly reported by some countries.
Universal family-based prevention largely takes the form 
of simple and low-cost interventions, such as parents’ 
evenings and dissemination of leaflets or brochures. 
More complex interventions such as parents’ peer-to-
peer groups (Germany, Ireland), personal and social 
competence training (Greece, Portugal) or manualised 
parenting programmes (Spain, United Kingdom) are 
rarely reported.
Figure 3: Provision of selective prevention interventions as estimated by national experts
Schoolchildren with 
social or academic 
problems
Young offenders
Socially disadvantaged
parents
Substance use
problems in 
family
Full Extensive Limited Rare None No information
NB: Provision relates to the general and geographical distribution of interventions, and is rated as: full, provided in nearly all relevant locations 
(areas in which the target population is sufficient for implementation of the intervention); extensive, provided in a majority of, but not all relevant 
locations; limited, provided in more than a few, but not the majority of relevant locations; rare, provided in just a few relevant locations; none, 
intervention not available. Information was collected by means of a structured questionnaire.
Sources: Reitox national focal points.
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(11) Some examples, though, are available on the ‘Exchange on drug demand reduction action’ website.
Selective prevention
Selective prevention intervenes with specific groups, 
families or communities who, due to their reduced social 
ties and resources, may be more likely to develop drug 
use or progress into dependency. Several Member States 
report a shift in focus in their strategies towards targeting 
vulnerability, while expert ratings suggest an overall 
increase in the provision of interventions for vulnerable 
groups from 2007 to 2010, with the exception of 
interventions for youths in care institutions. The largest 
increases are reported for pupils with academic and 
social problems (full or extensive provision in 16 
countries) and for young drug law offenders (full or 
extensive provision in 12 countries) (Figure 3). The 
former might be due to increasing attention from some 
Member States and the European Union to academic 
failure and early school leaving, which share the same 
risk factors as those for problem drug use (King et al., 
2006). The increase in provision for young offenders 
might be partially explained by the implementation 
of FRED, a multi-session psychosocial programme 
(EMCDDA, 2010a), in more countries, as well as by new 
interventions for first-time offenders in Greece, Ireland 
and Luxembourg.
An increase in the provision of interventions targeting 
vulnerable families was also reported, most notably 
for those with substance use problems (full or extensive 
provision in 14 countries) and socially disadvantaged 
families (full or extensive provision in seven countries) 
(Figure 3). In this context, the increasing popularity of the 
‘Strengthening families’ programme (Kumpfer et al., 2008) 
in Europe may be noted: this programme has recently been 
implemented in three more countries (Germany, Poland, 
Portugal) and in additional locations in the United Kingdom.
Selective prevention can be carried out through outreach 
work or by office-based services. Prevention work with 
ethnic groups and party/festival goers are the only areas 
where more outreach work is reported, while there are 
reports of a reduction in outreach work services for 
homeless youth. Overall, most service contact with socially 
excluded groups such as early school leavers, immigrants 
and homeless youth continues to be office based.
In addition, relatively little is known about the content 
of many selective prevention programmes (11). Overall, 
the available data indicate that the most common 
interventions in Europe are those that place an emphasis 
on information, awareness-raising and counselling, despite 
growing evidence of the effectiveness of approaches such 
as norm setting, motivation, skills and decision-making.
Indicated prevention
Indicated prevention aims to identify individuals with 
behavioural or psychological problems that may be 
predictive for developing substance use problems later 
in life, and to target them individually with special 
interventions. A number of indicated prevention programmes 
have been positively evaluated (EMCDDA, 2009c).
Only half of the EU Member States and Norway report the 
existence of indicated prevention activities, and very few 
report the use of structured and manual-based interventions. 
An increasing number of countries report that the school 
setting is being used to identify vulnerable pupils, in 
particular those with behavioural problems, often associated 
with later drug use. Belgium, the Czech Republic, Portugal 
and Norway report the use of new tools for screening and 
early detection in both school and community settings.
Early intervention and counselling for drug use are the 
most frequently reported indicated prevention strategies; 
there are few reports of interventions targeting early onset 
behavioural problems. This suggests that the potential 
for indicated prevention to help reduce the impact of 
neuro-behavioural problems during childhood, such as 
aggression and impulsiveness, on later substance use 
behaviour (EMCDDA, 2009c) is not being fully exploited 
in Europe. Indicated prevention can act as a bridge 
between prevention in community environments and the 
specialist treatment offered in clinical settings, particularly 
when providing early interventions for particular groups, 
such as vulnerable cannabis or alcohol users.
Treatment
Psychosocial interventions, opioid substitution and 
detoxification are the main modalities used for the treatment 
of drug problems in Europe. The relative importance of the 
different treatment modalities in each country is influenced 
by several factors, including the organisation of the 
national healthcare system. Drug treatment services may be 
provided in a variety of settings: specialist treatment units, 
including outpatient and inpatient centres, mental health 
clinics and hospitals, units in prison, low-threshold agencies 
and office-based general practitioners.
There is no dataset allowing a description of the full 
population of drug users currently undergoing drug 
treatment in Europe. However, information on an important 
subgroup of this population is gathered by the EMCDDA’s 
treatment demand indicator, which collects data on those 
entering specialist drug treatment services during the 
calendar year, enabling insights into their characteristics 
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(12) The treatment demand indicator received data for specialist drug treatment centres from 29 countries. Most countries provided data for more than 
60 % of their units, though for some countries the proportion of units covered is unknown (see Table TDI-7 in the 2011 statistical bulletin).
(13) See Table HSR-10 in the 2011 statistical bulletin.
(14) More detailed information on specific types of treatment for the different substances and their effectiveness, quality and evidence are available in 
the respective chapters.
(15) See Tables TDI-16 and TDI-19 in the 2011 statistical bulletin.
and drug-use profiles (12). In 2009, the indicator registered 
about 460 000 treatment entrants, 38 % of whom 
(175 000) were reported to have entered drug treatment 
for the first time in their life.
Based on a range of different sources, including the 
treatment demand indicator, it can be estimated that at 
least 1.1 million people received treatment for illicit drug 
use in the European Union, Croatia, Turkey and Norway 
during 2009 (13). While more than half of these clients 
received opioid substitution treatment, a substantial 
number received other forms of treatment for problems 
related to opioids, stimulants, cannabis and other illicit 
drugs (14). This estimate of drug treatment in the European 
Union, though still in need of refinement, does suggest a 
considerable level of provision, at least for opioid users. 
This is the consequence of a major expansion during the 
last two decades of specialised outpatient services, with 
a significant involvement of primary healthcare, self-help 
groups, general mental health services and outreach and 
low-threshold service providers.
Particularly in western Europe, there appears to be 
a gradual shift away from a view of drug treatment as 
the responsibility of a few specialist disciplines providing 
intensive, short-term interventions towards a multidisciplinary, 
integrated and longer-term approach. In part, this is 
a response to increasing recognition of drug addiction 
as a chronic condition, with the progress of many clients 
marked by cycles of remission, relapse, repeated treatments 
and disability (Dennis and Scott, 2007), a view supported 
by data collected by the EMCDDA that show that over half 
of treatment entrants have had a previous treatment episode. 
Another factor is that western European countries are 
witnessing a significant ageing of their populations of drug 
users in treatment, primarily long-term problem users with 
previous treatment episodes and reporting multiple health 
and social problems (EMCDDA, 2010f).
In response, some national and local drug strategies refer 
to a continuous care approach, emphasising coordination 
and integration of interventions between different drug 
treatment providers (e.g. discharge from residential to 
outpatient services) and between treatment and the 
broader spectrum of health and social services. Continuous 
care builds on regular monitoring of client status, early 
detection of potential problems, referral between health 
and social care services and ongoing client support with 
no set timeframe. General practitioners can play a key 
role in this area. A recent French survey among service 
providers recognised the role of general practitioners in 
facilitating access to specialist care for opioid users, both 
for referral to hospitals to initiate methadone treatment and 
for continuation of treatment upon discharge. In another 
example, the Dutch government and local authorities of the 
country’s four largest cities have adopted an integrated 
treatment approach within a broader social support 
strategy, involving a wide range of agencies.
Continuous care and integrated treatment responses 
may be aided by the establishment of care protocols, 
guidelines and management strategies between providers 
(Haggerty et al., 2003). A 2010 survey among national 
focal points found that 16 countries have partnership 
agreements between drug treatment agencies and social 
services. In six countries (France, Netherlands, Portugal, 
Romania, United Kingdom, Croatia), structured protocols 
are the most commonly used mechanisms for interagency 
coordination, while in the other countries, partnerships 
rely mainly on informal networks.
Outpatient treatment
In Europe, most drug treatment is provided in outpatient 
settings. Information is available on about 400 000 drug 
users entering specialist outpatient treatment during 2009. 
Half of the treatment entrants (51 %) report opioids, mainly 
heroin, as their primary drug, while 24 % report cannabis, 
18 % cocaine and 4 % stimulants other than cocaine. The 
most common route to treatment is self-referral (37 %), 
followed by drug, social and health services (28 %) 
and referral by the criminal justice system (20 %). The 
remaining clients are referred through family, friends and 
informal networks (15).
‘Selected issue’ on financing and cost of drug 
treatment
During this period of fiscal austerity, increased attention 
is being paid to all aspects of state expenditure, including 
treatment costs. A ‘Selected issue’ published this year by 
the EMCDDA maps the main funding sources for drug 
treatment in a number of European countries. It summarises 
the available data on how much is being spent on drug 
treatment services, and how much treatment costs.
This publication is available in print and on the EMCDDA 
website in English only.
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(16) See Tables TDI-9 (part iv), TDI-21 and TDI-103 in the 2011 statistical bulletin. For information on treatment clients according to primary substance, 
see the respective chapters. 
(17) See ‘Assistance to drug users in prison’, p. 38.
(18) See Tables HSR-1, HSR-2 and HSR-3 in the 2011 statistical bulletin.
(19) This figure should be interpreted with caution as it does not include all users who temporarily enter inpatient care as part of a more complex 
treatment process. 
(20) See Tables TDI-7, TDI-10, TDI-19 and TDI-21 in the 2011 statistical bulletin.
Those entering outpatient treatment are by far the largest 
group of drug users for which it is possible to describe 
personal and social characteristics and drug-use profiles. 
They are predominantly young men, with an average 
age of 32 years. Males outnumber females by almost 
four to one, which in part reflects the predominance of 
males among more problematic drug users. Among clients 
entering treatment, primary cannabis users are almost 
10 years younger (25) than primary users of cocaine (33) 
and opioids (34). On average, the youngest drug clients 
(25–26) are reported by Poland, Hungary and Slovakia — 
countries joining the EU since 2004 — and the oldest by 
Spain, Italy and the Netherlands (34). Male to female ratios 
are high for all substances, although varying with drug and 
country. Gender ratios are generally higher in countries in 
the south of Europe and lower in countries in the north (16).
The two main modalities of outpatient treatment in Europe 
are psychosocial interventions and opioid substitution 
treatment. Psychosocial interventions include counselling, 
motivational interviewing, cognitive-behavioural therapy, 
case management, group and family therapy and relapse 
prevention. They are mostly provided, depending on the 
country, by public institutions or by non-governmental 
organisations. Psychosocial interventions offer support 
to users as they attempt to manage and overcome their 
drug problems, and they are the main form of treatment 
for users of stimulant drugs, such as cocaine and 
amphetamines. They are also provided for opioid users, 
often in combination with substitution treatment. According 
to a 2008 survey of national experts, most European 
countries report the availability of outpatient psychosocial 
treatment to those who seek it. While there is considerable 
variation across Europe, most countries reported average 
waiting times of less than a month.
Substitution treatment is the predominant treatment option 
for opioid users in Europe. It is generally provided in 
specialist outpatient settings, though in some countries it 
is also available in inpatient settings, and is increasingly 
provided in prisons (17). Also, office-based general 
practitioners, often in shared-care arrangements with 
specialist centres, increasingly play a role. Opioid 
substitution is available in all EU Member States, as well 
as Croatia and Norway. In Turkey, substitution treatment in 
the form of the combination buprenorphine/naloxone was 
introduced in 2010. Overall, it is estimated that there were 
about 700 000 substitution treatments in Europe in 2009 
(see Chapter 6) (18).
Inpatient treatment
Data are available for about 44 000 drug users who 
have entered drug treatment in inpatient settings in Europe 
during 2009 (19). The primary drugs reported by half of 
these clients were opioids (53 %), followed by cannabis 
(16 %), cocaine (8 %) and non-cocaine stimulants (12 %). 
Inpatient clients are mainly young men, with a mean age 
of 31 years and about three males to every female (20).
Inpatient or residential treatment requires clients to stay 
overnight for a duration of several weeks to several 
months. In many cases, these programmes aim to enable 
clients to abstain from drug use, and do not allow 
substitution treatment. Drug detoxification, a short-term, 
medically supervised intervention aimed at resolving the 
withdrawal symptoms associated with cessation of chronic 
drug use, is sometimes a prerequisite for starting long-
term, abstinence-based inpatient treatment. Detoxification 
is usually provided as an inpatient intervention in 
hospitals, specialised treatment centres or residential 
facilities with medical or psychiatric wards.
In inpatient settings, clients receive accommodation and 
individually structured psychosocial treatments, and 
take part in activities geared towards rehabilitating and 
reintegrating them into society. A therapeutic community 
approach is often used in this context. Inpatient drug 
treatment is also provided by psychiatric hospitals, notably 
for clients with co-morbid psychiatric disorders.
According to a 2008 survey of national experts, most 
European countries report the availability of inpatient 
psychosocial treatment and detoxification services for those 
who seek it. Estimates of national waiting times for access to 
inpatient psychosocial treatment, provided by experts from 
16 countries, vary across Europe. Average waiting times 
were reported to be less than one month in 14 countries, a 
few months in Hungary and 25 weeks in Norway.
Social reintegration
The level of social exclusion among drug treatment clients 
is generally high, potentially preventing individuals 
from making a full recovery and undermining treatment 
gains. Data on clients who entered drug treatment in 
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(21) See Tables TDI-12, TDI-13 and TDI-15 in the 2011 statistical bulletin.
(22) Lithuania and Austria did not have a national drug strategy at the time of the survey.
2009 show that most of them were unemployed (59 %) 
and almost 1 in 10 lacked stable accommodation (9 %). 
Low educational attainment is common among treatment 
clients, with 37 % having completed only primary 
education, and 4 % not even achieving this level (21). There 
is increasing recognition that development of services 
tackling marginalisation and stigmatisation will improve 
the chances of clients’ successful social reintegration and 
increase their quality of life (Lloyd, 2010).
Social reintegration of drug users into their local 
communities is recognised as a key component of 
comprehensive drug strategies, setting a focus on 
improvement of social skills, promoting education and 
employability and meeting housing needs. Addressing 
the social needs of clients in drug treatment can play a 
role in reducing their drug use and sustaining long-term 
abstinence (Laudet et al., 2009).
Twenty-one European countries report having specific 
social reintegration sections in their national drug 
strategies (22), mainly focusing on the housing, education 
and employment needs of drug users. Social reintegration 
services are either provided concurrently with drug 
treatment or after completion of treatment, relying on 
collaboration between specialised treatment services and 
health and social care institutions.
Overall, while most countries report the existence of 
interventions in housing, education and labour-market 
participation, the available data indicate that levels of 
provision fall short of the needs of the drug treatment 
population.
Housing
Ensuring access to, and maintaining, stable 
accommodation are key to the reintegration process, 
helping to retain clients in treatment and support relapse 
prevention (Milby et al., 2005).
In Europe, overall, levels of service provision addressing 
the housing needs of drug treatment clients are low. Of 
the 29 countries responding to a recent survey, less than 
a third report that a majority of treatment clients could 
access emergency accommodation (nine), transitional 
housing (eight) and supported living services (five).
Despite the low level of provision reported by European 
countries, most report the availability of social housing 
facilities targeting vulnerable groups, which are to varying 
degrees accessible to people in drug treatment. Such 
accommodation is usually provided by local authorities 
or non-governmental organisations. The duration of stay 
can vary and entry can be with conditions (e.g. being 
drug-free, supervision from treatment staff). In addition, a 
number of countries have tailored housing for people in 
drug treatment; for example, 18 countries report provision 
of emergency accommodation (e.g. night shelters, bed 
and breakfast) and 20 countries provide some level of 
transitional accommodation such as halfway houses. 
Independent living can be an important step towards 
reintegration into society, and in 12 countries, treatment 
clients have some access to supported living facilities, 
while 15 countries report programmes that facilitate 
access to independent living within the general housing 
market. In France, so-called ‘sliding’ tenancies are 
provided by specialist treatment centres. The centre pays 
the rent for the housing, and sub-rents it to the client, 
who contributes a small portion of the rental fee. The 
client receives tenancy support with administrative tasks 
(e.g. paying bills) and budget management, and after a 
‘probationary period’ becomes the official tenant.
Training and education
The education needs of drug users in treatment can be 
addressed in a number of ways. While the mainstream 
educational system may be a first option, individual and 
systemic barriers, such as low expectations, stigma and 
fear of failure, can prevent clients from participating 
(Lawless and Cox, 2000). Eleven countries report the 
availability of supportive programmes that aim to facilitate 
drug treatment clients’ access to mainstream education. 
In addition, 15 countries report that drug treatment clients 
can access educational programmes targeting socially 
vulnerable groups.
Vocational or technical training helps people acquire the 
practical skills necessary for employment in a particular 
occupation or trade, and usually leads to a vocational 
qualification. In most countries (20), clients obtain vocational 
training through interventions targeted at socially vulnerable 
groups. In 16 countries, vocational training interventions 
also exist specifically for drug treatment populations.
Employment
Employability is a key concept in social reintegration, 
and the employment needs of drug users are addressed 
by a number of European countries in their national 
employment strategies. Activities that increase 
employability may address the psychological domain (e.g. 
personal development, self-efficacy, self-esteem, coping 
skills) and can provide recovering drug users with an 
alternative peer group and new skills to assist successful 
reintegration into the wider community. In 15 countries, the 
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(23) COM(2007) 199 final.
(24) See also the ‘Best practice’ portal.
(25) See Table HSR-3 in the 2011 statistical bulletin and Chapter 6.
employability of people in drug treatment is reported to be 
a regular, standard objective of individual care plans.
Evidence shows that employment and enhancing 
employability improve drug treatment outcomes (Kaskutas 
et al., 2004), have a positive impact on health and 
quality of life and reduce offending (Gregoire and 
Snively, 2001). Support systems, such as the intermediate 
labour market, which provides paid work in specially 
created temporary jobs, can help in bridging the gap 
between long-term unemployment and employment in the 
open labour market. These systems are generally targeted 
at disadvantaged individuals (e.g. through businesses 
created to employ the disabled or socially excluded), and 
may include occupational and voluntary work.
Twenty countries report intermediate labour market 
interventions available to socially vulnerable groups 
that are also accessible to people in drug treatment; in 
11 countries, such interventions are available specifically 
for treatment clients. In Ireland, for example, the Ready 
for Work initiative helps homeless people, including drug 
users, enter training or employment by providing them with 
pre-employment training, unpaid work experience and 
follow-up support. Drug treatment clients may be eligible 
for other initiatives, such as supported employment, which 
assist people with disabilities or other disadvantaged 
groups to secure and maintain paid employment. While 17 
countries report that supported employment interventions 
are accessible to treatment clients, only four report 
sufficient levels of provision.
Harm reduction
The prevention and reduction of drug-related harm is a 
public health objective in all EU Member States and in the 
EU drugs strategy (23). Reviews of the scientific evidence of 
harm-reduction interventions, as well as studies showing 
the combined impact of these interventions, are now 
available for service planning (EMCDDA, 2010b) (24).
Among the main interventions in this field are opioid 
substitution treatment and needle and syringe programmes, 
which target overdose deaths and the spread of infectious 
diseases. Substitution treatment is reported to be available 
in all countries, and needle and syringe programmes exist 
in all countries except Turkey. In the past two decades, 
Europe has seen the growth and consolidation of harm 
reduction, and its integration with a range of other 
healthcare and social services. From an initial focus in the 
late 1980s on the HIV/AIDS epidemic, harm reduction has 
expanded into the broader perspective of catering for the 
health and social needs of problem drug users, especially 
those who are socially excluded.
In 2009, the number of clients accessing substitution 
treatment increased in the majority of countries (25). In 
addition, increases in the use of low-threshold harm-
reduction facilities were reported in Bulgaria, the Czech 
Republic, Greece, Hungary, Latvia, Lithuania, Luxembourg, 
Poland, Romania and Croatia, and there was a geographical 
expansion of needle and syringe programmes in Hungary.
Most European countries provide a range of further 
healthcare and social services, including individual risk 
assessment and advice, targeted information and safer-
use education. The distribution of injecting equipment 
other than needles and syringes, promotion of condom 
use among injecting drug users, infectious disease testing 
and counselling, antiretroviral treatment and vaccination 
against viral hepatitis have increased in recent years. 
Model projections suggest that delivering interventions 
Drug user involvement
The concept of service user involvement in health policy 
gained momentum when a new agenda for public 
health and healthcare provision was set by the Ottawa 
Declaration of the World Health Organisation in 1986 
(WHO, 1986). Active involvement of drug users in shaping 
drug services can, however, be traced back to the 
Netherlands in the 1970s.
More recently, as a step towards facilitating the 
involvement of drug user organisations at national and 
European level, the European Harm Reduction Network has 
started to compile an inventory of drug user organisations 
in Europe.
User involvement varies in form and pursues a range of 
different aims (Bröring and Schatz, 2008). Activities may 
include service user surveys on accessibility and quality 
of services, seeking users’ advice on staff recruitment, 
conducting focus groups to develop new service areas 
and the inclusion of user organisations in health advocacy 
and drug policymaking. Drug user organisations are often 
engaged in peer support and education on infectious 
disease prevention, and in the production of information 
materials that support networking and help to raise public 
awareness about the main problems for drug users (Hunt et 
al., 2010). Involving users can be a pragmatic and ethical 
way to ensure the quality and acceptability of services. 
However, in order to empower drug users to contribute and 
to ensure that user involvement succeeds, adequate support 
is necessary.
See also the European Harm Reduction Network website.
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(26) See the ‘Best practice’ portal for further information.
with the greatest potential effect (needle and syringe 
programmes, substitution treatment and antiretroviral 
treatment) to a significant proportion of the target 
population and over an extended time reduces HIV 
transmission among injecting drug users; they also suggest 
that the greatest effects are achieved when levels of 
infection are still low (Degenhardt et al., 2010).
A multidisciplinary investigation of the evidence base for 
harm-reduction interventions to reduce the risk of infections 
among drug users was carried out in 2010 by the French 
National Institute for Health and Medical Research (Inserm). 
The study reviewed the scientific literature covering the 
medical, epidemiological, sociological, economic and 
public health aspects of harm reduction, and organised 
expert hearings and public debates. The ‘Collective expert 
report’ recommends that harm-reduction policies should be 
considered as an essential part of a broader strategy to 
reduce health inequalities. Furthermore, services need to be 
integrated with other drugs services as part of a continuum 
of care. While the priority remains that both drug use and 
the transition into injecting use should be prevented, those 
who inject drugs should be enabled to reduce injecting-
related risks. The report recommends that, as with medical 
and social interventions, harm-reduction measures should 
be part of personalised assistance plans.
Quality assurance
Most European countries undertake a range of activities 
geared towards ensuring the quality of drug-related 
interventions and services. These include the development 
of treatment guidelines, benchmarking of services, staff 
training and quality certification and accreditation 
processes.
Quality standards for Europe
The EQUS study, commissioned by the European 
Commission, aims to build consensus among European 
experts and stakeholders over existing quality standards 
in demand reduction interventions. This includes the 
development of a clearer definition of minimum standards, 
which has been used to cover both evidence-based 
recommendations and organisational procedures. The 
EQUS study addresses this confusion and distinguishes 
between three types of standards. These are defined 
as structural standards (e.g. physical environment, 
accessibility, staff composition and qualification), process 
standards (e.g. individualised planning, cooperation with 
other agencies, patient records keeping) and outcome 
standards (patient and staff satisfaction, setting and 
measurement of treatment goals). The results of the study 
should be available by the end of 2011, and will be used 
by the European Commission to develop an EU consensus 
to present to the Council by 2013 (26).
Staff training and education
Staff training and continuing education related to drug 
use are key activities in assuring the quality of services. 
Results from a recent ad hoc data collection reveal that 
specific training programmes in the drug addiction field 
exist in the 27 countries that reported, and are primarily 
geared towards the medical and nursing professions, 
psychologists and social workers. While some countries 
have developed specialised university courses, others 
provide post-graduate or continuing education courses. 
The most structured and developed training and 
education activities can be found in the medical field. 
Three countries report having developed a medical 
speciality in addiction. The Czech Republic introduced 
the specialism of addiction medicine in 1980 and the 
non-medical profession of ‘addictologist’ in 2008; a 
two-year specialist module in addiction medicine began 
in the Netherlands in 2007; Germany has post-graduate 
courses in substance use and addiction counselling 
as well as a module on heroin-assisted treatment. The 
evidence for the effectiveness of approaches such as 
‘continuing medical education’ remains limited and 
inconclusive. A recent, more interactive approach, 
known as ‘continuing professional development’ (Horsley 
et al., 2010), has been proposed, which involves 
training physicians in a broad range of skills including 
communication, management and health advocacy, but it 
still has to be tested.
Drug law enforcement and drug law 
offences
Drug law enforcement is an important component of 
national and EU drug policies. It includes a wide range of 
interventions that are mainly implemented by police and 
police-like institutions (e.g. customs). One group of such 
interventions, undercover operations, is briefly reviewed 
here. Data on drug law enforcement activities are often less 
developed and accessible than those in other areas of drug 
policy. A notable exception to this rule is data on drug law 
offences, which are reported at the end of this section.
Undercover operations
The successful prosecution of high-level drug offenders 
and the dismantling of organised drug supply networks 
are key supply reduction priorities under the current 
EU drug action plan. This poses a challenge to law 
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(27) For an overview of the legal aspects of controlled deliveries in Europe, see the European legal database on drugs.
(28) For a discussion of the relationships between drugs and crime and a definition of ‘drug-related crime’, see EMCDDA (2007b).
enforcement agencies, as most drug law offences will 
only be detected by means of proactive law enforcement 
operations (EMCDDA, 2009a). This is especially the case 
for serious offences involving intermediary and wholesale 
drug supply, which tend to be committed by highly 
secretive individuals and criminal organisations.
In their response to serious drug crime, European 
law enforcement institutions increasingly make use of 
undercover techniques, including both technology, such 
as wiretapping or electronic surveillance, and human 
undercover operations. These operations may involve 
police officers (undercover agents) and private individuals 
under police supervision (informants). Their deployment is 
legally admissible in all 27 EU Member States.
Undercover operations against drug trafficking networks are 
used to collect reliable information on the identity and roles 
of network members, detect smuggling routes, destinations 
and warehousing facilities and discover the time and 
place of drug deliveries. Agents or informants often have 
to infiltrate criminal networks, which tend to be secretive 
towards outsiders and to compartmentalise information. 
Intelligence gathering is mainly focused on the functioning 
of drug networks and the roles of their members.
Undercover operations pose legal challenges, in particular 
around the subject of incitement. The European Court of 
Human Rights established basic principles regarding the use 
of ‘agents provocateurs’ in a 1998 judgment (Teixeira de 
Castro v Portugal) (European Court of Human Rights, 1998). 
This states that the use of human undercover techniques 
should not infringe on the right to a fair trial, and therefore 
law enforcement agencies should not exert such an 
influence on a subject as to incite the commission of an 
offence that would otherwise not have been committed. 
Law enforcement agencies must, therefore, hold ‘objective 
suspicions’ on the targeted individuals before implementing 
undercover techniques. In most Member States, incitement 
of third parties to commit crime is prohibited.
National legal and administrative provisions govern 
undercover operations, and aim to ensure both 
compliance with the rule of law and the security of 
undercover agents. National laws and accompanying 
regulations differ but tend to provide a general framework 
which is specified in accompanying regulations that are 
rarely made public. Other information, such as the number 
of operations carried out each year, is also usually not 
available to the public. However, research has shown 
that 34 undercover operations were conducted in the 
Netherlands in 2004, and 12 of them contributed to 
investigations or trials (Kruisbergen et al., 2011).
In most EU Member States, approval from a judicial 
authority is required before launching an undercover 
operation and most operations require monitoring by a 
superior authority, typically the prosecutor or a court. 
Thirteen Member States specify the proportionality and 
subsidiarity rules, under which the intervention must be 
proportional to the investigated drug offence, which must 
be serious enough to warrant an undercover measure. In 
addition, before conducting an undercover operation, it 
must be clear that no other, less intrusive law enforcement 
measure would be as successful.
The use of operational cover, including false identity 
documents and ‘front organisations’ — created to provide 
plausible occupations and means of income for undercover 
agents — is legally admissible in most Member States.
A variety of techniques are used in undercover operations. 
For example, covert drug purchases are used primarily 
to arrest individuals in the act of selling illicit drugs. 
Controlled deliveries are a technique that allows the 
transport of illicit consignments, with the knowledge and 
under the supervision of the competent authorities, across 
and within national borders. The consignments may include 
drugs or precursors, weapons, cigarettes, money from illicit 
activities or even human beings. Most controlled deliveries 
in Europe involve drug consignments (Council of the 
European Union, 2009) and, depending on national law, 
they may be escorted by undercover agents or informants, 
or may be under technological surveillance (27).
Drug law offences
The only data on drug-related crime routinely available in 
Europe are initial reports on offences against national drug 
laws, mainly from the police (28). These data usually refer 
to offences related to drug use (use and possession for 
use) or drug supply (production, trafficking and dealing), 
although other types of offences may be reported (e.g. 
related to drug precursors) in some countries.
Data on drug law offences are a direct indicator of 
law enforcement activity, since they refer to consensual 
crimes, which usually go unreported by potential victims. 
They are often viewed as indirect indicators of drug 
use and drug trafficking, although they include only 
those activities that have come to the attention of law 
enforcement. Additionally, they are also likely to reflect 
national differences in legislation, priorities and resources. 
Furthermore, national information systems differ across 
Europe, especially in relation to recording and reporting 
practices. For these reasons, it is difficult to make robust 
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(29) See Figure DLO-1 and Table DLO-1 in the 2011 statistical bulletin.
(30) See Table DLO-2 in the 2011 statistical bulletin.
(31) See Figure DLO-1 and Table DLO-5 in the 2011 statistical bulletin.
(32) See Table DLO-3 in the 2011 statistical bulletin.
(33) See Figure DLO-3 and Table DLO-6 in the 2011 statistical bulletin.
(34) See Figure DLO-3 and Table DLO-8 in the 2011 statistical bulletin.
(35) See Figure DLO-3 and Table DLO-7 in the 2011 statistical bulletin.
comparisons between countries, and it is more appropriate 
to compare trends rather than absolute numbers.
Overall, the increase in the number of reported drug law 
offences observed in previous years slowed down in 2009. 
An EU index, based on data provided by 21 Member 
States, representing 95 % of the population aged 15–64 
in the European Union, shows that reported offences 
increased by an estimated 21 % between 2004 and 2009. 
If all reporting countries are considered, the data reveal 
upward trends in 18 countries and a stabilisation or an 
overall decline in 11 countries over the period (29).
Use- and supply-related offences
There has been no major shift in the balance between drug 
law offences related to use and those related to supply 
compared with previous years. In most (22) European 
countries, offences related to drug use or possession for use 
continued to comprise the majority of drug law offences in 
2009, with Estonia, Spain, France, Hungary, Austria and 
Sweden reporting the highest proportions (81–94 %) (30).
The increase in the number of use offences reported 
in previous years slowed down in 2009. Between 
2004 and 2009, the number of drug law offences 
related to use increased in 15 reporting countries, with 
only Bulgaria, Germany, Estonia, Malta, Austria and 
Norway reporting a decline across the period. Overall, 
the number of drug law offences related to use in 
the European Union increased by an estimated 29 % 
between 2004 and 2009.
Offences related to the supply of drugs have remained 
stable since 2007, although they show an estimated 
increase during the period 2004–09 of about 7 % in the 
European Union. Over this period, 15 countries report an 
increase in supply-related offences, while three countries 
report an overall decline (31).
Trends by drug
Cannabis continues to be the illicit drug most often 
mentioned in reported drug law offences in Europe (32). 
In the majority of European countries, offences involving 
cannabis accounted for between 50 % and 75 % of 
reported drug law offences in 2009. Offences related 
to other drugs exceeded those related to cannabis in 
only three countries: the Czech Republic and Latvia with 
methamphetamine (55 % and 27 %); and Malta with 
cocaine (36 %).
In the period 2004–09, the number of drug law offences 
involving cannabis increased in 11 reporting countries, 
resulting in an estimated increase of 20 % in the European 
Union (Figure 4). Downward trends are reported by 
France, Italy, Cyprus, Malta and the Netherlands (33).
Cocaine-related offences increased over the period 
2004–09 in 11 reporting countries, while Bulgaria, 
Germany, Italy, Austria and Croatia reported decreasing 
trends. In the European Union, overall, offences related to 
cocaine increased by about 39 % over the same period, 
but showed a levelling-off in the last two years (34).
The number of heroin-related offences slightly declined in 
2009. The EU figure for such offences increased by 22 % 
over 2004–09. The number of heroin-related offences has 
increased in 11 reporting countries, while a decline was 
reported in Bulgaria, Germany, Malta, the Netherlands 
and Austria over the same period (35).
The number of offences related to amphetamines reported 
in the European Union slightly decreased in 2009, though 
the general trend since 2004 shows an overall estimated 
increase of 16 %. In contrast, the number of ecstasy-related 
offences halved over the same period (a 54 % decrease).
Training the European police
The European Police College (CEPOL) is an agency of 
the European Union operating as a network of national 
police academies and universities. One of its main tasks 
is to organise around 100 training activities a year, 
primarily for senior police officers, on key topics relevant 
to European police forces. The overall aim is to promote a 
common European approach to policing issues.
To support its own training activities and those of the 
EU Member States, CEPOL has developed common 
curricula for various target groups, including senior 
officers, investigators and case managers, but also 
representatives of national governments and police 
academies. The common curriculum on drug trafficking 
provides an overview of the international drug situation, 
drug legislation, basic information on illicit substances, 
international cooperation, existing policing strategies 
as well as crime-specific tactical options, such as covert 
operations and challenges including drug-related crime 
but also drug prevention and demand reduction.
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(36) There were over 640 000 people in penal institutions in the European Union on 1 September 2009. Data on penal statistics in Europe are available 
from the Council of Europe. 
(37) See Tables DUP-1, DUP-2 and DUP-105 in the 2011 statistical bulletin.
(38) See Tables DUP-3 and DUP-105 in the 2011 statistical bulletin.
(39) See Table INF-117 in the 2011 statistical bulletin, and the Reitox national reports of Malta (2005) and the Czech Republic (2010).
Health and social responses for drug users 
in prison
In the European Union, the proportion of sentenced 
prisoners convicted of drug law offences ranges from 3 % 
to 53 %, with half of the countries reporting proportions 
between 9 % and 25 % (36). These figures do not include 
those sentenced for acquisitive crimes committed to support 
their drug addiction, or other drug-related offences.
Drug use in prison populations
There is still a lack of standardisation in the methodologies 
used in studies on drug use in the prison population 
(Carpentier et al., 2011). Research, nevertheless, shows that 
drug use is more prevalent among prisoners than among 
the general population. Data from several studies carried 
out since 2006 show that there are considerable variations 
in the prevalence of drug use among prisoners: ever-use of 
an illicit drug before entering prison was reported by as 
few as 8 % of respondents in some countries and by up to 
65 % in others. Studies also indicate that the most harmful 
forms of drug use may be more frequent among prisoners, 
with between 5 % and 31 % of those surveyed reporting to 
have ever injected drugs (37).
On admission to prison, most users reduce or stop 
consuming drugs, mainly due to difficulties in acquiring 
the substances. However, the fact that illicit drugs find 
their way into most prisons, despite all the measures being 
taken to reduce their supply, is recognised. In studies 
carried out since 2006, estimates of levels of drug use 
within prison vary from 1 % to 51 % of inmates. The drug 
most frequently used by prisoners is cannabis, usually 
followed by cocaine and heroin (38). Prison may be a 
setting for initiation into drug use or into more harmful 
forms of use. For example, a Belgian study carried out in 
2008 found that more than a third of drug-using prisoners 
had initiated use of a new drug during detention, with 
heroin being the drug most frequently mentioned (Todts et 
al., 2009). Injecting drug users in custody appear to share 
their equipment more often than users in the community, 
which raises issues around the potential spread of 
infectious diseases among prison populations.
HIV and viral hepatitis among injecting drug users in prison
Data on HIV infection among injecting drug users in prison 
are scarce in Europe. In particular, they are unavailable for 
those countries reporting the highest prevalence levels of 
infection related to injecting drug use. Generally, among 
the eight countries providing data since 2004 (Bulgaria, 
Czech Republic, Spain, Hungary, Malta, Finland, Sweden, 
Croatia) (39), no large differences can be observed in HIV 
prevalence between injecting drug users in prison and those 
in other settings in the country, although this may be partly 
due to the limitations of the data. HIV prevalence among 
injecting drug users in prisons was mostly low (0 % to 7.7 %) 
in seven countries, while Spain reported a prevalence of 
39.7 %. Data on hepatitis C virus (HCV) prevalence among 
injecting drug users in prison were reported by eight 
countries, where it ranged from 11.5 % (Hungary) to 90.7 % 
(Luxembourg). In the Czech Republic, Luxembourg and 
Malta, HCV appears to be more prevalent among injectors 
Figure 4: Reports for offences related to drug use or possession 
for use and to drug supply in the EU Member States: indexed 
trends 2004–09 and breakdown by drug of reports for 2009
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NB: The trends are based on available information on the number 
of reports for drug law offences (criminal and non-criminal) 
reported in the EU Member States; all series are indexed to a 
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to form an overall EU trend; the breakdown by drugs refers to 
the total number of reports for 2009. For further information, see 
Figures DLO-4 and DLO-5 in the 2011 statistical bulletin.
Sources: Reitox national focal points.
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tested in prison compared with those tested in other settings. 
Data on HBV infection (hepatitis B surface antigen) among 
injecting drug users in prison are available for four countries: 
Bulgaria (11.6 % in 2006), the Czech Republic (15.1 % in 
2010), Hungary (0 % in 2009) and Croatia (0.5 % in 2007).
Prison health in Europe
Prisoners with a history of drug injecting, in particular, 
often have multiple and complex health needs, requiring 
a multi-disciplinary approach and specialist medical 
care. Prisoners are entitled to have access to the health 
services available in the country without discrimination on 
the grounds of their legal situation (40), and prison health 
services are expected to be able to provide treatment for 
problems related to drug use in conditions comparable 
to those offered outside prison (CPT, 2006). Although 
this general principle of equivalence is recognised in 
the European Union through Council Recommendation 
2003/488/EC of 18 June 2003 on the prevention and 
reduction of health-related harm associated with drug 
dependence (41), and the current EU drugs action plan 
(2009–12) calls for its implementation, the provision of 
services in prisons often lags behind that in the community.
Assistance to drug users in prison
A range of services related to drug use and its 
associated problems may be provided in European 
prisons. These include information on drugs and 
health, healthcare for infectious diseases, detoxification 
and treatment for drug dependence, combined with 
psychosocial assistance, harm-reduction measures and 
preparation for release (42).
Most countries have established interagency partnerships 
between prison health services and providers in the 
community, including non-governmental organisations, 
to deliver health education and treatment in prison and 
ensure continuity of care upon release. Several European 
countries have gone one step further and have placed 
prison health under the responsibility of the Ministry of 
Health or organised delivery of healthcare through public 
health services, in order to reduce health inequalities. 
Pioneers in this respect were Norway and France, followed 
by Sweden, Italy, England and Wales and Slovenia. In 
Scotland and Spain, this reform is currently underway.
Opioid substitution treatment is increasingly accepted 
in the community, but its adoption within prison settings 
has been slow and coverage is highly variable (43). In 
2009, drug users receiving substitution treatment in six 
EU countries (Estonia, Greece, Cyprus, Latvia, Lithuania, 
Slovakia) were unable to continue this treatment after 
arrest. Continuity and coherence of drug treatment 
between community and prison and vice versa is 
particularly important, given the high rates of overdose 
deaths on release (Merrall et al., 2010).
Hepatitis C in prison populations is a growing public health 
concern in Europe, and specific screening programmes are 
reported from Belgium, Bulgaria, France, some German 
Länder, Lithuania, Luxembourg, Hungary and Finland. 
Despite the importance of detecting these infections on 
prison entry (Sutton et al., 2006) and the documented cost-
effectiveness of providing HCV treatment in prison settings 
(Tan et al., 2008), many inmates go untested and untreated.
(40) UN General Assembly, Resolution A/RES/45/111, Basic principles for the treatment of prisoners (available online). 
(41) OJ L 165, 3.7.2003, p. 31.
(42) See Table HSR-7 in the 2011 statistical bulletin.
(43) See Table HSR-9 in the 2011 statistical bulletin.
Developing indicators on drug markets, crime 
and supply reduction in Europe
Scaling up the monitoring of illicit drug supply in Europe 
is a priority of the current EU drug strategy and action 
plan. Following the publication of a European Commission 
working paper on improving the collection of data on drug 
supply in October 2010 (1), the first European conference on 
drug supply indicators, organised jointly by the European 
Commission and the EMCDDA, initiated a process to 
develop indicators for monitoring drug supply in Europe (2).
The overall conceptual framework to monitor illicit drug 
supply in Europe will integrate three components: drug 
markets, drug-related crime and drug supply reduction. Three 
working groups, supported by the EMCDDA, will produce 
a roadmap for these areas in 2011, focusing on short-, 
medium- and long-term monitoring objectives. Attention will 
be paid to the potential for standardisation, extension and 
improvement of existing data collection systems in each of 
these areas, and targeted research will be carried out.
In the area of drug markets, future activities will focus on 
the improvement of drug price and purity datasets, and 
on the potential of forensic science data. The development 
of a European standard monitoring instrument on drug 
law offences and of indicators on intra-European drug 
production will be key in the drug-related crime area, 
together with defining priorities for research. Policing 
and criminal justice agencies will play a central role in 
monitoring drug supply reduction. Work in this under-
researched area will start with a mapping exercise to 
provide an overview of drug supply reduction activities in 
Europe. The existence, role and practices of specialised 
drug law enforcement units will be a starting point, with a 
survey launched by the EMCDDA in 2011.
(1) SEC(2010) 1216 final (available online).
(2) The conclusions of the conference are available online.
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Introduction
Cannabis is the illicit drug most widely available 
in Europe, where it is both imported and produced 
domestically. In most European countries, cannabis use 
increased during the 1990s and early 2000s. Europe may 
now be moving into a new phase, as data from general 
population and school surveys point to a stabilising or 
even decreasing trend in cannabis use in many countries. 
Levels of use, nevertheless, remain high by historical 
standards. The last few years have also seen a growing 
understanding of the public health implications of the 
long-term and widespread use of this drug, and rising 
levels of treatment demand for cannabis-related problems. 
Therefore, what constitutes an effective response to 
cannabis use remains a key question in the European 
debate on drugs.
Supply and availability
Production and trafficking
Cannabis can be cultivated in a wide range of 
environments and grows wild in many parts of the 
world. It has been estimated that cannabis is cultivated 
in 172 countries and territories (UNODC, 2009). The 
difficulties in arriving at accurate figures for global 
cannabis production are acknowledged in the UNODC’s 
most recent estimates, which place global production for 
2008 at between 13 300 and 66 100 tonnes of herbal 
cannabis and between 2 200 and 9 900 tonnes of 
cannabis resin.
Cannabis cultivation in Europe is widespread and 
appears to be increasing. All 29 European countries 
reporting information to the EMCDDA mentioned domestic 
cannabis cultivation, though the scale and nature of the 
Chapter 3
Cannabis
Table 3: Seizures, price and potency of herbal cannabis and resin
Cannabis resin Herbal cannabis Cannabis plants (1)
Global quantity seized 1 261 tonnes 6 022 tonnes n.a.
Quantity seized 
EU and Norway  
(Including Croatia and Turkey)
584 tonnes 
(594 tonnes)
57 tonnes 
(99 tonnes)
1.4 million plants and 42 tonnes
(1.4 million plants and 42 tonnes)  (2) 
Number of seizures 
EU and Norway 
(Including Croatia and Turkey)
400 000 
(405 000)
324 000 
(354 000)
25 000 
(25 100)
Mean retail price (EUR per gram) 
Range 
(Interquartile range) (3)
3–19 
(6.8–10.2)
2–70 
(6.3–10.9)
n.a. 
n.a.
Mean potency (THC content, %) 
Range 
(Interquartile range) (3)
3–17 
(4.3–11.5)
1–15 
(4.4–8.9)
n.a. 
n.a.
(1) Countries report the quantity seized either as a number of plants seized or by weight; the totals for both quantities are given here.
(2) The total amount of cannabis plants seized in 2009 is likely to be underestimated, largely due to the lack of recent data for the Netherlands, a country reporting 
relatively large seizures up to 2007. In the absence of 2008 and 2009 data, values for the Netherlands cannot be included in European estimates for 2009.
(3) Range of the middle half of the reported data.
NB: All data are for 2009; n.a., not applicable.
Sources: UNODC (2011) for global values, Reitox national focal points for European data.
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(44) The data on European drug seizures mentioned in this chapter can be found in Tables SZR-1 to SZR-6 in the 2011 statistical bulletin.
(45) Due to differences in shipment size and distances travelled, as well as the need to cross international borders, cannabis resin may be more at risk of 
being seized than domestically produced herbal cannabis.
(46) The analysis does not include the seizures reported by Turkey of 20.4 million plants in 2004, since data on quantities seized are not available for 
subsequent years.
phenomenon seem to vary considerably. A significant 
proportion of cannabis used in Europe is, nevertheless, 
likely to be the result of intraregional trafficking. The 
International Narcotics Control Board (2011b) mentioned 
Albania, Bulgaria, the former Yugoslav Republic of 
Macedonia, Moldova, Montenegro, Serbia and Ukraine 
as sources of the cannabis used in central and eastern 
Europe.
Herbal cannabis in Europe is also imported, mostly from 
Africa (e.g. Ghana, South Africa, Egypt), and less often 
from the Americas (especially the Caribbean islands), the 
Middle East (Lebanon) and Asia (Thailand).
A recent survey suggests that Afghanistan has displaced 
Morocco as the largest producer of cannabis resin. 
Production of cannabis resin in Afghanistan is estimated 
at between 1 200 and 3 700 tonnes a year (UNODC, 
2011). Although some of the cannabis resin produced in 
Afghanistan is sold in Europe, it is likely that Morocco 
remains Europe’s main supplier of this drug. Cannabis 
resin from Morocco is typically smuggled into Europe 
primarily through the Iberian Peninsula, with the 
Netherlands and Belgium having a role as a secondary 
distribution and storage centre (Europol, 2011).
Seizures
In 2009, an estimated 6 022 tonnes of herbal cannabis 
and 1 261 tonnes of cannabis resin were seized 
worldwide (Table 3), an overall decrease of about 11 % 
over the previous year. North America continued to 
account for the bulk of herbal cannabis seized (70 %), 
while quantities of resin seized remained concentrated in 
western and central Europe (48 %) (UNODC, 2011).
In Europe, an estimated 354 000 seizures of herbal 
cannabis were made in 2009, amounting to an estimated 
99 tonnes, of which Turkey accounted for over one 
third (42 tonnes), a record amount; in addition, record 
seizures were reported by Greece (7 tonnes) and Portugal 
(5 tonnes) (44). Between 2004 and 2009, the total number 
of seizures doubled and the amount of herbal cannabis 
seized also increased. Since 2005, the United Kingdom 
has accounted for about half of the total number of 
seizures, amounting to a minimum of about 20 tonnes per 
year.
Seizures of cannabis resin in Europe continued to exceed 
herbal cannabis seizures, both in number and amount 
seized, although the difference is decreasing (45). In 2009, 
about 405 000 seizures of cannabis resin were made, 
resulting in the interception of an estimated 594 tonnes of 
the drug, six times the quantity of herbal cannabis seized. 
Between 2004 and 2009, the number of cannabis resin 
seizures increased steadily, while the total amount seized 
has been declining from a peak of 1 080 tonnes in 2004. 
In 2009, similar to other years, Spain reported half of 
the total number of cannabis resin seizures and about 
three quarters of the quantity seized.
The number of seizures of cannabis plants has increased 
since 2004, reaching an estimated 25 100 cases in 2009. 
Countries report the quantity seized either as an estimate of 
the number of plants seized or by weight. Seizures reported 
by number of plants increased from 1.7 million in 2004 
to about 2.5 million in 2005–07 in Europe (46). Available 
data may point to a decrease in 2008 at European level, 
but current trends in reported numbers of cannabis plants 
seized cannot be plotted due to the lack of recent data 
from the Netherlands, a country historically reporting large 
quantities. Since 2004, seizures reported by weight of 
plants have more than trebled, reaching 42 tonnes in 2009, 
most of which continued to be accounted for by Spain 
(29 tonnes) and Bulgaria (10 tonnes).
Potency and price
The potency of cannabis products is determined by their 
content of delta-9-tetrahydrocannabinol (THC), the primary 
active constituent. Cannabis potency varies widely 
between and within countries, between different cannabis 
products and between genetic varieties. Information on 
cannabis potency is mainly based on forensic analysis of 
selected samples of cannabis seized. The extent to which 
the samples analysed reflect the overall market is unclear, 
and for this reason, data on potency should be interpreted 
with caution.
In 2009, the reported mean THC content of cannabis 
resin ranged from 3 % to 17 %. The mean potency of 
herbal cannabis (including sinsemilla — the form of herbal 
cannabis with the highest potency) ranged from 1 % to 
15 %. The mean potency of sinsemilla was reported by 
only three countries: 2 % in Romania, 11 % in Germany 
and 15 % in the Netherlands. Over the period 2004–09, 
the mean potency of cannabis resin has been diverging in 
the 15 countries reporting sufficient data. The potency of 
herbal cannabis remained relatively stable or decreased 
in 10 reporting countries, and increased in the Czech 
Republic, Estonia, the Netherlands and Slovakia. Trend 
data on the potency of locally produced herbal cannabis 
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(47) See Tables PPP-1 and PPP-5 in the 2011 statistical bulletin for potency and price data. For definitions of cannabis products, see the online glossary. 
(48) See Figure GPS-1 in the 2011 statistical bulletin.
(49) See Table GPS-5 (part iii) and (part iv) in the 2011 statistical bulletin.
are available only for the Netherlands, where a decline 
in the mean potency of ‘nederwiet’ was observed: from a 
peak of 20 % in 2004 to 15 % in 2009 (47).
The mean retail price of cannabis resin, in 2009, ranged 
from EUR 3 to EUR 19 per gram in the 18 countries 
providing information, with 12 countries reporting prices 
between EUR 7 and EUR 10. The mean retail price of 
herbal cannabis ranged between EUR 2 and EUR 70 per 
gram in the 20 countries supplying information, with 12 
of them reporting prices of between EUR 5 and EUR 10. 
Over the period 2004–09, the mean retail price of both 
cannabis resin and herb remained stable or increased 
in most of the 18 countries providing data, with the 
exceptions being Latvia, Hungary and Poland, where the 
price of resin decreased.
Prevalence and patterns of use
Cannabis use among the general population
It is conservatively estimated that cannabis has been 
used at least once (lifetime prevalence) by about 78 
million Europeans, that is over one in five of all 15- to 
64-year-olds (see Table 4 for a summary of the data). 
Considerable differences exist between countries, with 
national prevalence figures varying from 1.5 % to 32.5 %. 
For most of the countries, the prevalence estimates are in 
the range of 10–30 % of all adults.
An estimated 22.5 million Europeans have used cannabis 
in the last year, or on average 6.7 % of all 15- to 64-year-
olds. Estimates of last month prevalence will include those 
using the drug more regularly, though not necessarily in a 
daily or intensive way. It is estimated that about 12 million 
Europeans used the drug in the last month, on average 
about 3.6 % of all 15- to 64-year-olds.
Cannabis use among young adults
Cannabis use is largely concentrated among young 
people (15–34 years), with the highest prevalence of last 
year use generally being reported among 15- to 24-year-
olds. This is the case in all the reporting countries, with the 
exception of Cyprus and Portugal (48).
Population survey data suggest that, on average, 32.0 % 
of young European adults (15–34 years) have ever used 
cannabis, while 12.1 % have used the drug in the last 
year and 6.6 % have used it in the last month. Still higher 
proportions of Europeans in the 15–24 age group are 
estimated to have used cannabis in the last year (15.2 %) 
or last month (8.0 %). National prevalence estimates 
of cannabis use vary widely between countries in all 
measures of prevalence. For example, estimates of last 
year prevalence of use among young adults in countries at 
the upper end of the scale are more than 20 times those of 
the lowest-prevalence countries.
Cannabis use is generally higher among males, with, 
for example, the ratio of males to females among young 
adults reporting use of cannabis in the last year ranging 
from just over six to one in Portugal to just under unity in 
Norway (49).
International comparisons
Figures from Australia, Canada and the United States 
on lifetime and last year use of cannabis among young 
adults are all above the European averages, which are 
32.0 % and 12.1 % respectively. For instance, in Canada 
(2009) lifetime prevalence of cannabis use among young 
adults was 48.4 % and last year prevalence 21.6 %. In 
the United States, SAMHSA (2010) estimated a lifetime 
prevalence of cannabis use of 51.6 % (16–34 years, 
recalculated by the EMCDDA) and a last year prevalence 
of 24.1 %, while in Australia (2007) the figures are 
46.7 % and 16.2 % for the 14- to 39-year-olds. Among 
15- to 16-year-old school students, a small number of 
European countries (Czech Republic, Spain, France, 
Slovakia) report levels of lifetime prevalence of cannabis 
use that are comparable to those reported in Australia and 
the United States.
Cannabis use among school students
The ESPAD survey, carried out every four years, provides 
comparable data on alcohol and drug use among 15- to 
16-year-old school students in Europe (Hibell et al., 2009). 
In 2007, the survey was conducted in 25 EU Member 
States as well as Norway and Croatia. In addition, in 
2009–10, national school surveys were carried out by 
Italy, Slovakia, Sweden and the United Kingdom.
The data from the 2007 ESPAD and 2009–10 national 
school surveys reveal that the highest lifetime prevalence 
of cannabis use among 15- to 16-year-old school 
students is in the Czech Republic (45 %), while Estonia, 
Spain, France, the Netherlands, Slovakia and the United 
Kingdom (England) report prevalence levels ranging from 
26 % to 33 %. Lifetime prevalence levels of cannabis use 
of between 13 % and 25 % are reported by 15 countries. 
The lowest levels (less than 10 %) are reported in Greece, 
Cyprus, Romania, Finland, Sweden and Norway.
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(50) See Table EYE-20 (part ii) and (part iii) in the 2011 statistical bulletin.
The gender gap in cannabis use is less marked among 
school students than among young adults. Male to female 
ratios for cannabis use among school students range from 
close to unity in Spain and the United Kingdom to two to 
one or higher in Cyprus, Greece, Poland and Romania (50).
Trends in cannabis use
During the late 1990s and early 2000s, many European 
countries reported increases in cannabis use, both in 
general population surveys and in school surveys. Since 
then, the European picture has become more complex. 
Many countries report that cannabis use is stabilising 
or even decreasing, while a small number of countries 
(Bulgaria, Estonia, Finland, Sweden) may be witnessing 
an increase. While almost all European countries have 
carried out general population surveys in recent years, 
only 16 countries have provided sufficient data to analyse 
trends in cannabis use over a longer period of time.
Trends in these 16 countries can be grouped according to 
prevalence levels (Figure 5). First, a group of six countries 
(Bulgaria, Greece, Hungary, Finland, Sweden, Norway), 
located mainly in northern and south-eastern Europe, have 
Table 4: Prevalence of cannabis use in the general population — summary of the data
Age group Time frame of use
Lifetime Last year Last month
15–64 years
Estimated number of users in Europe 78 million 22.5 million 12 million
European average 23.2 % 6.7 % 3.6 %
Range 1.5–32.5 % 0.4–14.3 % 0.1–7.6 %
Lowest-prevalence countries Romania (1.5 %)
Malta (3.5 %)
Bulgaria (7.3 %)
Hungary (8.5 %)
Romania (0.4 %)
Malta (0.8 %)
Greece (1.7 %)
Hungary (2.3 %)
Romania (0.1 %)
Malta (0.5 %)
Greece, Poland (0.9 %)
Sweden (1.0 %)
Highest-prevalence countries Denmark (32.5 %)
Spain (32.1 %)
Italy (32.0 %)
France, United Kingdom (30.6 %)
Italy (14.3 %)
Czech Republic (11.1 %)
Spain (10.6 %)
France (8.6 %)
Spain (7.6 %)
Italy (6.9 %)
France (4.8 %)
Czech Republic (4.1 %) 
15–34 years
Estimated number of users in Europe 42 million 16 million 9 million
European average 32.0 % 12.1 % 6.6 %
Range 2.9–45.5 % 0.9–21.6 % 0.3–14.1 %
Lowest-prevalence countries Romania (2.9 %)
Malta (4.8 %)
Greece (10.8 %)
Bulgaria (14.3 %)
Romania (0.9 %)
Malta (1.9 %)
Greece (3.2 %)
Poland (5.3 %)
Romania (0.3 %)
Greece (1.5 %)
Poland (1.9 %)
Sweden, Norway (2.1 %)
Highest-prevalence countries Czech Republic (45.5 %)
Denmark (44.5 %)
France (43.6 %)
Spain (42.4 %)
Czech Republic (21.6 %) 
Italy (20.3 %)
Spain (19.4 %)
France (16.7 %)
Spain (14.1 %)
Italy (9.9 %)
France (9.8 %)
Czech Republic (8.6 %)
15–24 years
Estimated number of users in Europe 19 million 9.5 million 5 million
European average 30.0 % 15.2 % 8.0 %
Range 3.7–53.8 % 1.5–29.5 % 0.5–17.2 %
Lowest-prevalence countries Romania (3.7 %)
Malta (4.9 %)
Greece (9.0 %)
Cyprus (14.4 %)
Romania (1.5 %)
Greece (3.6 %)
Portugal (6.6 %)
Slovenia, Sweden (7.3 %)
Romania (0.5 %)
Greece (1.2 %)
Sweden (2.2 %)
Norway (2.3 %)
Highest-prevalence countries Czech Republic (53.8 %)
France (42.0 %)
Spain (39.1 %)
Denmark (38.0 %)
Czech Republic (29.5 %)
Spain (23.9 %)
Italy (22.3 %)
France (21.7 %)
Spain (17.2 %)
France (12.7 %)
Czech Republic (11.6 %)
Italy (11.0 %)
European estimates are computed from national prevalence estimates weighted by the population of the relevant age group in each country. To obtain estimates of the overall 
number of users in Europe, the EU average is applied for countries lacking prevalence data (representing not more than 3 % of the target population). Populations used as basis: 
15–64, 336 million; 15–34, 132 million; 15–24, 63 million. As European estimates are based on surveys conducted between 2001 and 2009/10 (mainly 2004–08), they do not 
refer to a single year. The data summarised here are available under ‘General population surveys’ in the 2011 statistical bulletin.
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always reported low last year prevalence of cannabis use 
among 15- to 34-year-olds, at levels not exceeding 10 %. 
Secondly, a group of five countries (Denmark, Germany, 
Estonia, Netherlands, Slovakia), located in different parts of 
Europe, report higher prevalence levels, but not exceeding 
15 % in their latest survey. All of the countries in this group, 
except the Netherlands, reported notable increases of 
cannabis use in the 1990s and early 2000s. With the 
exception of Estonia, this group of countries reported an 
increasingly stable trend in the following decade. Finally, 
there is a group of five countries that have all, at some 
point in the past 10 years, reached the highest levels of 
cannabis use in Europe, with last year use among young 
adults in the region of 20 % and higher. These are countries 
in the south and west of Europe (France, Spain, Italy, United 
Kingdom) and the Czech Republic. In this group, trends may 
be diverging. While the United Kingdom and, to a lesser 
extent, France have reported decreases in their most recent 
surveys, Spain has reported a relatively stable situation 
since 2003. All three had reported increases in cannabis 
use during the 1990s. Italy and the Czech Republic have 
both reported increases followed by decreases in recent 
years. Differences in survey methods and response rates, 
however, do not yet allow confirmation of the most recent 
trends in these two countries.
It is worth noting the particular case of the United 
Kingdom, where surveys are conducted annually. After a 
history of the highest levels of cannabis use in Europe at 
the beginning of the 2000s, in 2010 last year prevalence 
of cannabis use fell below the EU average for the first time 
since EU monitoring began.
The recorded stabilisation or decrease in cannabis use 
refers to last year use, which includes recreational patterns 
of use. However, it is not clear whether intensive and long-
term use have also stabilised.
Similar patterns were found across Europe in the time 
trends in cannabis use among school students between 
1995 and 2007 (EMCDDA, 2009a). Seven countries, 
located mainly in northern or southern Europe, reported 
overall stable and low lifetime prevalence of cannabis 
use during the whole period. Most western European 
countries, as well as Slovenia and Croatia (11 countries), 
which had high or strongly increasing lifetime cannabis 
use prevalence until 2003, saw a decrease or stabilisation 
in 2007. In most of central and eastern Europe, the 
increasing trend observed between 1995 and 2003 
appears to have levelled out. In this region, six countries 
reported a stable situation and two an increase between 
2003 and 2007.
New school survey data from the latest HBSC (‘Health 
behaviour in school-aged children’) surveys also point to 
an overall stable or decreasing trend in drug use among 
students (15–16 years) in most countries during the period 
2006–10. Mirroring the trend among adults, in England, 
lifetime cannabis use among school students has almost 
halved from 40 % in 2002 to 22 % in 2010. In Germany, 
lifetime cannabis use among school students has also 
Figure 5: Trends in last year prevalence of cannabis use among young adults (aged 15–34), countries with three surveys or more and 
grouped according to highest prevalence level (below 10 %, 10–15 %, above 15 %)
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(51) See Figure EYE-2 (part vi) in the 2011 statistical bulletin.
(52) See Figure GPS-2 in the 2011 statistical bulletin.
halved, from 24 % in 2002 to 11 % in 2010. However, 
increases have been recorded since 2006 in the Czech 
Republic, Greece, Latvia, Lithuania, Romania and Slovenia.
Long-term trend data from school surveys in Australia 
and the United States also indicate a decreasing trend 
in cannabis use up to 2009 (51). However, the most 
recent US school survey, carried out in 2010, indicates a 
possible resurgence in cannabis use, with school students 
reporting increased last year cannabis use and lower 
levels of disapproval of the drug (Johnston et al., 2010). 
In the 2010 survey, American school students aged 15- to 
16-years-old reported levels of use of cannabis higher 
than those of cigarette smoking, on some measures: 
16.7 % had used cannabis in the past month, while only 
13.6 % had smoked cigarettes (Johnston et al., 2010).
The picture is different among school students in Europe, 
where levels of last month cigarette smoking remain 
considerably higher than those for cannabis use. Between 
2003 and 2007, ESPAD school surveys in 23 EU countries 
reported an overall reduction in last month cigarette 
smoking (from 33 % to 28 %) and a reduction, or at 
least a stabilisation, in cannabis use (from 9 % to 7 %) 
(Figure 6). In Europe, where cannabis and tobacco are 
commonly mixed together for smoking, decreases in 
tobacco smoking may exert some influence on cannabis 
trends.
Patterns of cannabis use
Available data point to a variety of patterns of cannabis 
use, ranging from experimental use to dependent use. 
Many individuals tend to discontinue their cannabis use 
after one or two experiments; others use it occasionally or 
during a limited period of time. Of those aged 15–64 who 
have ever used cannabis, 70 % have not done so during 
the last year (52). Among those who have used the drug in 
the last year, on average, nearly half have done so in the 
last month, possibly indicating more regular use. These 
proportions, however, vary considerably across countries 
and between genders.
Cannabis use is particularly high among certain groups 
of young people, for instance, those frequently attending 
nightclubs, pubs and music events. Targeted surveys 
recently conducted in nightlife or dance music settings in 
Belgium, the Czech Republic, the Netherlands, Lithuania 
and the United Kingdom reported prevalence levels that 
are much higher than the European average among 
young adults. Cannabis use is also often associated with 
heavy alcohol use: among young adults (aged 15 to 34), 
frequent or heavy alcohol users were, in general, between 
two and six times more likely to report the use of cannabis 
compared with the general population.
The types of cannabis product and the ways they are used 
can have different associated risks. Patterns of cannabis use 
that result in high doses being consumed may put the user 
Looking for a relationship between penalties 
and cannabis use
Over the past 10 years, a number of European countries 
have changed their drug laws regarding cannabis, and 
many of these have prevalence estimates for the use of the 
drug before and after the legal change. A simple before–
after comparison using these data can explore whether an 
observable change in prevalence can be seen in the years 
after law change. As cannabis use is concentrated among 
the younger age groups, the analysis was performed using 
prevalence data for 15- to 34-year-olds. In the graph, last 
year cannabis prevalence is plotted against time, with 
zero on the horizontal axis representing the year of legal 
change. Because of differences between countries in the 
year in which they changed their laws and in the extent of 
their survey data, the trend lines cover varying times.
Countries increasing the penalty for cannabis possession 
are represented in the graph by dotted lines, and those 
reducing the penalty by solid lines. The legal impact 
hypothesis, in its simplest form, states that a change in the 
law will lead to a change in prevalence, with increased 
penalties leading to a fall in drug use and reduced 
penalties to a rise in drug use. On this basis, the dotted 
lines would fall and the solid lines would rise after the 
change. However, in this 10-year period, for the countries 
in question, no simple association can be observed 
between legal changes and cannabis use prevalence.
NB:  Legal changes took place in 2001–06; see Chapter 1 and 
ELDD Topic overview on possession.
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at greater risk of developing dependence or other problems 
(Chabrol et al., 2003; Swift et al., 1998). Examples of these 
practices include using cannabis with very high THC content 
or in large amounts, and inhaling from a water pipe.
General population surveys seldom distinguish between 
use of different types of cannabis. However, in 2009 new 
questions were introduced in a UK general population 
survey to identify the prevalence of the use of herbal 
cannabis, including ‘skunk’ (the street name given to a 
generally high potency form of the drug). The 2009/10 
British Crime Survey estimates that around 12.3 % of adults 
have ever taken what they believed to be ‘skunk’. While 
similar proportions of cannabis users report lifetime use of 
herbal cannabis (50 %) and cannabis resin (49 %), those 
using the drug in the last year are more likely to have 
used herbal cannabis (71 %) than resin (38 %) (Hoare and 
Moon, 2010). While these estimates cannot be generalised 
to other populations in Europe, the findings illustrate some 
changes in cannabis consumption over time.
Data from a sample of 14 European countries accounting 
for 65 % of the adult population of the European Union 
and Norway show that almost half of those who used 
cannabis in the last month had consumed the drug on one 
to three days during that month, about one third on 4 to 
19 days and one fifth on 20 days or more. In most of these 
14 countries, females are more likely to use cannabis on 
an occasional basis, while the majority of daily or almost 
daily cannabis users are male (Figure 7). Based on these 
figures, male users in many countries appear to be at 
particular risk of becoming frequent users, and this should 
be considered when developing prevention activities.
New data on drug use among adolescents show that daily 
cannabis use is also a growing problem in the United 
States. Prevalence of daily use of cannabis increased 
significantly, to 6 % among 17- to 18-year-old high school 
students in 2010 (Johnston et al., 2010).
Dependence is increasingly recognised as a possible 
consequence of regular cannabis use, even among 
younger users, and the number of individuals seeking help 
due to their cannabis use is growing in some European 
countries (see below). It has, however, been reported that 
half of dependent cannabis users who stopped using the 
drug were able to do so without treatment (Cunningham, 
2000). Some cannabis users — particularly, heavy users 
— can experience problems without necessarily fulfilling 
the clinical criteria for dependence.
Figure 6: Trends in last month prevalence of cannabis use and 
cigarette smoking among 15- to 16-year-old school students in 
17 European countries and the United States
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16-year-old school students in 15 EU countries together with 
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 US school student average is based on a sample of about 
16 000 10th grade students (aged 15–16).
Sources: Hibell et al. (2009), Johnston et al. (2010).
Figure 7: Prevalence of daily or almost daily cannabis use among 
young adults (aged 15–34), by gender 
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NB: Those that declared having used cannabis in 20 days or more in 
the 30 days previous to the interview are referred to as ‘daily or 
almost daily users’ in the texts. For more information, see Table 
GPS-10 (part iv) in the 2011 statistical bulletin.
Sources: Reitox national focal points.
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(53) See Figure TDI-2 (part ii) and Tables TDI-5 (part ii) and TDI-22 (part i) in the 2011 statistical bulletin. 
(54) In addition, many opioid users in France are treated by general practitioners and are not reported to the treatment demand indicator, thereby 
inflating the proportions of users of other drugs.
(55) See Figure TDI-1 (part i) and (part ii) in the 2011 statistical bulletin.
(56) See Tables TDI-10 (part ii) and (part iii), TDI-11 (part i), TDI-18 (part ii), TDI-21 (part ii), TDI-24, TDI-103 (part vii) and TDI-111 (part viii) in the 2011 
statistical bulletin.
Treatment demand
In 2009, cannabis was the primary drug of about 98 000 
reported treatment entrants in 26 countries (23 % of the 
total), making it the second most reported drug after 
heroin. Cannabis was also the most reported secondary 
drug, mentioned by around 93 000 clients (28 %). 
Primary cannabis users account for more than 30 % of 
treatment entrants in Belgium, Denmark, Germany, France, 
Hungary, the Netherlands and Poland, but less than 10 % 
in Bulgaria, Estonia, Greece, Lithuania, Malta, Romania 
and Slovenia (53).
Differences in the prevalence of cannabis use and its 
related problems are not the only factors explaining the 
differences in treatment levels between countries. Other 
factors, such as referral practices and the level and type 
of treatment provision are also important. Examples of 
this are evident in France and Hungary, two countries 
that report a high proportion of cannabis users entering 
treatment. France has a system of counselling centres, 
which target young clients (54). In Hungary, cannabis 
offenders are offered drug treatment as an alternative to 
punishment, which can swell the numbers.
In terms of trends over the last 10 years, among the 
21 countries for which data are available, all countries, 
except Bulgaria, report an increase in the proportion 
of clients entering treatment for the first time in their life 
because of cannabis use. For the period 2004–09, in the 
18 countries for which data are available, the number of 
primary cannabis users among those reported entering 
treatment for the first time in their life increased by about 
40 % from 27 000 to 38 000 (55). The most recent 
figures (2008–09) show a continuing upward trend in the 
majority of reporting countries.
Profile of treatment clients
Cannabis clients mainly enter treatment in outpatient 
settings and are reported to be one of the youngest 
client groups entering treatment, with a mean age of 
25 years. Young people citing cannabis as their primary 
drug represent 74 % of reported treatment entrants aged 
15–19 years and 86 % of those younger than 15 years. 
The male to female ratio is the highest among drug clients 
(about five males to every female). Overall, 49 % of 
primary cannabis clients are daily users, about 18 % use 
it two to six times a week, 12 % use cannabis weekly or 
less often and 22 % are occasional users, some of whom 
have used it in the month before entering treatment. These 
proportions differ between countries (56).
Treatment
Treatment provision
In Europe, cannabis treatment includes a broad range of 
measures including Internet-based treatment, counselling 
and structured psychosocial interventions and treatment 
in residential settings. There is also a frequent overlap 
between selective and indicated prevention and treatment 
interventions (see Chapter 2).
Cannabis treatment is mainly provided in specialist 
outpatient facilities, and services specifically targeting 
cannabis-related problems are now available in more 
than half of the Member States. For example, more than 
300 youth counselling centres have been set up across 
France to cater primarily for the needs of young users with 
cannabis problems. In Germany, alongside several specific 
cannabis programmes, 161 counselling centres have 
adopted the programme ‘Realize it’, which requires clients 
to set goals for controlling consumption and addresses 
individual and environmental factors associated with their 
cannabis use. The intervention is delivered in five sessions 
Adverse health effects of cannabis use
The individual health risk related to cannabis use is 
generally accepted to be lower than those associated with 
drugs such as heroin or cocaine. However, due to the high 
prevalence of cannabis use, the impact of the drug on 
public health may be significant.
A range of acute and chronic health problems associated 
with cannabis use have been identified. Acute adverse 
effects include anxiety, panic reaction and psychotic 
symptoms, which may be more commonly reported by 
first-time users. Cannabis use can also increase the risk of 
being involved in a traffic accident.
Chronic effects linked to cannabis use have been 
documented, including dependence and a number of 
respiratory diseases. The impact of cannabis use on 
cognitive performance remains unclear. Regular cannabis 
use in adolescence might adversely affect mental health 
in young adults, and there is evidence of increased risks 
of psychotic symptoms and disorders with increasing 
frequency of use (EMCDDA, 2008a, 2008b; Hall and 
Degenhardt, 2009; Moore et al., 2007).
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over a period of 10 weeks to up to 1 400 cannabis 
users per year. In Hungary, the large majority (80 %) of 
cannabis clients attend preventive consulting services. 
These services are provided by accredited organisations.
Germany and the Netherlands have been particularly active 
in the development of cannabis programmes. Cannabis 
problems are commonly associated with other substance 
or psychosocial problems, and this is reflected in the types 
of programme available to cannabis users. For example, 
the Amsterdam Medical Centre has developed a family 
motivational intervention for young cannabis users with 
schizophrenia and their parents (Dutch Reitox national 
report, 2009). A randomised controlled trial has shown 
positive results for this intervention. After three months, 
the young people involved in the trial reported reduced 
cannabis use and craving, while the parents reported 
reduced stress and improved well-being. Cases involving the 
co-occurrence of cannabis use and psychiatric problems, 
such as psychosis or depression, require integrated 
approaches between specialised treatment providers and 
mental health centres. In practice, however, treatment 
of dual diagnoses is still often handled sequentially and 
cooperation between care providers remains difficult.
A recent German study predicts increasing numbers 
seeking treatment for problems related to cannabis use 
in future years, especially among male adolescents and 
young adults. Currently, estimates of the proportion of drug 
users reached by drug facilities in Germany show that, 
although specialised addiction services are able to reach 
between 45 % and 60 % of users with opioid dependence, 
only between 4 % and 8 % of cannabis users estimated 
to be in need of treatment are reached. In some cases, 
Internet-based interventions, which are now available 
in three Member States, may provide further treatment 
options to cannabis users who seek support but who are 
reluctant to approach traditional treatment services.
Recent studies on treatment of cannabis users
Treatment evaluation studies are still scarce in comparison 
with those for other illicit drugs, in spite of the increasing 
demand for cannabis treatment. Research is nevertheless 
increasing in Europe, with studies currently being conducted 
in Germany, Denmark, Spain, France and the Netherlands.
A number of these studies confirm that psychosocial 
interventions can have positive results with cannabis 
users. This is the case, for example, for multidimensional 
family therapy, a comprehensive family-based outpatient 
intervention targeting adolescents with drug use 
and behaviour problems (Liddle et al., 2009), which 
reported success in reducing levels of drug consumption. 
Conclusions from a comparison with other available 
treatments in a cross-country multisite trial were, however, 
unclear. This has prompted the EMCDDA to commission a 
meta-analysis of European and American studies.
Other psychosocial interventions that are currently 
being evaluated include psycho-education (based on 
behavioural therapeutic and motivational interviewing 
elements) and relapse prevention, brief interventions, 
contingency management and various types of cognitive 
behavioural therapy.
Research is also being conducted on pharmacological 
products that may support psychosocial interventions 
(Vandrey and Haney, 2009). In this area, the three 
principal lines of research currently being followed 
investigate the possibilities of using pharmaceuticals to 
help reduce cannabis withdrawal symptoms, craving or 
use (Marshall, K., et al., 2011).
Medical use of cannabis in the United States
Since 1996, 15 US states and the District of Columbia have 
passed laws permitting personal possession of a defined 
amount of cannabis for medical use. The patient must 
have a written recommendation from a doctor in all states 
except California and Maine, where the recommendation 
can be oral. All states except Washington have established 
confidential registries with patient identity cards, and in a 
number of states these are mandatory. While each state 
has its own list of conditions, most states allow cannabis 
use to treat pain, whether ‘chronic’, ‘severe’ or ‘intractable’.
Almost all states have adopted the caregiver model, 
whereby a designated person is permitted to grow a 
limited quantity of cannabis for the use of the patient. 
Depending on the state, patients may designate one or two 
caregivers, and caregivers may supply up to five patients. 
The amounts permitted range from 1 ounce — about 
28 grams — (Alaska, Montana, Nevada) to 24 ounces 
(Oregon, Washington) of usable herbal cannabis, and 
from six to 24 plants, some of which should be ‘immature’. 
Provision of cannabis for medical use by not-for-profit 
dispensaries or state treatment centres is permitted in about 
half of the states. In all but two jurisdictions, New Jersey 
and Washington DC, patients are allowed to grow their 
own medicinal cannabis.
Federal law, in contrast, classifies cannabis as a dangerous 
substance with no medical use. This allows the federal 
government to prosecute any users and suppliers of 
cannabis. However, in October 2009, the Deputy Attorney 
General issued a memo to federal prosecutors not to 
prioritise the prosecution of cases relating to medical use 
of cannabis if authorised under state law.
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Introduction
Amphetamines (a generic term that includes both 
amphetamine and methamphetamine) and ecstasy are 
among the most commonly used illicit drugs in Europe. 
In many countries, either ecstasy or amphetamines 
is the second most commonly used illicit substance 
after cannabis. In addition, in some countries, use of 
amphetamines constitutes an important part of the drug 
problem, accounting for a substantial proportion of those 
in need of treatment.
Amphetamine and methamphetamine are central nervous 
system stimulants. Of the two drugs, amphetamine is by 
far the more commonly available in Europe, whereas 
significant methamphetamine use has historically been 
restricted to the Czech Republic and Slovakia. More 
recently, there have been reports of the increased 
presence of this drug on the amphetamines market in some 
countries in the north of Europe.
Ecstasy refers to synthetic substances that are chemically 
related to amphetamines, but which differ to some extent 
in their effects. The best-known member of the ecstasy 
group of drugs is 3,4-methylenedioxy-methamphetamine 
(MDMA), but other analogues are also sometimes found in 
ecstasy tablets (MDA, MDEA). The drug’s popularity has 
historically been linked with the dance music scene. While 
still popular in these settings, recent years have seen a 
gradual decline in use and availability of ecstasy in many 
European countries.
The most widely known synthetic hallucinogenic drug in 
Europe is lysergic acid diethylamide (LSD), consumption 
of which has been low and somewhat stable for a 
considerable time. In recent years, there appears to 
have been a growing interest among young people in 
naturally occurring hallucinogens such as those found 
in hallucinogenic mushrooms. Since the mid-1990s, 
recreational use of ketamine and gamma-hydroxybutyrate 
(GHB) — both anaesthetics, and widely used in human 
and veterinary medicine for 30 years — has been 
reported in certain settings and among sub-groups of drug 
users in Europe. The illicit use of these substances has 
become a cause for concern for treatment services in a 
limited number of European countries.
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Table 5: Seizures, price and purity of amphetamine, methamphetamine, ecstasy and LSD
Amphetamine Methamphetamine Ecstasy LSD
Global quantity seized  
(tonnes)
33 31 5.4 0.1 
Quantity seized 
EU and Norway  
(Including Croatia and Turkey) (1)
 
5.3 tonnes 
(6.5 tonnes)
 
500 kg 
(600 kg)
Tablets 
1.9 million 
(2.4 million)
Units 
59 700 
(59 700)
Number of seizures  
EU and Norway  
(Including Croatia and Turkey)
 
34 000 
(34 200)
 
7 400 
(7 400)
 
10 300 
(11 000)
 
960 
(970)
Mean retail price (EUR) 
Range 
(Interquartile range) (2)
Gram 
8–42 
(10–23)
Gram 
9–71
Tablet 
3–16 
(4–9)
Dose 
4–29 
(7–11)
Mean purity or MDMA content 
Range 
(Interquartile range) (2)
 
1–29 % 
(6–21 %)
 
10–76 % 
(25–64 %)
 
3–108 mg 
(26–63 mg)
 
n.a.
(1) The total amounts of amphetamine, ecstasy and LSD seized in 2009 are likely to be underestimated, largely due to the lack of recent data for the Netherlands, a country 
reporting relatively large seizures up to 2007. In the absence of 2008 and 2009 data, values for the Netherlands cannot be included in European estimates for 2009.
(2) Range of the middle half of the reported data.
NB: All data are for 2009; n.a., not available.
Source: UNODC (2011) for global values, Reitox national focal points for European data.
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(57) See the box ‘Diversifying the supply of precursors for synthetic drug production in Europe’.
Supply and availability
Drug precursors
Amphetamine, methamphetamine and ecstasy are 
synthetic drugs requiring chemical precursors in the 
manufacturing process. Insights into the production of 
these substances can be gleaned from reports of seizures 
of controlled chemicals — diverted from licit trade — that 
are necessary for their manufacture. 
The International Narcotics Control Board (INCB) reports 
that global seizures of 1-phenyl-2-propanone (P2P, BMK), 
which can be used for the illicit manufacture of both 
amphetamine and methamphetamine, decreased from 
5 620 litres in 2008 to 4 900 litres in 2009, with China 
(2 275 litres in 2009) and Russia (1 731 litres in 2009) 
continuing to report the highest seizures. In the European 
Union, seizures of P2P increased from 62 litres in 2008 to 
635 litres in 2009. World seizures of two key precursors 
of methamphetamine have also increased in 2009: 
ephedrine, to 42 tonnes, from 18 tonnes in 2008 and 
22.6 tonnes in 2007; and pseudoephedrine, to 7.2 tonnes, 
from 5.1 tonnes in 2008, though still below the 25 tonnes 
seized in 2007. EU Member States accounted for about 
0.5 tonnes of ephedrine, almost double the amount seized 
the year before, and for 67 kg of pseudoephedrine.
Two precursor chemicals are primarily associated with 
the manufacture of MDMA: 3,4-methylenedioxyphenyl-2-
propanone (3,4-MDP2P, PMK) and safrole. The 40 litres 
of PMK seized in 2009, up from zero in 2008, could 
suggest that the availability of this substance remains low. 
This is in contrast to the higher levels recorded in earlier 
years (8 816 litres in 2006, 2 297 litres in 2007). World 
seizures of safrole, which may be increasingly replacing 
PMK in the synthesis of MDMA in Europe, fell to 1 048 
litres in 2009 from a peak of 45 986 litres in 2007 (57). 
All of the PMK and most of the safrole confiscations in 
2009 were made in the European Union.
International efforts to prevent the diversion of precursor 
chemicals used in the illicit manufacture of synthetic drugs 
are coordinated through ‘Project Prism’. The project uses 
a system of pre-export notifications for licit trade, and the 
reporting of shipments stopped and seizures made when 
suspicious transactions occur. Information on activities in 
this area is reported to the International Narcotics Control 
Board (INCB, 2011b). Another recent initiative by the 
INCB is the publication of a set of guidelines to assist 
national governments in establishing voluntary control 
measures in cooperation with industrial manufacturers of 
chemicals, with the aim of preventing their diversion for 
the production of illicit drugs (INCB, 2009).
Amphetamine
Global amphetamine production remains concentrated 
in Europe, which accounted for more than 80 % of all 
amphetamine laboratories reported in 2009 (UNODC, 
2011). In 2009, global seizures of amphetamine increased 
to about 33 tonnes (see Table 5). Western and central 
Europe continued to seize large amounts of amphetamine, 
although the UNODC reported a reduction of 20 % 
in the quantities seized there compared with 2008, 
when 7.9 tonnes was seized. The largest increase in 
amphetamine seizures was reported in Saudia Arabia, 
Jordan and Syria. Together, the UNODC’s Near and 
Diversifying the supply of precursors for 
synthetic drug production in Europe
Synthetic drugs, including ecstasy (MDMA, MDEA, MDA) 
and amphetamine, are manufactured illegally in Europe 
from imported precursor chemicals. In response to the 
increased efficiency of international control efforts, some 
illicit manufacturers now synthesise, rather than purchase, 
precursors from so-called ‘pre-precursors’. In addition, 
manufacturers are masking traditional precursors as other 
non-controlled chemicals before importation (Europol, 
2007, INCB, 2011a).
Recent fluctuations in the European market for ecstasy 
illustrate such phenomena. Following successful measures 
to limit diversion to the illicit market of the MDMA 
precursor PMK (1), it now appears that a range of pre-
precursors including safrole are being used as starting 
materials in the synthesis of MDMA.
PMK is under international control, both under the UN 
Convention of 1988 and European legislation. Licit 
international trade in PMK is small and restricted to a few 
countries. Safrole is obtained from safrole-rich essential 
oils extracted from several plant species from South 
America and south-east Asia (TNI, 2009). While safrole 
is a scheduled chemical, trade in safrole-rich oils is not 
controlled. Safrole is also widely used internationally in 
the manufacture of perfumes and insecticides, which may 
diminish the impact of international control efforts.
Reports from the Netherlands, the country most closely 
associated with ecstasy production, suggest that many 
manufacturers of the drug have used safrole rather 
than PMK as the starting material. About 40 legitimate 
shipments of safrole totalling 101 840 litres were reported 
to the International Narcotic Control Board between 
November 2009 and October 2010. However, reports of 
suspicious shipments remain low compared to the estimated 
amount of ecstasy produced (INCB, 2011a). Some 
1 050 litres of safrole and safrole-rich oils were seized in 
2009/10, mostly in Lithuania, while neighbouring Latvia 
reported confiscating 1 841 litres in 2008 (INCB, 2011a).
(1) 3,4-Methylenedioxyphenyl-2-propanone.
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(58) Most (94 %) of the amphetamine tablets intercepted were labelled as captagon, and recovered in Turkey. Captagon is one of the registered trade 
names for fenetylline, a synthetic central nervous system stimulant. Tablets sold on the illicit drug market as captagon are commonly found to contain 
amphetamine mixed with caffeine.
(59) This analysis is preliminary, as data for the Netherlands are not yet available for 2008 and 2009.
(60) The data on European drug seizures mentioned in this chapter can be found in Tables SZR-11 to SZR-18 in the 2011 statistical bulletin.
(61) The data on European drug purities mentioned in this chapter can be found in Table PPP-8 in the 2011 statistical bulletin. EU trend indexes can be 
found in Figure PPP-2 in the 2011 statistical bulletin.
(62) The data on European drug prices mentioned in this chapter can be found in Table PPP-4 in the 2011 statistical bulletin.
Middle East and south-west Asia region seized about 
25 tonnes in 2009, almost all in the form of ‘captagon’ 
tablets (UNODC, 2011).
Most amphetamine seized in Europe is produced, in 
order of importance, in the Netherlands, Poland, Belgium, 
Bulgaria and Turkey. Europol reports that 19 sites involved 
in the production, tableting or storage of amphetamine 
were discovered in the European Union in 2009.
An estimated 34 200 seizures amounting to 5.8 tonnes 
of amphetamine powder and 3 million amphetamine 
tablets (58) were made in Europe in 2009 (59). The number 
of amphetamine seizures has been fluctuating for the last 
five years, with a decrease reported in 2008 and 2009. 
While the number of amphetamine tablets confiscated in 
Europe has decreased sharply over the period 2004–
09 due to falling seizures in Turkey, the quantities of 
amphetamine powder intercepted have remained stable 
or increased in most European countries (60). However, this 
assessment is preliminary, as recent data are not available 
for the Netherlands, which in 2007, the last year for 
which data are available, reported seizing 2.8 tonnes of 
amphetamine powder.
The purity of amphetamine samples intercepted in Europe 
in 2009 continued to vary widely, ranging from less than 
8 % in Bulgaria, Hungary, Austria, Portugal, Slovenia, 
Slovakia and Croatia, to greater than 20 % in countries 
where amphetamine production is reported or where 
consumption levels are relatively high (Estonia, Lithuania, 
the Netherlands, Poland, Finland, Norway) (61). Over the 
past five years, the purity of amphetamine has fallen in 
17 out of the 18 countries reporting sufficient data for 
trend analysis.
In 2009, the mean retail price of amphetamine ranged 
between EUR 10 and EUR 23 a gram for over half of the 
14 countries providing data. Amphetamine retail prices 
either decreased or remained stable in all 17 countries 
reporting data over 2004–09, except in the Netherlands, 
where they increased over the period, and Slovenia, 
which reported a major increase in 2009 (62).
Methamphetamine
The number of dismantled methamphetamine laboratories 
reported worldwide increased by 22 % in 2009. As in 
the previous year, the strongest increase was registered in 
North America, especially the United States, but reports 
of clandestine laboratories continued to increase in 
east and south-east Asia. In addition, increased activity 
related to methamphetamine production was reported 
in Latin America and Africa. In 2009, 31 tonnes of 
methamphetamine was seized, a marked increase from the 
22 tonnes seized in 2008. Most of the drug was seized 
in North America (44 %), where Mexico accounted for an 
exceptionally high 6.1 tonnes in 2009 (UNODC, 2011).
In Europe, illicit methamphetamine production is 
concentrated in the Czech Republic, where 342 
production sites, mostly small-scale ‘kitchen laboratories’, 
were detected in 2009 (down from 434 in 2008). 
Production of the drug also occurs in Slovakia, where it 
increased in 2009, as well as in Germany, Lithuania and 
Poland.
In 2009, almost 7 400 seizures of methamphetamine, 
amounting to about 600 kg of the drug, were reported 
in Europe. Both the number of seizures and the quantities 
of methamphetamine seized increased over 2004–09, 
with a strong increase between 2008 and 2009. 
Quantities seized doubled between 2008 and 2009, 
mainly due to increases in the amounts recovered in 
Sweden and Norway, the main seizing countries in 
Europe for this drug, where it might partially replace 
amphetamine. Turkey reported methamphetamine 
seizures for the first time in 2009, ranking third in terms of 
quantities recovered: the relatively large consignments of 
methamphetamine intercepted in Turkey were reported to 
be in transit from Iran to east and south-east Asia.
Methamphetamine purity varied greatly in 2009 in the 
17 countries reporting data, with mean purities of under 
15 % in Bulgaria and Estonia, and over 65 % in the 
Czech Republic, the Netherlands, Slovakia and Croatia. 
No overall trend in methamphetamine purity can be 
discerned. The range of retail prices for methamphetamine 
also varied greatly in 2009, in the six countries reporting 
it, from about EUR 10 per gram in Bulgaria, Lithuania 
and Slovenia, to about EUR 70 per gram in Germany and 
Slovakia.
Ecstasy
The reported number of dismantled laboratories producing 
ecstasy was virtually unchanged at 52 in 2009. Most 
of these laboratories were situated in Australia (19), 
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(63) This analysis is preliminary, as data for the Netherlands, which reported one third of the amount of LSD seized in Europe in 2007, are not available 
for subsequent years.
Indonesia (18) and Canada (12). Production of the drug 
appears to have continued to spread geographically, with 
manufacture occurring closer to consumer markets in east 
and south-east Asia, North America and Oceania. Despite 
this, it is likely that western Europe remains an important 
location for ecstasy production.
Worldwide, seizures of ecstasy amounted to 5.4 tonnes 
in 2009 (UNODC, 2011), with the United States reporting 
63 % of the total.
The number of ecstasy seizures reported in Europe 
remained stable between 2004 and 2006, and then 
declined, while quantities seized in most European 
countries show a downward trend since 2004. In 2009, 
about 11 000 ecstasy seizures were reported in Europe, 
resulting in the interception of over 2.4 million ecstasy 
tablets. However, this is an underestimate, as recent data 
are not available for the Netherlands, which reported 
seizures of 8.4 million tablets in 2007, the last year for 
which data are available.
The average MDMA content of ecstasy tablets tested in 
2009 was between 3 and 108 mg in the 18 countries 
providing data. In addition, the availability of high-
dose ecstasy tablets containing over 130 mg of MDMA 
was reported by several countries (Belgium, Bulgaria, 
Germany, Italy, Netherlands, Turkey). Over the period 
2004–09, the MDMA content of ecstasy tablets declined 
in all 14 countries reporting sufficient data.
Over the last few years, there has been a change in the 
content of illicit drug tablets in Europe, from a situation 
where most tablets analysed contained MDMA or 
another ecstasy-like substance (MDEA, MDA) as the only 
psychoactive substance, to one where the contents are 
more diverse, and MDMA-like substances less present. 
This shift accelerated in 2009, to the extent that the only 
countries where MDMA-like substances continued to 
account for a large proportion of the tablets analysed 
were Italy (58 %), the Netherlands (63 %) and Malta 
(100 %).
Amphetamines, sometimes in combination with MDMA-like 
substances, are relatively common in tablets analysed in 
Greece, Spain, Hungary, Poland, Slovenia and Croatia. 
Most of the other reporting countries mention that 
piperazines, and in particular mCPP, were found, alone 
or in combination with other substances, in a substantial 
proportion of the tablets analysed.
Ecstasy is now considerably cheaper than it was in the 
1990s, when it first became widely available. While 
there are some reports of tablets being sold for as little 
as EUR 1, most countries are reporting mean retail prices 
in the range of EUR 4 to EUR 9 per tablet. The data 
available for 2004–09 suggest that the retail price of 
ecstasy has continued to fall or remained stable across 
Europe as a whole. In 2009, however, an increase was 
reported in the Netherlands, which is also the country 
reporting the lowest prices for the drug.
Hallucinogens and other substances
Use and trafficking of LSD in Europe is considered 
marginal. The number of LSD seizures increased between 
2004 and 2009, while quantities, after a peak in 2005 
to 1.8 million units due to record seizures in the United 
Kingdom, have since been fluctuating at relatively low 
levels (63). LSD retail prices have remained stable in most 
reporting countries since 2004, while increases were 
reported in Belgium and decreases in Latvia, Austria and 
Croatia. In 2009, the mean price was between EUR 7 
and EUR 11 per unit for the majority of the 11 countries 
reporting data.
Seizures of hallucinogenic mushrooms, ketamine and 
GHB and GBL are only reported for 2009 by four or five 
countries, depending on the drug. The extent to which 
the reported seizures reflect the use of these substances 
or the fact that they are not routinely targeted by law 
enforcement services is not clear.
Prevalence and patterns of use
In a few countries, the use of amphetamine or 
methamphetamine, often by injection, accounts for a 
substantial proportion of the overall number of problem 
drug users and those seeking help for drug problems. In 
contrast to these chronic user populations, a more general 
association exists between the use of synthetic drugs, 
often together with alcohol, and attendance at nightclubs 
and dance events. This results in significantly higher 
levels of use being reported among young people, and 
exceedingly high levels of use being found in some settings 
or specific sub-populations. The overall prevalence levels 
of hallucinogenic drugs such as lysergic acid diethylamide 
(LSD) and hallucinogenic mushrooms are generally low and 
have been largely stable in recent years.
Amphetamines
Drug prevalence estimates suggest that about 12.5 million 
Europeans have tried amphetamines, and about 2 million 
have used the drug during the last year (see Table 6 for a 
summary of the data). Among young adults (15–34 years), 
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(64) See Table EYE-11 in the 2011 statistical bulletin.
lifetime prevalence of amphetamines use varies considerably 
between countries, from 0.1 % to 14.3 %, with a weighted 
European average of 5.0 %. Last year use of amphetamines 
in this age group ranges from 0.1 % to 2.5 %, with most 
countries reporting prevalence levels of 0.5–2.0 %. It is 
estimated that about 1.5 million (1.1 %) young Europeans 
have used amphetamines during the last year.
Among 15- to 16-year-old school students, lifetime 
prevalence of amphetamines use ranged from 1 % to 
8 % in the 26 EU Member States, Norway and Croatia, 
surveyed in 2007, although only Bulgaria and Latvia 
reported prevalence levels of more than 5 %. The four 
countries that conducted school surveys in 2009 and 
2010 (Italy, Slovakia, Sweden, United Kingdom) reported 
lifetime prevalence of amphetamines of 3 % or less (64).
Data on the prevalence of amphetamines use in nightlife 
settings in 2009, provided by four countries (Belgium, 
Czech Republic, Netherlands, United Kingdom), show 
considerable variation, ranging from 6 % to 24 % for last 
year use of amphetamines.
Over the last decade, last year amphetamines use has 
remained relatively low and stable in most European 
countries, with prevalence levels of less than 3 % for 
almost all reporting countries, with the exception of the 
United Kingdom and Denmark. In the United Kingdom, last 
year use of amphetamines among young adults (15–34) 
declined from 6.2 % in 1998 to 1.8 % in 2009–10; in 
Denmark, after increasing to 3.1 % in 2000, it declined to 
2 % in 2010 (see Figure 8). During the period 2004–09, 
only Norway and the Czech Republic reported a change 
of more than one percentage point in last year prevalence 
of amphetamines use among young adults. In the Czech 
Republic, differences in survey methods do not allow 
confirmation of recent trends. School surveys suggest, 
overall, little change in the levels of experimentation with 
amphetamines among school students aged 15–16 years. 
Between 2003 and 2007, most countries reported both 
low and stable trends in lifetime prevalence in this group.
Table 6: Prevalence of amphetamines use in the general population — summary of the data 
Age group Time frame of use
Lifetime Last year
15–64 years
Estimated number of users in Europe 12.5 million 1.5–2 million
European average 3.8 % 0.5 %
Range 0.0–11.7 % 0.0–1.1 %
Lowest-prevalence countries Romania (0.0 %)
Greece (0.1 %)
Malta (0.4 %)
Cyprus (0.7 %)
Romania, Malta, Greece (0.0 %)
France (0.1 %)
Czech Republic, Portugal (0.2 %)
Highest-prevalence countries United Kingdom (11.7 %)
Denmark (6.2 %)
Sweden (5.0 %)
Norway (3.8 %)
Estonia (1.1 %)
United Kingdom (1.0 %)
Bulgaria, Latvia (0.9 %)
Sweden (0.8 %)
15–34 years
Estimated number of users in Europe 6.5 million 1.5 million
European average 5.0 % 1.1 %
Range 0.1–14.3 % 0.1–2.5 %
Lowest-prevalence countries Romania (0.1 %)
Greece (0.2 %)
Malta (0.7 %)
Cyprus (1.2 %)
Romania, Greece (0.1 %)
France (0.2 %)
Czech Republic (0.3 %)
Portugal (0.4 %)
Highest-prevalence countries United Kingdom (14.3 %)
Denmark (10.3 %)
Latvia (6.1 %)
Norway (6.0 %)
Estonia (2.5 %)
Bulgaria (2.1 %)
Denmark (2.0 %)
Germany, Latvia (1.9 %)
European estimates are computed from national prevalence estimates weighted by the population of the relevant age group in each country. To obtain estimates of the overall 
number of users in Europe, the EU average is applied for countries lacking prevalence data (representing not more than 3 % of the target population). Populations used as basis: 
15–64, 336 million; 15–34, 132 million. As European estimates are based on surveys conducted between 2001 and 2009/10 (mainly 2004–08), they do not refer to a single 
year. The data summarised here are available under ‘General population surveys’ in the 2011 statistical bulletin.
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(65) Problem amphetamines use is defined as the injecting or long duration and/or regular use of the substances.
(66) See Tables TDI-5 (part ii) and TDI-22 in the 2011 statistical bulletin.
(67) See Tables TDI-5 (part iv) and TDI-37 in the 2011 statistical bulletin.
(68) See Tables TDI-2 (part i), TDI-3 (part iii) and TDI-5 (part ii) and (part iv) in the 2011 statistical bulletin and Table TDI-5 (part ii) in the 2006 statistical 
bulletin.
(69) See Table GPS-7 (part iv) in the 2011 statistical bulletin. 
(70) See Table EYE-11 in the 2011 statistical bulletin.
Problem amphetamines use
Only a small number of countries can provide estimates of 
the prevalence of problem amphetamines use (65), but data 
on users entering treatment for problems related to these 
substances are available across Europe.
A small proportion of those entering treatment in Europe 
mention amphetamine as their primary drug: about 5 % of 
reported drug clients in 2009 (20 000 clients). However, 
amphetamine users account for a sizeable proportion 
of reported treatment entries in Sweden (28 %), Poland 
(25 %) and Finland (17 %). Amphetamine clients make 
up between 6 % and 10 % of reported treatment entrants 
in five other countries (Belgium, Denmark, Germany, 
Hungary, Netherlands); elsewhere the proportion is 
less than 5 %. In addition, non-cocaine stimulants are 
mentioned as a secondary drug by almost 20 000 clients 
entering treatment for problems related to other primary 
drugs (66).
Amphetamine users entering treatment are on average 
30 years old, with a lower male to female ratio (two 
to one) than for any other illicit drug. High levels of 
amphetamine injecting are reported by the countries 
where amphetamine users make up the highest proportions 
of treatment entrants (Latvia, Sweden, Finland), with 
between 59 % and 83 % of primary amphetamine clients 
injecting the drug (67).
Trends in amphetamine users entering treatment between 
2004 and 2009 have remained stable in most countries, 
with a slight decrease among the clients who entered 
treatment for the first time in their life, mainly attributable 
to a decrease in the number of new amphetamine clients 
in Finland and Sweden (EMCDDA, 2010d).
In contrast to other parts of the world, where the use of 
methamphetamine has increased in recent years, levels 
of use in Europe appear limited. Historically, use of this 
drug in Europe has been concentrated in the Czech 
Republic and, more recently, Slovakia. In 2009, the 
number of problem methamphetamine users in the Czech 
Republic was estimated to be approximately 24 600 to 
25 900 (3.3 to 3.5 cases per 1 000 aged 15–64 years), 
roughly twice the estimated number of problem opioid 
users. This represents a statistically significant increase in 
comparison to the previous years. For Slovakia, there were 
estimated to be approximately 5 800 to 15 700 problem 
methamphetamine users in 2007 (1.5 to 4.0 cases per 
1 000 aged 15–64 years), about 20 % fewer than the 
estimated number of problem opioid users.
Methamphetamine is cited as the primary drug by a 
large proportion of clients reported entering treatment 
in the Czech Republic (61 %) and Slovakia (30 %). 
Both countries report an increase in the number and 
overall proportion of new treatment entrants related to 
methamphetamine over the last decade. Among those 
seeking help for a methamphetamine problem, injecting 
is common in the Czech Republic (79 %) and to a lesser 
extent in Slovakia (37 %), with overall declining levels 
since 2004. Methamphetamine clients in these countries 
are on average around 25 years old when entering 
treatment (68).
In recent years, methamphetamine has also appeared 
on the drug market in other countries, particularly in 
the north of Europe (Norway, Sweden, Latvia and, to a 
lesser extent, Finland), where it appears to have partially 
replaced amphetamine, the two substances being virtually 
indistinguishable to users.
Ecstasy
Drug prevalence estimates suggest that about 11 million 
Europeans have tried ecstasy, and about 2.5 million have 
used the drug during the last year (see Table 7 for a 
summary of the data). Use of the drug in the last year is 
concentrated among young adults, with males reporting 
levels of use much higher than females in all countries 
except Greece, Romania, Finland and Sweden. Lifetime 
prevalence of ecstasy use among the 15–34 age group 
ranges from under 0.6 % to 12.7 %, with most countries 
reporting estimates in the 2.1 % to 5.8 % range (69).
Among 15- to 16-year-old school students, lifetime 
prevalence of ecstasy use ranged from 1 % to 5 % in most 
of the European countries surveyed in 2007. Only four 
countries reported higher prevalence levels: Bulgaria, 
Estonia, Slovakia (all 6 %) and Latvia (7 %). The four 
countries that conducted school surveys in 2009 (Italy, 
Slovakia, Sweden, United Kingdom) reported lifetime 
prevalence of ecstasy use of 5 % or less (70).
Qualitative studies provide a window into ‘recreational’ 
use of stimulant drugs by young adults attending a range 
of different nightlife venues across Europe. These studies 
highlight significant differences in the drug-use profiles of 
customers, with those attending electronic dance music 
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venues much more likely to report drug use than those in 
other nightlife settings. Data on the prevalence of ecstasy 
use in nightlife settings in 2009 is only available for 
four countries (Belgium, Czech Republic, Netherlands, 
United Kingdom), but does show considerable variation 
in reported levels of recent (last year) use, ranging from 
10 % to 75 %. Ecstasy use was more common than 
amphetamines use in the settings sampled.
Over the period 2003–09, no country reported an 
increase in ecstasy use, while Estonia, Spain, Germany, 
Hungary and the United Kingdom reported a decrease 
of about one percentage point in last year ecstasy use in 
the 15–34 age group. There is, however, some variation 
between countries. In the countries reporting higher than 
average levels of last year ecstasy use, consumption of 
the drug among 15- to 34-year-olds typically peaked at 
somewhere between 3 % and 5 % in the early 2000s 
(Estonia, Spain, Slovakia, United Kingdom; see Figure 8). 
An exception to this is the Czech Republic, where last 
year ecstasy use estimates peaked in 2008 at 7.7 % 
and decreased to 2.8 % in 2009. In the Czech Republic, 
differences in survey methods do not allow confirmation of 
recent trends.
School surveys suggest, overall, little change in the levels 
of experimentation with ecstasy among students aged 
15–16 years. Between 2003 and 2007, most countries 
reported low and stable trends in lifetime prevalence of 
ecstasy among this group, while seven countries reported 
an increase and three a decrease — using a difference 
of two percentage points as the threshold. A decrease 
in the prevalence of ecstasy may be suggested by 
studies carried out in recreational settings in Europe. In 
Amsterdam, a study of visitors to ‘coffee shops’ reported 
a sharp drop in last month use of ecstasy, from 23 % in 
2001 to 6 % in 2009; the study also reported a decline 
in lifetime amphetamine use, from 63 % to 41 % over 
the same period. A Belgian study conducted regularly 
in nightlife settings reported that ecstasy is no longer the 
second most used illicit drug. In previous surveys, last year 
Table 7: Prevalence of ecstasy use in the general population — summary of the data
Age group Time frame of use
Lifetime Last year
15–64 years
Estimated number of users in Europe 11 million 2.5 million
European average 3.2 % 0.7 %
Range 0.3–8.3 % 0.1–1.6 %
Lowest-prevalence countries Romania (0.3 %)
Greece (0.4 %)
Malta (0.7 %)
Norway (1.0 %)
Romania, Sweden (0.1 %)
Malta, Greece (0.2 %)
Denmark, Poland, Norway (0.3 %)
Highest-prevalence countries United Kingdom (8.3 %)
Ireland (5.4 %)
Spain (4.9 %)
Latvia (4.7 %)
United Kingdom, Slovakia (1.6 %)
Latvia (1.5 %)
Czech Republic (1.4 %)
15–34 years
Estimated number of users in Europe 7.5 million 2 million
European average 5.5 % 1.4 %
Range 0.6–12.7 % 0.2–3.2 %
Lowest-prevalence countries Romania, Greece (0.6 %)
Malta (1.4 %)
Poland, Norway (2.1 %)
Portugal (2.6 %)
Romania, Sweden (0.2 %)
Greece (0.4 %)
Norway (0.6 %)
Poland (0.7 %)
Highest-prevalence countries United Kingdom (12.7 %)
Czech Republic (9.3 %)
Ireland (9.0 %)
Latvia (8.5 %)
United Kingdom (3.2 %)
Czech Republic (2.8 %)
Slovakia, Latvia, Netherlands (2.7 %)
European estimates are computed from national prevalence estimates weighted by the population of the relevant age group in each country. To obtain estimates of the overall 
number of users in Europe, the EU average is applied for countries lacking prevalence data (representing not more than 3 % of the target population). Populations used as basis: 
15–64, 336 million; 15–34, 132 million. As European estimates are based on surveys conducted between 2001 and 2009/10 (mainly 2004–08), they do not refer to a single 
year. The data summarised here are available under ‘General population surveys’ in the 2011 statistical bulletin.
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ecstasy use always ranged between 15 % and 20 %, but 
decreased to 10 % in 2009.
Few drug users seek treatment for problems relating to 
ecstasy. In 2009, ecstasy was mentioned as the primary 
drug by less than 1 % (1 300) of all reported treatment 
entrants. With an average age of 26 years, ecstasy 
clients are among the youngest entering drug treatment, 
and there are three to four males for every female. 
Ecstasy clients often report the concomitant use of other 
substances, including alcohol, cocaine and, to a lesser 
extent, cannabis and amphetamines (71).
The combined use of ecstasy or amphetamines with 
alcohol has been reported in European studies. In nine 
European countries, general population surveys show that 
frequent or heavy alcohol users report levels of prevalence 
of amphetamines or ecstasy use that are much higher than 
the population average (EMCDDA, 2009b). Similarly, 
ESPAD school survey data for 22 countries show that 
86 % of the 15- to 16-year-old students who reported 
using ecstasy during the last month also reported drinking 
five or more alcoholic drinks on one occasion (EMCDDA, 
2009b).
Hallucinogens, GHB and ketamine
Among young adults (15–34 years), lifetime prevalence 
estimates of LSD use in Europe range from zero to 
5.5 %. Much lower prevalence levels are reported 
for last year use (72). In the few countries providing 
comparable data, most report higher levels of use for 
hallucinogenic mushrooms than for LSD, among both 
the general population and school students. Lifetime 
prevalence estimates for hallucinogenic mushrooms 
among young adults range from 0.3 % to 14.1 %, and 
last year prevalence estimates are in the range of 0.2 % 
to 5.9 %. Among 15- to 16-year-old school students, most 
countries report lifetime prevalence estimates for the use of 
hallucinogenic mushrooms of between 1 % and 4 %, with 
Slovakia (5 %) and the Czech Republic (7 %) reporting 
higher levels (73).
Estimates of the prevalence of GHB and ketamine use in 
the adult and school populations are much lower than 
those for the use of cocaine and ecstasy. However, use of 
these substances can be higher in specific groups, settings 
and geographical areas. Targeted surveys that report 
prevalence estimates for the use of these substances have 
recently been conducted in Belgium, the Czech Republic, 
the Netherlands and the United Kingdom. These studies 
report lifetime prevalence of GHB use ranging from 3.9 % 
to 14.3 %, and last month prevalence of up to 4.6 %. 
Estimates of ketamine use in the same surveys range from 
2.9 % to 62 % for lifetime use and 0.3 % to 28 % for last 
month use. There are marked differences between surveys 
and countries, and the high prevalence of ketamine use 
reported is unique to a 2010 UK music magazine survey 
(71) See Tables TDI-5, TDI-8 and TDI-37 (part i), (part ii) and (part iii) in the 2011 statistical bulletin.
(72) See Table GPS-1 in the 2011 statistical bulletin.
(73) Data are from ESPAD for all countries but Spain. See Figure EYE-3 (part v) in the 2011 statistical bulletin.
Figure 8: Trends in last year prevalence of use of amphetamines 
(top) and ecstasy (bottom) among young adults (aged 15–34)
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NB: Only data for countries with at least three surveys in the 
period 1998 to 2009/10 are presented. The Czech Republic 
is exploring reasons for the wide variability in survey results, 
which in part seem related to changes in methods. The data 
is provided for information, but comparisons should be treated 
with caution. See Figures GPS-8 and GPS-21 in the 2011 
statistical bulletin for further information.
Sources: Reitox national reports, taken from population surveys, reports 
or scientific articles.
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(Winstock, 2011). In this survey, levels of ketamine use are 
very much higher than those for GHB. Such high ketamine 
prevalence may be due to the self-selection of respondents 
to the survey and their particular drug-use profiles and 
attitudes. The Netherlands reported that ketamine has 
gained some popularity among trendsetters in the western 
region, but last month prevalence levels among visitors 
to large-scale parties in 2009 remain lower (at 1.2 %) 
than those for GHB (4.6 %). Among visitors to Amsterdam 
‘coffee shops’ in 2009, last month GHB use equalled last 
month amphetamine use at 1.5 %. A high perceived risk of 
overdose leading to unconsciousness or coma, associated 
with the use of GHB, is highlighted by qualitative studies 
in Germany, Estonia, France and the Netherlands.
No overall trends can be identified for GHB and 
ketamine use from repeat surveys among party-goers or 
in recreational settings, and the changes reported are 
in most cases small. Studies of recreational settings in 
Belgium report that last month use of GHB and ketamine 
increased from 2 % to 3 % between 2008 and 2009. In 
the Czech Republic, studies in nightlife settings report that 
last year prevalence of GHB use increased from 1.4 % 
in 2007 to 3.9 % in 2009, and ketamine use increased 
from 2.2 % to 2.9 % over the same period. Decreases 
in last month use of GHB were reported among visitors 
to Amsterdam ‘coffee shops’, from 2.8 % in 2001 to 
1.5 % in 2009. However, trends in Amsterdam are not 
representative for the rest of the Netherlands. Also, among 
respondents to the UK music magazine survey, last month 
use of GHB decreased from 1.7 % in 2009 to less than 
1 % in 2010, and ketamine use decreased from 32.4 % to 
28 % over the same period.
Interventions in recreational settings
In spite of high levels of drug use in recreational settings, 
only 13 countries report on the implementation of 
prevention or harm-reduction interventions in these arenas. 
The reported interventions continue to focus on information 
provision and counselling. This focus is also evident in the 
interventions included in the Healthy Nightlife Toolbox, 
an EU-funded, Internet-based initiative aimed at helping 
reduce harm from alcohol and drug use in nightlife 
settings. The ‘Safer Nightlife’ project, another EU-funded 
initiative under the ‘Democracy, Cities & Drugs II (2008–
11)’ programme, aims to go beyond information provision 
and improve nightlife prevention programmes and training 
for professionals.
A recent systematic review of harm-reduction strategies 
implemented in recreational settings found that they are 
rarely evaluated and their effectiveness is not always clear 
(Akbar et al., 2011). The review found that interventions 
with a focus on training service staff in recreational 
settings were the most common type of programme 
available. These programmes typically include topics such 
as how to recognise signs of intoxication, and when and 
how to refuse service to customers. In the Austrian ‘taktisch 
klug’ (clever tactics) project, organisers of party events 
are assisted at the preparation stage and party-goers are 
offered counselling to help them develop a more critical 
approach to psychoactive substances and risk behaviour. 
Multi-component environmental models, which are among 
the programmes with more promising evaluation results, 
are mainly reported by countries in the north of Europe.
Studies in international nightlife resorts show that these 
settings may be associated with recruitment, escalation 
and relapse in relation to drug use, and may have a role 
in the international spread of drug cultures. Research 
points to high levels of drug use and initiation into drug 
use in some resorts. For example, a study of young people 
(16–35 years) from Spain, Germany and the United 
Kingdom visiting Ibiza and Majorca, found significant 
differences in drug use between nationalities and between 
the two resorts. Levels of drug use were particularly high 
among Spanish and British visitors to Ibiza, and one in five 
of the British visitors tried at least one new drug on their 
holiday there (Bellis et al., 2009).
Treatment
Problem amphetamines use
The treatment options available for amphetamines users 
in European countries often follow the national history 
and patterns of problem amphetamines use, which 
differ considerably between countries. In western and 
southern European countries, treatment systems have 
mainly specialised in responding to the needs of opioid 
users. Despite the low levels of problem amphetamines 
use in these countries, the lack of dedicated services may 
hinder access to treatment for such users, especially for 
more socially integrated amphetamine users (EMCDDA, 
2010d). In those northern and central European countries 
with a long history of treating amphetamines use, 
some programmes are tailored towards the needs of 
amphetamines users. In the central and eastern European 
countries where significant problem amphetamines use 
is more recent, treatment systems are primarily geared 
towards problem opioid users and have been slow to 
address the needs of amphetamines users. A 2008 survey 
of national experts found that less than half of European 
countries report the availability of specialist treatment 
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programmes for users of amphetamines who actively seek 
treatment.
Psychosocial treatment provided in outpatient drug 
services is the most common form of treatment for 
amphetamines users. The more problematic users, for 
example those whose amphetamines dependence is 
complicated by co-occurring psychiatric disorders, may 
receive treatment in inpatient drug services, psychiatric 
clinics or hospitals. In Europe, pharmaceuticals such 
as antidepressants, sedatives and antipsychotics are 
administered for the treatment of abstinence symptoms 
at the beginning of detoxification, which is usually 
provided at specialist inpatient psychiatric departments. 
Longer-term treatment with antipsychotics is sometimes 
prescribed in cases of lasting psychopathologies due to 
chronic use of amphetamines. European professionals 
report that the psychiatric problems often presented by 
problem amphetamines users are difficult to handle within 
the therapeutic context. In Hungary, the first professional 
protocol dealing with the treatment of amphetamines users 
was published by the Ministry of Health at the beginning 
of 2008. The protocol covers diagnosis, the indicated 
structure of medically assisted and drug-free treatment and 
other therapies and rehabilitation.
Studies on treatment of amphetamines dependence
Although some limited substitution prescribing is reported 
in the Czech Republic and the United Kingdom, there is 
currently no evidence available to support the efficacy of 
this approach. Clinicians are, however, actively exploring 
pharmacological therapies that may be helpful in treating 
amphetamines dependence. The central nervous system 
stimulant dextroamphetamine, when tested among 
methamphetamine patients, gave positive results for 
reduction of craving and withdrawal symptoms, and for 
retaining clients in treatment, but did not reduce use of 
methamphetamine compared to a placebo (Galloway et 
al., 2011; Longo et al., 2010). Studies testing the effect 
of Modafinil, a drug used to regulate sleepiness, on 
methamphetamine-dependent individuals found possible 
improvements in working memory (Kalechstein et al., 
2010), but no difference compared to a placebo for levels 
of drug use, retention in treatment, depression or craving 
(Heinzerling et al., 2010).
Bupropion, an antidepressant that has been used to assist 
smoking cessation, was piloted with a small group of 
methamphetamine-dependent men who have sex with 
men (Elkashef et al., 2008); a more powerful study is 
needed to confirm the positive results found. Another 
pilot study, aiming to control the symptoms of attention 
deficit hyperactivity disorder in problem amphetamine 
users, combined sustained release methylphenidate with 
weekly sessions of skills training, but no difference with the 
placebo group was found (Konstenius et al., 2010).
A number of ongoing trials have been registered in this 
area, including studies on extended-release naltrexone 
for amphetamine dependence, and for methamphetamine 
dependence, studies on monoamine antagonist, an 
angiotensin converting enzyme inhibitor, N -acetylcysteine, 
rivastigmine and varenicline.
Psychological and behavioural interventions for 
methamphetamine problems are the focus of a small number 
of studies. An Australian study attempted to compare two 
psychological approaches for methamphetamine use, but 
Health consequences of amphetamines
Medical use of amphetamines has been associated with 
a number of side-effects including anorexia, insomnia 
and headaches. Illicit amphetamines use is associated 
with a broader set of negative consequences (EMCDDA, 
2010d), such as short-term negative effects (restlessness, 
tremor, anxiety, dizziness), a ‘crash’ or coming down 
after-effect (depression, sleeping difficulties, suicidal 
behaviour), psychological and psychiatric effects of 
long-term use (psychosis, suicidal behaviour, anxiety and 
violent behaviour) and dependence with a wide range of 
withdrawal symptoms.
Many studies on the health consequences of amphetamines 
use have been conducted in Australia and the United 
States, countries where methamphetamine use, notably 
crystal methamphetamine smoking, is a significant part 
of the drug problem. Although methamphetamine use 
is comparatively rare in Europe, these health effects 
have also been reported in Europe. Cerebrovascular 
problems have also been identified (risk of ischemic 
and haemorrhagic stroke), as well as acute and chronic 
cardiovascular pathology (acute increase in heart rate 
and blood pressure). In the context of chronic use or 
pre-existing cardiovascular pathology these may trigger 
serious and potentially fatal events (myocardial ischemia 
and infarction). Other health effects include neurotoxicity, 
foetal growth restriction associated with amphetamine use 
during pregnancy and dental disease.
Injecting, although rare among European amphetamines 
users, increases the risk of infectious diseases (HIV and 
hepatitis). High rates of sexual risk behaviour have been 
reported in Czech Republic for methamphetamine users, 
making them more vulnerable to sexually transmitted 
infections. Studies in the Czech Republic, Latvia and the 
Netherlands showed elevated mortality rates among 
dependent or chronic amphetamines users. However, 
estimating the mortality associated with amphetamines is 
complicated by polydrug use (mainly concurrent use of 
heroin and cocaine).
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participant dropout was too high to obtain significant results 
(Smout et al., 2010). Ongoing trials registered in this area 
are studying the impact of motivational interviewing and 
cognitive behavioural skills training on methamphetamine 
dependence.
Gamma-hydroxybutyrate dependence and treatment
Dependence on gamma-hydroxybutyrate (GHB) is 
a recognised clinical condition, with a potentially 
severe withdrawal syndrome when the drug is abruptly 
discontinued following regular or chronic use. There 
is evidence that physical dependence may occur in 
recreational users, and cases of withdrawal symptoms 
on cessation of use of GHB and its precursors have been 
documented. GHB dependence has also been reported 
among former alcoholics (Richter et al., 2009).
Available studies mainly focus on the description of GHB 
withdrawal syndrome and related complications, which 
can be difficult to recognise in emergency cases (van 
Noorden et al., 2009). These symptoms may include 
unrest, anxiety attacks, insomnia, sweating, tachycardia 
and hypertension. Patients in withdrawal may also 
develop psychosis and delirium. Mild withdrawal can 
be managed in outpatient settings, otherwise inpatient 
supervision is recommended. As yet, no standard 
protocols have been devised for the treatment of GHB 
withdrawal syndrome.
Benzodiazepines and barbiturates are the 
pharmaceuticals most commonly used to treat acute 
problems related to GHB use. In the United States, a 
small study is in progress to compare the benzodiazepine 
lorazepam with the barbiturate pentobarbital for the 
reduction of subjective withdrawal symptoms in GHB-
dependent individuals. In the Netherlands, research 
is now being conducted to establish evidence-based 
guidelines for the treatment of GHB dependence.
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Cocaine remains the second most commonly used illicit 
drug in Europe, although prevalence levels and trends 
differ considerably between countries. High levels of 
cocaine use are observed only in a small number of, 
mostly, western European countries, while elsewhere the 
use of this drug remains limited. There is also considerable 
diversity among cocaine users, including occasional users 
and more socially integrated regular users, who commonly 
snort cocaine powder, and more marginalised and often 
dependent users, who inject cocaine or use crack cocaine.
Supply and availability
Production and trafficking
Cultivation of coca bush, the source of cocaine, continues 
to be concentrated in three Andean countries, Colombia, 
Peru and Bolivia. The UNODC (2011) estimated that the 
area under coca bush cultivation in 2010 amounted to 
149 000 hectares, a 6 % decrease from the estimate of 
158 000 hectares in 2009. This decrease was largely 
attributed to a reduction in the area under coca cultivation 
in Colombia, which has been partially offset by increases 
in Peru and Bolivia. The 149 000 hectares of coca bush 
translated into a potential production of between 786 and 
1 054 tonnes of pure cocaine, compared to an estimated 
842 to 1 111 tonnes in 2009 (UNODC, 2011).
The conversion of coca leaves into cocaine hydrochloride 
is mainly carried out in Colombia, Peru and Bolivia, 
although it may also occur in other countries. Colombia’s 
importance in the production of cocaine is corroborated 
by information on laboratories dismantled and seizures of 
potassium permanganate, a chemical reagent used in the 
manufacture of cocaine hydrochloride. In 2009, 2 900 
cocaine laboratories were dismantled (UNODC, 2011) and 
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Table 8: Production, seizures, price and purity of cocaine and crack cocaine
Cocaine powder (hydrochloride) Crack (cocaine base) (1)
Global production estimate (tonnes) 786–1 054 n.a.
Global quantity seized (tonnes) 732 (2) n.a.
Quantity seized (tonnes) 
EU and Norway  
(Including Croatia and Turkey) (3)
 
49 
(49)
 
0.09 
(0.09)
Number of seizures 
EU and Norway  
(Including Croatia and Turkey)
 
98 500 
(99 000)
 
7 500 
(7 500)
Mean retail price (EUR per gram) 
Range 
(Interquartile range) (4)
 
45–104 
(50.2–78.2)
 
55–70
Mean purity (%) 
Range 
(Interquartile range) (4)
 
18–51 
(25.0–38.7)
 
6–75
(1) Due to the small set of countries reporting information, data should be interpreted with caution.
(2) UNODC estimates this figure to be equivalent to 431 to 562 tonnes of pure cocaine.
(3) The total amount of cocaine seized in 2009 is likely to be underestimated, largely due to the lack of recent data for the Netherlands, a country reporting relatively large 
seizures up to 2007. In the absence of 2008 and 2009 data, values for the Netherlands cannot be included in European estimates for 2009.
(4) Range of the middle half of the reported data.
NB: All data are for 2009; n.a., data not available.
Source: UNODC (2011) for global values, Reitox national focal points for European data.
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(74) See Tables SZR-9 and SZR-10 in the 2011 statistical bulletin.
(75) For purity and price data, see Tables PPP-3 and PPP-7 in the 2011 statistical bulletin.
a total of 23 tonnes of potassium permanganate (90 % of 
global seizures) was seized in Colombia (INCB, 2011a).
Cocaine consignments to Europe appear to be transited 
through most countries in South and Central America, 
though mainly through Argentina, Brazil, Ecuador, 
Venezuela and Mexico. Caribbean islands are also 
frequently used in the transhipment of the drug to Europe. 
In recent years, alternative routes through West Africa have 
been detected (EMCDDA and Europol, 2010). Although 
a ‘substantive decline’ in seizures of cocaine transiting 
West Africa since 2007 has been reported (UNODC, 
2011), it is likely that significant amounts of the drug still go 
through the region (EMCDDA and Europol, 2010).
Spain, the Netherlands and Portugal, and to some 
extent Belgium, appear to be the main points of entry to 
Europe for cocaine. Within Europe, reports frequently 
mention Germany, France and the United Kingdom as 
important transit or destination countries. The United 
Kingdom estimates that 25 to 30 tonnes of cocaine are 
imported into the country each year. Recent reports 
also indicate that cocaine trafficking may be expanding 
eastward (EMCDDA and Europol, 2010; INCB, 2011b). 
The aggregate figure for 12 central and eastern European 
countries shows an increase in the number of cocaine 
seizures, from 666 cases in 2004 to 1 232 in 2009, but 
these still represent only about 1 % of the European total. 
Quantities of cocaine intercepted in this region more than 
doubled between 2008 and 2009, mainly due to record 
seizures in Bulgaria (0.23 tonnes) and Romania (1.3 
tonnes), two countries that lie along the so-called Balkan 
route, usually associated with heroin trafficking.
Seizures
Cocaine is the most trafficked drug in the world after 
herbal cannabis and cannabis resin. In 2009, global 
seizures of cocaine remained largely stable at about 
732 tonnes (Table 8) (UNODC, 2011). South America 
continued to report the largest amount seized, accounting 
for 60 % of the global figure, followed by North America 
with 18 %, and Europe with 8 % (UNODC, 2011).
The number of cocaine seizures in Europe has been rising 
for the last 20 years, and more notably since 2004, 
reaching an estimated 99 000 cases in 2009. The total 
quantity intercepted peaked in 2006, and has halved 
since then to an estimated 49 tonnes in 2009. This fall 
is largely accounted for by decreases in the amounts 
recovered in Spain and Portugal (74), though it is unclear to 
what extent this is due to changes in trafficking routes or 
practices, or in law enforcement priorities. In 2009, Spain 
continued to be the country reporting both the highest 
number of seizures of cocaine and the largest quantity 
of the drug seized in Europe, about half the total in both 
cases. However, this assessment is preliminary, as recent 
data are not available for the Netherlands. In 2007, the 
last year for which data are available, the Netherlands 
reported seizing around 10 tonnes of cocaine.
Purity and price
The mean purity of cocaine samples tested ranged 
between 25 % and 43 % in half of the countries providing 
data for 2009. The lowest values were reported in 
Denmark (retail only, 18 %) and the United Kingdom 
(England and Wales, 20 %), and the highest ones in 
Belgium (51 %) and Spain and the Netherlands (49 %) (75). 
Twenty-two countries provided sufficient data for analysis 
of trends in cocaine purity over the period 2004–09, 
with 19 of the countries reporting a decline, two a stable 
situation (Germany, Slovakia) and Portugal observing an 
increase. Overall, cocaine purity declined by an estimated 
Wholesale and retail drug prices: cocaine
Wholesale drug prices are the prices paid for large 
quantities that will be distributed within a country, whereas 
retail prices are those paid by the drug user. By comparing 
the two, estimates can be made of the maximum profit 
margins that drug traffickers may obtain in the retail 
market.
Recent data collected by the EMCDDA from 14 European 
countries show that, in 2008, the wholesale price for 
consignments of 1 kg of cocaine can be estimated 
at between EUR 31 000 and EUR 58 000, with most 
countries reporting figures of around EUR 35 000. When 
reported, the average purity level of such consignments 
was close to 70 %.
In 2008, retail cocaine prices varied from EUR 50 000 to 
EUR 80 000 for the equivalent of 1 kg of cocaine in these 
countries, and were thereby 25 % to 83 % higher than 
wholesale prices. Purity levels decreased when moving 
from the wholesale to the retail market, where they were 
reported to be on average between 13 % and 60 %, 
depending on the country. Additional data are, however, 
required to precisely estimate purity-adjusted price 
differences between the wholesale and the retail level.
An overview of methods and data availability in Europe 
is available in an EMCDDA report on a pilot study on 
wholesale drug prices published in 2011.
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(76) See Figure PPP-2 in the 2011 statistical bulletin. 
(77) See Figure PPP-1 in the 2011 statistical bulletin.
average of 20 % in the European Union in the period 
2004–09 (76).
The mean retail price of cocaine ranged between EUR 50 
and EUR 80 per gram in most of the countries reporting 
data for 2009. The United Kingdom reported the lowest 
mean price (EUR 45), while Luxembourg reported the 
highest (EUR 104). Almost all countries with sufficient data 
to make a comparison reported a stabilisation or decrease 
in cocaine retail prices between 2004 and 2009. In the 
period 2004–09, the retail price of cocaine in the European 
Union declined by an estimated average of 21 % (77).
Prevalence and patterns of use
Cocaine use among the general population
Cocaine is, after cannabis, the second most tried drug 
in Europe, although its use is concentrated in a small 
number of high-prevalence countries, some of which have 
large populations. It is estimated that about 14.5 million 
Europeans have used cocaine at least once in their life, on 
average 4.3 % of adults aged 15–64 years (see Table 9 for 
a summary of the data). National figures vary from 0.1 % 
to 10.2 %, with half of the 24 reporting countries, including 
most central and eastern European countries, reporting low 
levels of lifetime prevalence (0.5 % to 2.5 %).
About 4 million Europeans are estimated to have used the 
drug in the last year (1.2 % on average). Recent national 
surveys report last year prevalence estimates of between 
zero and 2.7 %. The prevalence estimate for last month 
cocaine use in Europe represents about 0.5 % of the adult 
population or about 1.5 million individuals.
Levels of last year cocaine use above the European 
average are reported by Ireland, Spain, Italy, Cyprus and 
the United Kingdom. In all of these countries, last year 
prevalence data show that cocaine is the most commonly 
used illicit stimulant drug.
Table 9: Prevalence of cocaine use in the general population — summary of the data
Age group Time frame of use
Lifetime Last year Last month
15–64 years
Estimated number of users in Europe 14.5 million 4 million 1.5 million
European average 4.3 % 1.2 % 0.5 %
Range 0.1–10.2 % 0.0–2.7 % 0.0–1.3 %
Lowest-prevalence countries Romania (0.1 %)
Malta (0.4 %)
Lithuania (0.5 %)
Greece (0.7 %)
Romania (0.0 %)
Greece (0.1 %)
Hungary, Poland, Lithuania (0.2 %)
Malta (0.3 %)
Romania, Greece (0.0 %)
Czech Republic, Malta, Sweden, 
Poland, Lithuania, Estonia, Finland 
(0.1 %)
Highest-prevalence countries Spain (10.2 %)
United Kingdom (8.8 %)
Italy (7.0 %)
Ireland (5.3 %)
Spain (2.7 %)
United Kingdom (2.5 %)
Italy (2.1 %)
Ireland (1.7 %)
Spain (1.3 %)
United Kingdom (1.1 %)
Cyprus, Italy (0.7 %)
Austria (0.6 %) 
15–34 years
Estimated number of users in Europe 8 million 3 million 1 million
European average 5.9 % 2.1 % 0.8 %
Range 0.1–13.6 % 0.1–4.8 % 0.0–2.1 %
Lowest-prevalence countries Romania (0.1 %)
Lithuania (0.7 %)
Malta (0.9 %)
Greece (1.0 %)
Romania (0.1 %)
Greece (0.2 %)
Poland, Lithuania (0.3 %)
Hungary (0.4 %)
Romania (0.0 %)
Greece, Poland, Lithuania, Norway 
(0.1 %)
Czech Republic, Hungary, Estonia 
(0.2 %)
Highest-prevalence countries Spain (13.6 %)
United Kingdom (13.4 %)
Denmark (8.9 %)
Ireland (8.2 %)
United Kingdom (4.8 %)
Spain (4.4 %)
Ireland (3.1 %)
Italy (2.9 %)
United Kingdom (2.1 %)
Spain (2.0 %)
Cyprus (1.3 %)
Italy (1.1 %)
European estimates are computed from national prevalence estimates weighted by the population of the relevant age group in each country. To obtain estimates of the overall number 
of users in Europe, the EU average is applied for countries lacking prevalence data (representing not more than 3 % of the target population). Populations used as basis: 15–64, 336 
million; 15–34, 132 million. As European estimates are based on surveys conducted between 2001 and 2009/10 (mainly 2004–08), they do not refer to a single year. The data 
summarised here are available under ‘General population surveys’ in the 2011 statistical bulletin.
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(78) See Figure GPS-13 in the 2011 statistical bulletin.
(79) See Table GPS-5 (part iii) and (part iv) in the 2011 statistical bulletin.
(80) See Tables EYE-10 to EYE-30 in the 2011 statistical bulletin.
Cocaine use among young adults
In Europe, it is estimated that about 8 million young 
adults (15–34 years), or an average of 5.9 %, have used 
cocaine at least once in their life. National figures vary 
from 0.1 % to 13.6 %. The European average for last 
year use of cocaine among this age group is estimated at 
2.1 % (about 3 million) and for last month use at 0.8 % 
(1 million).
Use is particularly high among young males 
(15–34 years), with last year prevalence of cocaine use 
reported at between 4 % and 6.7 % in Denmark, Spain, 
Ireland, Italy and the United Kingdom (78). In 13 of the 
reporting countries, the male to female ratio for last year 
prevalence of cocaine use among young adults is at least 
two to one (79).
International comparisons
Overall, the estimated last year prevalence of cocaine 
use is lower among young adults in Europe (2.1 %) than 
among their counterparts in Australia (3.4 % among 14- 
to 39-year-olds), Canada (3.3 %) and the United States 
(4.1 % among 16- to 34-year-olds). Spain (4.4 %) and the 
United Kingdom (4.8 %) report, however, higher figures 
(Figure 9). It is important to note that small differences 
between countries should be interpreted with caution.
Cocaine use among school students
Lifetime prevalence of cocaine use among 15- to 16-year-
old school students in the most recent surveys available is 
1 % to 2 % in over half of the 29 reporting countries. Most 
of the remaining countries report prevalence levels of 3 % 
to 4 %, while France and the United Kingdom report 5 %. 
Where data are available for older school students (17–18 
years old), lifetime prevalence of cocaine use is generally 
higher, rising to 8 % in Spain (80).
Trends in cocaine use
Trends in cocaine use in Europe have followed different 
patterns. In Spain and the United Kingdom, the countries 
with the highest prevalence levels, use of cocaine increased 
greatly in the late 1990s, before moving to a more stable, 
Figure 9: Last year prevalence of cocaine use among young adults (15–34) in Europe, Australia, Canada and the USA
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NB: Data are from the last survey available for each country. The European average prevalence rate was calculated as the average of the national 
prevalence rates weighted by national population of 15- to 34-year-olds (2007, taken from Eurostat). US and Australian data have been 
recalculated from original survey results to the age bands 16–34 and 14–39 years, respectively. Data for Australia refer to 2007, data for 
Canada and the USA to 2009. See Figure GPS-20 in the 2011 statistical bulletin for further information.
Sources: Reitox national focal points, AIHW (2008), CADUMS (2010), SAMHSA (2010).
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(81) See Figure GPS-14 (part i) in the 2011 statistical bulletin. 
(82) It should be noted that trends in Amsterdam are not representative of those in the Netherlands as a whole. 
(83) Heavy episodic drinking, also known as binge drinking, is here defined as drinking six glasses or more of an alcoholic beverage on the same 
occasion at least once a week during the past year.
though generally upward, trend. In four other countries 
(Denmark, Ireland, Italy, Cyprus), the increase in prevalence 
has been less pronounced and occurred later. All of these 
countries reported last year cocaine prevalence among 
young adults (15–34 years) above the EU average of 
2.1 % (Figure 9). Four of these six countries reported an 
overall increase over the past 10 years, though observing 
a decrease in their most recent survey (Denmark, Spain, 
Italy, United Kingdom), echoing the trend observed in 
Canada and the United States (Figure 10). The other two 
countries report increases in their most recent surveys: 
Ireland from 2.0 % in 2003 to 3.1 % in 2007; and Cyprus 
from 0.7 % in 2006 to 2.2 % in 2009.
In 17 other countries with repeated surveys, cocaine use is 
relatively low and, in most cases, stable. Possible exceptions 
to this include Bulgaria and Sweden, which have reported 
signs of an increase, and Norway, where the trend appears 
to be downward. It should be borne in mind, however, that 
small changes at low prevalence must be interpreted with 
caution. In Bulgaria, last year use of cocaine among young 
adults rose from 0.7 % in 2005 to 1.5 % in 2008, and in 
Sweden from zero in 2000 to 1.2 % in 2008 (81). Norway 
reported a decrease from 1.8 % in 2004 to 0.8 % in 2009.
Among the four countries that conducted national school 
surveys in 2009–10 (Italy, Slovakia, Sweden, United 
Kingdom), only Slovakia reported a change (decrease) 
of more than one percentage point in lifetime cocaine 
use among 15- to 16-year-old school students. A recent 
study among older students in Germany found that the 
proportion of 15- to 18-year-old students in Frankfurt 
reporting lifetime experience of cocaine increased slightly 
to 6 % in 2008 and fell to 3 % in 2009.
Targeted surveys can provide a valuable window on the 
drug-using behaviour of young people in dance music and 
other recreational settings. While these surveys generally 
report relatively high prevalence of cocaine, recent 
studies in some European countries report a decrease. For 
example, a study of visitors to ‘coffee shops’ in Amsterdam 
reported a drop in lifetime cocaine use from 52 % in 2001 
to 34 % in 2009, and a drop in last month use from 19 % 
to 5 % over the same period (82). Also in the Netherlands, 
a qualitative trend monitor noted that, compared to 
earlier generations of 20- to 24-year-olds, people now 
of this age are less interested in cocaine use. A Belgian 
study conducted regularly in nightlife settings since 2003 
reported an increase in last year cocaine use during 
the period 2003–07 from 11 % to 17 %, followed by 
a decrease to 13 % in the 2009 study. Similar studies in 
the Czech Republic report an increase in lifetime cocaine 
use from 19 % in 2007 to 23 % in 2009. Such findings, 
however, need to be confirmed by other datasets.
Patterns of cocaine use
Surveys show that, in recreational settings, cocaine use is 
strongly linked with the consumption of alcohol. Data from 
general population surveys in nine countries reveals that 
the prevalence of cocaine use is between two and nine 
times higher among heavy episodic drinkers (83) than in the 
general population (EMCDDA, 2009b). Surveys have also 
shown that cocaine use is associated with the use of other 
illicit drugs. For example, an analysis of data from the 
2009/10 British Crime Survey found that 89 % of adults 
(16–59 years old) who had used cocaine powder during 
the past year had also used other drugs, compared with 
only 42 % of cannabis users (Hoare and Moon, 2010).
In some European countries, a substantial number of 
people use cocaine experimentally only once or twice 
(Van der Poel et al., 2009). Among more regular cocaine 
users, two broad groups can be distinguished. The first 
group is made up of more socially integrated users, who 
tend to use cocaine at weekends, parties or other special 
Figure 10: Trends in last year prevalence of cocaine use among 
young adults in the six EU Member States with the highest figures, 
Australia, Canada and the USA
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(84) See Table PDU-102 (part i) in the 2011 statistical bulletin.
occasions, sometimes in large amounts. Many of these 
users report controlling their cocaine use by setting rules, 
for example, about the amount, frequency or context 
of use (Reynaud-Maurupt and Hoareau, 2010). Some 
of these may suffer health problems related to their use 
of cocaine or go on to develop compulsive patterns of 
use that require treatment. Studies suggest, however, 
that a substantial proportion of those with cocaine-
related problems may recover without formal treatment 
(Cunningham, 2000; Toneatto et al., 1999).
The second group is composed of intensive cocaine and 
crack users belonging to more socially marginalised or 
disadvantaged groups, and may also include former 
or current opioid users who use crack or inject cocaine 
(Prinzleve et al., 2004).
Health consequences of cocaine use
The health consequences of cocaine use are likely to be 
underestimated. This may be due to the often unspecific 
or chronic nature of the pathologies typically arising 
from long-term use of cocaine (see Chapter 7). Regular 
use, including by snorting, can be associated with 
cardiovascular, neurological and psychiatric problems, and 
with the risk of accidents and of transmission of infectious 
diseases through unprotected sex (Brugal et al., 2009) and 
possibly through the sharing of straws (Aaron et al., 2008), 
for which evidence appears to be growing (Caiaffa et al., 
2011). Studies in countries with high levels of use indicate 
that a considerable proportion of cardiac problems in 
young people could be related to cocaine use (Qureshi 
et al., 2001). In Spain, for example, cocaine use appears 
to be involved in a significant proportion of drug-related 
hospital emergencies, and a recent Spanish study indicated 
that 3 % of sudden deaths are cocaine related (Lucena et 
al., 2010). Increases in use in Denmark have coincided with 
increasing numbers of cocaine-related emergency cases, 
which rose from 50 cases in 1999 to almost 150 in 2009.
Cocaine injection and crack use are associated with 
the highest health risks among cocaine users, including 
cardiovascular and mental health problems. These are 
generally aggravated by social marginalisation and the 
risks associated with injection, including the transmission 
of infectious diseases and overdoses (EMCDDA, 2007a).
Problem cocaine use and treatment demand
Regular cocaine users, those who use it over long periods 
and those who inject the substance are defined by the 
EMCDDA as problem cocaine users. Estimates of the size 
of this population provide an approximation of the number 
of people potentially in need of treatment. More socially 
integrated problem cocaine users are generally under-
represented in the estimates.
National estimates of problem cocaine users are available 
only for Italy, where the number was estimated to be about 
178 000 (between 4.3 and 4.7 per 1 000 aged 15–64) 
in 2009 (84). Trend data on problem cocaine use and other 
data sources (e.g. treatment entries) point to a gradual 
increase in problem cocaine use in Italy.
Crack use is unusual among socially integrated 
cocaine users, occurs mainly among marginalised and 
disadvantaged groups such as sex workers and problem 
opioid users and is largely an urban phenomenon 
(Prinzleve et al., 2004; Connolly et al., 2008). In London, 
crack use is considered to be a major component of the 
city’s drugs problem. Regional crack cocaine estimates are 
only available for England (United Kingdom), where there 
were an estimated 189 000 problem crack cocaine users 
in 2008/09, which corresponds to 5.5 (5.4 to 5.8) cases 
per 1 000 inhabitants aged 15–64. A majority of these 
crack users were also reported to be opioid users.
Cocaine and alcohol
Cocaine users commonly also use alcohol. Population 
surveys show that cocaine use and alcohol use — in 
particular heavy episodic drinking — are often associated. 
And two studies found that more than half of cocaine-
dependent users in treatment were also alcohol dependent.
The popularity of this combination may be explained by 
context; both substances are strongly associated with 
nightlife and party scenes, but also by pharmacological 
factors. The ‘high’ achieved by combining these substances 
is perceived to be beyond that with either drug alone. 
In addition, cocaine can make the effects of alcohol 
inebriation less intense and may also counteract some of the 
behavioural and psychomotor deficits induced by alcohol. 
Alcohol is also used to temper the discomfort felt when 
coming down from a cocaine ‘high’. In this respect, the 
combination can lead to increased use of both substances.
There are documented risks and toxic effects associated 
with simultaneous use of alcohol and cocaine including 
increasing the heart rate, raising systolic blood pressure, 
which may result in cardiovascular complications, and 
impairment of cognitive and motor functions. However, 
retrospective studies show combined use does not appear 
to cause more cardiovascular problems than expected 
from the additive use of each drug (Pennings et al., 2002). 
In addition, combined use results in the formation of a new 
substance, cocaethylene, a metabolite formed in the liver. 
There is ongoing debate as to whether cocaethylene is 
responsible for increased heart rate and cardiotoxicity.
For more information see EMCDDA (2007a).
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(85) See Figure TDI-2 and Tables TDI-5 (part i) and (part ii) and TDI-24 in the 2011 statistical bulletin; data for Spain refer to 2008.
(86) See Table TDI-18 (part ii) in the 2011 statistical bulletin.
(87) See Table TDI-22 in the 2011 statistical bulletin.
(88) See Table TDI-115 in the 2011 statistical bulletin.
Treatment demand
Further insights into problem cocaine use may be gained 
from data on the number and characteristics of people 
entering treatment due to cocaine use. Nearly all reported 
cocaine clients are treated in outpatient centres, although 
some might be treated in private clinics for which data are 
not available. Many problem cocaine users, however, do 
not seek treatment (Escot and Suderie, 2009; Reynaud-
Maurupt and Hoareau, 2010).
Cocaine, mainly powder cocaine, was cited as the 
principal reason for entering treatment by 17 % of all 
reported drug users entering treatment in 2009. Among 
those entering treatment for the first time in their life, the 
proportion of primary cocaine users was higher (23 %).
Wide differences exist between countries in the proportion 
and number of primary cocaine clients, with the highest 
proportions reported by Spain (46 %), the Netherlands 
(31 %) and Italy (28 %). In Belgium, Ireland, Cyprus and 
the United Kingdom, cocaine clients represent between 
11 % and 15 % of all drug clients. Elsewhere in Europe, 
cocaine users account for 10 % or less of drug treatment 
clients, with six countries reporting less than 1 % (85). 
Overall, Spain, Italy and the United Kingdom report 
together almost 58 000 of the 72 000 cocaine clients 
reported by 26 European countries.
The number of clients entering drug treatment for primary 
cocaine use has been increasing in Europe for several 
years. Based on 17 countries that have provided data 
across the period 2004–09, the number of cocaine clients 
increased from about 38 000 in 2004 to around 55 000 
in 2009. Over the same period, the number of cocaine 
clients entering treatment for the first time in their life 
increased by almost a third, from about 21 000 to 27 000 
(based on 18 reporting countries).
Profile of outpatient treatment clients
Clients entering outpatient treatment for primary use of 
cocaine, including powder and crack cocaine, present 
a high male to female ratio (about five men for every 
woman), and one of the highest mean ages (about 32 
years) among drug treatment clients. The average age is 
highest in France, Italy and the Netherlands (35 years). 
Primary users of cocaine report first use of the drug at 
a mean age of 22.5 years, with 86 % of them starting 
before the age of 30. The average time lag between 
first cocaine use and first treatment entry is about nine 
years. Almost a third of all cocaine clients are reported 
by the United Kingdom, and their profile differs from 
that of clients in other countries with a high number of 
cocaine users in treatment: they are younger on average 
(31 years), have a lower gender ratio (about three males 
for every female) and a shorter time lag between first use 
and treatment entry (around seven years).
Most cocaine clients report snorting (66 %) or smoking 
(29 %) the drug as their main route of administration. 
Injecting is reported as the main route of administration 
by only 3 % of cocaine clients, and a decrease in 
cocaine injecting has been observed between 2005 and 
2009. Almost half of cocaine clients have used the drug 
one to six times a week in the month before entering 
treatment, about a quarter have used it daily while the 
remaining quarter have not used it or have used it only 
occasionally during that period (86). Cocaine is often 
used in combination with other drugs, especially alcohol, 
cannabis, other stimulants and heroin. An analysis of 
treatment data from 14 countries in 2006 revealed that 
about 63 % of primary cocaine clients were polydrug 
users, reporting problems with at least one other drug. 
The most frequently cited additional problem drug was 
alcohol, used by 42 % of cocaine clients, followed by 
cannabis (28 %) and heroin (16 %) (EMCDDA, 2009b). 
Cocaine is also mentioned as a secondary substance (87), 
and has been increasingly reported by primary heroin 
users in Italy and the Netherlands.
Analysis of treatment entry data shows that the crack 
problem remains geographically limited in Europe. In 
2009, 10 540 clients were reported entering outpatient 
treatment for primary use of crack cocaine, representing 
16 % of all cocaine clients and 3 % of all drug clients 
entering outpatient treatment. Most crack clients are 
reported by the United Kingdom, where they number 
about 7 500, accounting for 40 % of the country’s 
cocaine clients and 6 % of its drug clients in outpatient 
centres. The Netherlands reported 1 231 crack clients, 
accounting for 38 % of the country’s cocaine clients and 
12 % of all drug clients (88). Heroin use is common among 
users of crack cocaine entering treatment. In the United 
Kingdom, for example, around 31 % of primary crack 
clients reported heroin as a secondary drug, and this 
proportion is increasing.
Treatment and harm reduction
Historically, treatment for drug use problems in Europe has 
focused on opioid dependence. However, with growing 
public health concern related to cocaine and crack 
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cocaine use, in many countries more attention has been 
given to responding to problems related to these drugs. 
Although treatment for cocaine dependence is mainly 
provided in specialised outpatient facilities, specific 
services for cocaine users are delivered in Denmark, 
Ireland, Italy, Austria and the United Kingdom. There is 
also limited provision of cocaine treatment in primary 
healthcare settings. Currently, only Germany and the 
United Kingdom provide guidance for the treatment of 
cocaine problems.
The primary treatment options for cocaine dependence 
are psychosocial interventions, including motivational 
interviewing, cognitive behavioural therapies, behavioural 
self-control training, relapse prevention interventions and 
counselling. Self-help groups such as Cocaine Anonymous 
can also play a role in the recovery process for individuals 
with cocaine use problems. The support they provide may 
be combined with formal treatment.
Studies on treatment of cocaine dependence
In Germany, Koerkel and Verthein (2010) evaluated the 
effects of behavioural self-control training for reducing 
heroin and cocaine use among dependent individuals. 
The training was reported to have helped participants to 
reduce the use of both substances and to maintain drug 
use at self-defined levels. Two recent studies investigated 
the effectiveness of drug treatment programmes in 
England. The Drug Treatment Outcomes Research Study 
(Jones, A., et al., 2009) found that more than half the 
cocaine clients stopped using the drug within three to five 
months of starting treatment. After a full year in treatment, 
60 % were abstinent. Similar results were reported for 
crack cocaine users undergoing treatment in 12 community 
services in London (Marsden and Stillwell, 2010).
There are numerous randomised trials underway to test 
new drugs for the treatment of cocaine dependence. At 
present, two substances show some promise. Disulfiram, 
a substance that interferes with the metabolism of 
alcohol, has proved promising in treating cocaine 
dependence (Pani et al., 2010a), and is now being tested 
in conjunction with cognitive behavioural therapy in 
the treatment of crack cocaine addiction in a Brazilian 
study. Vigabatrin, an anti-epilectic drug, was tested in 
103 Mexican parolees with positive results at short-
term follow-up. It is now being tested in 200 patients 
in the USA. In the Netherlands, a new approach using 
rimonabant (a selective cannabinoid antagonist formerly 
used as an anti-obesity drug), is currently being tested. 
In addition, multiple pharmacotherapeutic options 
(topiramate, dexamphetamine and modafinil) are 
being compared in a randomised controlled study for 
crack cocaine dependence, recently registered in the 
Netherlands (Hicks et al., 2011).
A number of other trials have produced weak or non-
significant results for cocaine dependence. Modafinil, 
a central nervous system stimulant, was no better than 
the placebo in addressing cocaine use (Anderson et 
al., 2009). Both naltrexone (an opioid antagonist) and 
varenicicline (used to treat smoking addiction) were tested 
on patients with multiple addiction to cocaine and alcohol 
or tobacco, but made no difference to use compared with 
the placebo. Memantine (an Alzheimer’s medication) was 
tested in combination with voucher incentives, but was no 
more successful than the placebo in reducing cocaine use.
Contingency management has been found to be effective 
regardless of ethnicity (Barry et al., 2009), and has 
proved to be a successful strategy when combined with 
relapse prevention (McKay et al., 2010). In a Spanish 
study, the use of vouchers as an incentive alongside 
community reinforcement was found to support abstinence 
among cocaine-dependent users (Garcia-Rodriguez et 
al., 2009). However, in another study, voucher incentives 
showed weak results in reinforcing abstinence for longer 
periods (Carpenedo et al., 2010).
Other interventions with promising results include 
employment-based abstinence reinforcement, in which 
clients receive job skills training for six months, followed 
by a year’s employment, subject to random testing for 
cocaine use. Other methods being tested to help users 
reach abstinence include mindfulness training and 
integrative meditation. Tests being carried out in the 
Netherlands aim to reduce craving with transcranial 
magnetic stimulation, a technique which has been used to 
treat neurologic and psychiatric conditions.
Attempts to develop a cocaine vaccine are continuing. 
A randomised controlled trial conducted in the United 
States (Martell et al., 2009) linked a derivative of cocaine 
to a cholera B protein, but the results appear too weak to 
proceed with planned field studies in Spain and Italy. The 
American research group is now recruiting 300 patients 
to test a modified version of the vaccine and the results 
are expected in 2014 (Whitten, 2010). Another study 
is developing a vaccine using a common cold virus as 
a carrier to boost antibody reaction, but the model is yet 
to be tested with humans.
Harm reduction
The use of cocaine and crack cocaine represents 
a relatively new focus for harm-reduction interventions, 
and requires a rethinking of traditional strategies. Member 
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States usually provide cocaine injectors with the same 
services and facilities as opioid users. However, cocaine 
injecting is associated with specific risks. In particular, 
it involves a potentially higher frequency of injecting, 
chaotic injecting behaviour and increased sexual risk 
behaviours. Safer-use recommendations need to be 
tailored to the needs of this group. Due to the potential 
high frequency of injecting, the supply of sterile equipment 
to injectors should not be restricted, but rather based on 
local assessment of cocaine use patterns and the social 
situation of injectors (Des Jarlais et al., 2009).
Provision of specific harm-reduction programmes for 
crack cocaine smokers in Europe is limited. Although 
controversial, such interventions may have the potential to 
reduce self-reported injecting behaviour and sharing of 
drug pipes (Leonard et al., 2008), although their overall 
effectiveness in reducing transmission of blood-borne 
viruses requires further study. Some drug consumption 
facilities in three countries (Germany, Spain, Netherlands) 
provide facilities for inhalation of drugs, including cocaine. 
Hygienic inhalation devices including clean crack pipes 
or ‘crack kits’ (glass stem with mouth piece, metal screen, 
lip balm and hand wipes) are reported to be sporadically 
provided to drug users who smoke crack cocaine by 
some low-threshold facilities in Belgium, Germany, Spain, 
France, Luxembourg and the Netherlands. Foil is also 
made available to heroin or cocaine smokers at some low-
threshold facilities in seven EU Member States.
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Introduction
Heroin use, particularly injecting the drug, has been 
closely associated with public health and social problems 
in Europe since the 1970s. Today, this drug still accounts 
for the greatest share of morbidity and mortality related 
to drug use in the European Union. After two decades of 
mostly growing heroin problems, Europe saw a decline in 
heroin use and associated harm during the late 1990s and 
the early years of the present century. Since 2003–04, 
however, the trend has become less clearly defined, with 
indicators suggesting a more stable or mixed picture. In 
addition to heroin, reports of the use of synthetic opioids, 
such as fentanyl, and the injection of stimulant drugs, such 
as cocaine or amphetamines, reflect the increasingly multi-
faceted nature of problem drug use in Europe.
Supply and availability
Two forms of imported heroin have historically been 
offered on the illicit drugs market in Europe: the commonly 
available brown heroin (its chemical base form), which 
comes mainly from Afghanistan; and white heroin (a salt 
form), which typically originates from south-east Asia, 
though this form is considerably less common. In some 
northern European countries (e.g. Estonia, Finland, 
Norway), fentanyl, a synthetic opioid, and its analogues 
are in use. In addition, some opioid drugs are produced 
within Europe, principally home-made poppy products 
(e.g. poppy straw, concentrate from crushed poppy 
stalks or heads) in some east European countries (Latvia, 
Lithuania, Poland).
Production and trafficking
Heroin consumed in Europe originates predominantly in 
Afghanistan, which accounts for most of the global illicit 
opium output. The other producing countries are Burma/
Myanmar, which mainly supplies markets in east and 
south-east Asia, Pakistan and Laos, followed by Mexico and 
Colombia, which are considered the largest suppliers of 
heroin to the United States (UNODC, 2011). Global opium 
production is estimated to have decreased from a peak in 
2007, mainly due to a decline in Afghan production, which 
has fallen from 6 900 tonnes in 2009 to 3 600 tonnes in 
2010. The most recent estimate of global potential heroin 
production is 396 tonnes (see Table 10), down from an 
estimated 667 tonnes in 2009 (UNODC, 2011).
Heroin arrives in Europe mainly by two trafficking routes. 
The historically important Balkan route brings heroin 
produced in Afghanistan through Pakistan, Iran and 
Turkey, and then towards other transit or destination 
countries, mainly in western and southern Europe. Heroin 
is also trafficked via the ‘silk route’ through central Asia 
and towards Russia. To a limited extent, this heroin is then 
smuggled through Belarus, Poland and Ukraine to other 
destinations such as Scandinavian countries via Lithuania 
(INCB, 2010, 2011a). Within the European Union, the 
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Table 10: Production, seizures, price and purity of 
heroin
Production and seizures Heroin
Global production estimate (tonnes) 396
Global quantity seized (tonnes) 76
Quantity seized (tonnes) 
EU and Norway  
(Including Croatia and Turkey)
 
8 
(24)
Number of seizures 
EU and Norway  
(Including Croatia and Turkey)
 
56 000 
(59 000)
Price and purity in Europe (1) Heroin base (‘brown’)
Mean retail price (EUR per gram) 
Range 
(Interquartile range) (2)
 
23–135 
(37.5–67.9)
Mean purity (%) 
Range 
(Interquartile range) (2)
 
13–37 
(16.8–33.2)
(1) Since few countries report the retail price and the purity of heroin 
hydrochloride (‘white’), the data are not presented here. They can be 
consulted in Tables PPP-2 and PPP-6 in the 2011 statistical bulletin.
(2) Range of the middle half of the reported data.
NB: Data are for 2009, except the global production estimate (2010).
Source: UNODC (2011) for global values, Reitox national focal points for 
European data.
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(89) See Tables SZR-7 and SZR-8 in the 2011 statistical bulletin. Note that where data for 2009 are absent, data for 2008 are used to estimate European 
totals.
(90) See Tables PPP-2 and PPP-6 in the 2011 statistical bulletin for purity and price data.
Netherlands and, to a lesser extent, Belgium play an 
important role as secondary distribution hubs.
Seizures
Worldwide reported seizures of opium remained stable 
between 2008 and 2009, at 657 and 653 tonnes, 
respectively. Iran accounted for nearly 90 % of the total 
and Afghanistan for about 5 %. Global reported seizures 
of heroin remained stable in 2009 (76 tonnes), while 
global seizures of morphine decreased to 14 tonnes 
(UNODC, 2011).
In Europe, an estimated 59 000 seizures resulted in the 
interception of 24 tonnes of heroin in 2009, two thirds 
of which (16.1 tonnes) was reported by Turkey. The 
United Kingdom (followed by Spain) continued to report 
the highest number of seizures (89). Data for the years 
2004–09 from 28 reporting countries show an overall 
increase in the number of seizures. The overall trend in the 
quantity of heroin intercepted in Turkey differs from that 
observed in the European Union, which may be due in 
part to greater collaboration between Turkish and EU law 
enforcement agencies. While Turkey reported a doubling 
in the quantity of heroin seized between 2004 and 2009, 
the amount seized in the European Union has shown a 
limited decline during this period, mainly due to decreases 
reported in Italy and the United Kingdom, the two countries 
seizing the largest quantities in the European Union.
Global seizures of acetic anhydride used in the 
manufacture of heroin decreased from a peak of about 
200 000 litres in 2008 to 21 000 litres in 2009. 
Figures for the European Union show an even stronger 
downward trend: from a peak of almost 150 800 litres 
seized in 2008 to 866 litres in 2009. For 2010, however, 
Slovenia has reported seizing a record quantity of acetic 
anhydride — 110 tonnes. The INCB (2011a) placed the 
success of EU efforts to prevent diversion of the precursor 
in the context of several EU Member States and Turkey 
combining their investigations.
Purity and price
The mean purity of brown heroin tested in 2009 ranged 
between 16 % and 32 % for most reporting countries; 
lower mean values were reported in France (14 %) and 
Austria (retail only, 13 %) and higher ones in Malta 
(36 %), Romania (36 %) and Turkey (37 %). Between 2004 
and 2009, the purity of brown heroin increased in four 
countries, remained stable in four others and decreased 
in three. The mean purity of white heroin was generally 
higher (25 % to 50 %) in the three European countries 
reporting data (90).
The retail price of brown heroin continued to be 
considerably higher in the Nordic countries than in the 
rest of Europe, with Sweden reporting a mean price 
of EUR 135 per gram and Denmark EUR 95 in 2009. 
Overall, it ranged between EUR 40 and EUR 62 per 
gram in half of the reporting countries. Over the period 
2004–09, the retail price of brown heroin decreased in 
half of the 14 European countries reporting time trends.
Problem drug use
Problem drug use is defined by the EMCDDA as injecting 
drug use or long duration/regular use of opioids, cocaine 
and/or amphetamine. Injecting drug use and the use 
of opioids form the greater part of problem drug use in 
Europe, although in a few countries users of amphetamines 
or cocaine are important components. It is also worth 
noting that problem drug users are mostly polydrug users, 
and that prevalence figures are much higher in urban 
areas and among socially excluded groups.
Given the relatively low prevalence and the hidden nature 
of problem drug use, statistical extrapolations are required 
to obtain prevalence estimates from the available data 
Major fall in opium production in Afghanistan
At 3 600 tonnes, opium production in Afghanistan in 2010 
is estimated to have fallen to about half the level reached 
in the previous year. Among the causes suggested for this 
major reduction in the yield of the opium poppy crop are 
unfavourable weather conditions and the spread of poppy 
blight, a fungal infection, which affected opium fields in the 
major poppy-growing provinces, particularly Helmand and 
Kandahar (UNODC and MCN, 2010). The blight did not 
significantly change the area under opium cultivation, but 
had an impact on the quantity of opium produced.
The decline in crop yield also led to a dramatic rise in 
reported opium prices at harvest time. The average farm 
gate price of 1 kg of dry opium increased by a factor of 
2.6, from USD 64 in 2009 to USD 169 in 2010 (UNODC 
and MCN, 2010). At the same time, the average price of 
heroin in Afghanistan increased by a factor of 1.4.
The high opium price may not last long. A price rise that 
occurred in 2004, when opium production fell due to 
disease, lasted less than a year (UNODC and MCN, 
2010). The effects of the recent drop in opium production 
on the consumer markets, particularly in Europe, need to 
be followed closely.
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sources (mainly drug treatment data and law enforcement 
data). Overall prevalence of problem drug use is reported 
to range from 2 to 10 cases per 1 000 population aged 
15–64. Such estimates may have large uncertainty 
ranges and specific limitations. For example, while users 
in treatment are generally included, drug users currently 
in prison, especially those with longer sentences, may be 
under-represented in the estimates.
Problem opioid use
Most European countries are now able to provide 
prevalence estimates of ‘problem opioid use’. Recent 
national estimates vary between one and eight cases 
per 1 000 population aged 15–64 (Figure 11). The 
countries reporting the highest well-documented estimates 
of problem opioid use are Ireland, Italy, Luxembourg 
and Malta, while the lowest are reported by the Czech 
Republic, the Netherlands, Poland, Slovakia and Finland. 
Only Turkey and Hungary report less than one case per 
1 000 population aged 15–64.
The average prevalence of problem opioid use in the 
European Union and Norway, computed from national 
studies, is estimated to be between 3.6 and 4.4 cases 
per 1 000 population aged 15–64. This corresponds to 
some 1.3 million (1.3 million to 1.4 million) problem opioid 
users in the European Union and Norway in 2009. By 
comparison, estimates for Europe’s neighbouring countries 
are high, with Russia at 16 per 1 000 population aged 
15–64 (UNODC, 2009), and Ukraine at 10–13 cases per 
1 000 population aged 15–64 (UNODC, 2010). Estimates 
of problem opioid prevalence that are higher than the 
European average are reported elsewhere in the developed 
world, where the number of cases per 1 000 population 
aged 15–64 is 6.3 in Australia (Chalmers et al., 2009), 
5.0 in Canada and 5.8 in the USA (UNODC, 2010). 
Comparisons between countries should be made with 
caution, as definitions of the target population may vary.
Opioid users entering treatment
Opioids, mainly heroin, were cited as the primary drug 
for entering treatment by around 216 000 or 51 % of 
all those reported entering specialist drug treatment in 
29 European countries in 2009. However, considerable 
differences exist across Europe, with opioid clients 
accounting for more than 80 % of those entering treatment 
in six countries, between 60 % and 80 % in seven, and 
with only two of the remaining 16 countries reporting 
opioid clients accounting for less than 20 % of treatment 
Figure 11: Estimates of the annual prevalence of problem opioid use (among the population aged 15–64)
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NB: A symbol indicates a point estimate; a vertical mark indicates an uncertainty interval: a 95 % confidence interval, or one based on sensitivity 
analysis. Target groups may vary slightly, owing to different estimation methods and data sources; therefore, comparisons should be made with 
caution. Non-standard age ranges were used in the studies from Finland (15–54), Malta (12–64) and Poland (all ages). All three rates were 
adjusted to the population aged 15–64. For Germany, the interval represents the highest and lowest bounds of all existing estimates, and the 
point estimate a simple average of the midpoints. Methods of estimation are abbreviated: CR, capture-recapture; TM, treatment multiplier; MM, 
mortality multiplier; CM, combined methods; TP, truncated Poisson; PM, police multiplier; OT, other methods. See Figure PDU-1 (part ii) and Table 
PDU-102 in the 2011 statistical bulletin for further details.
Sources: Reitox national focal points.
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(91) See Figure TDI-2 (part ii) and Tables TDI-5 and TDI-22 in the 2011 statistical bulletin. Data are from outpatient and inpatient treatment centres.
(92) See Tables TDI-10, TDI-12, TDI-13, TDI-21, TDI-32 and TDI-103 in the 2011 statistical bulletin.
(93) See Tables TDI-11, TDI-33, TDI-106 (part i) and TDI-107 (part i) in the 2011 statistical bulletin.
(94) See Tables TDI-18 and TDI-111 in the 2011 statistical bulletin.
(95) See Figures TDI-1 and TDI-3 in the 2011 statistical bulletin. 
(96) See Tables TDI-3 and TDI-5 in the 2009 and 2011 statistical bulletin.
(97) See Table DRD-2 (part i) in the 2011 statistical bulletin.
(98) See Table TDI-113 in the 2008, 2009, 2010 and 2011 statistical bulletins and Table TDI-114 in the 2009 statistical bulletin. Data are available with a 
breakdown by type of opioid for the years 2005 and 2009. See also EMCDDA (2010f).
entrants (Figure 12). In addition, a further 30 000 users 
(9 % of drug clients) of other drugs cited opioids as a 
secondary drug (91).
Opioid users entering specialist treatment are on average 
34 years old, with female clients and those entering 
treatment for the first time being younger in most countries. 
Across Europe, male opioid clients outnumber their 
female counterparts by a ratio of about three to one, 
with generally lower male to female ratios in northern 
countries. In general, opioid users entering treatment have 
higher rates of unemployment, lower levels of educational 
attainment and higher levels of psychiatric disorders than 
clients reporting other primary drugs (92).
Almost half of opioid clients reported first using the drug 
before the age of 20 (47 %) and the great majority have 
done so by the age of 30 (88 %). Opioid clients report 
an average interval of nine years between first use of 
opioids and entering treatment for the first time, with 
female clients reporting a shorter average time lag (seven 
years) (93). Injecting the drug is reported as the usual 
mode of administration by about 40 % of opioid clients 
entering treatment in Europe; the remaining 60 % report 
that they snort, inhale or smoke the drug. Almost two 
thirds of opioid clients (64 %) report daily use of the drug 
in the month prior to entering treatment (94), and most use 
a secondary drug, often alcohol, cannabis, cocaine or 
other stimulants. The combination of heroin and cocaine 
(including crack) is quite common among clients, either 
injected together or used separately.
Trends in problem opioid use
During the period 2004–09, data from eight countries 
with repeated prevalence estimates in problem opioid use 
suggest a relatively stable situation. Based on a sample 
of 17 European countries where data were available for 
the period 2004–09, there has been an overall increase 
in the reported number of clients entering specialist drug 
treatment in Europe, including those entering treatment 
for primary heroin use (from 123 000 to 143 000). This 
increase may, however, be largely due to heroin users 
re-entering treatment rather than to first-time treatment 
entrants (95). For clients entering treatment for the first 
time, the number of heroin users has remained almost 
stable (around 32 000 in a sample of 18 countries) (96). 
Data on drug-induced deaths over the period 2004–09, 
which are mostly associated with opioid use, were stable 
or increasing in the majority of reporting countries until 
2008. Provisional data for 2009 now point to a stable or 
decreasing number of deaths (97).
Despite indications of an overall stable situation, the 
characteristics of Europe’s opioid problem are changing. 
Opioid treatment clients have become older on average, 
while the proportion of injectors among them has 
decreased and the proportion of users of opioids other 
than heroin and of polydrug users has increased (98).
Injecting drug use
Injecting drug users are among those at highest risk of 
experiencing health problems from their drug use, such 
as blood-borne infections (e.g. HIV/AIDS, hepatitis) or 
drug overdoses. In most European countries, injection is 
Figure 12: Primary opioid users as a percentage of all reported 
drug treatment entrants in 2009
80.01+
60.01–80.00
40.01–60.00
20.01–40.00
  0.00–20.00
Missing or excluded
NB: Data are expressed as a percentage of those for whom the primary 
drug is known (92 % of the reported clients). Data are for 2009 
or for the most recent year available. Data for Latvia, Lithuania 
and Portugal refer to clients entering treatment for the first time in 
their lives. Primary opioid users may be under-reported in some 
countries including Belgium, the Czech Republic, Germany and 
France, as many are treated by general practitioners and may not 
be reported to the treatment demand indicator.
Sources: Reitox national focal points.
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(99) See Figure PDU-2 in the 2011 statistical bulletin.
(100) See Table PDU-6 (part iii) in the 2011 statistical bulletin.
commonly associated with opioid use, although in a few 
countries, it is associated with use of amphetamines.
Only 14 countries were able to provide recent estimates 
of the prevalence of injecting drug use (99). The available 
data suggest large differences between countries, with 
estimates ranging from less than one to five cases per 
1 000 population aged 15–64 for most of the countries, 
with an exceptionally high level of 15 cases per 1 000 
reported in Estonia. Taking these 14 countries together 
as a whole, it can be calculated that there are about 2.6 
injecting drug users per 1 000 population aged 15–64. 
In addition to active injectors, there are a large number 
of former injecting drug users in Europe (Sweeting et al., 
2008), but figures are not available for most EU countries.
About 41 % of primary opioid clients entering specialist 
drug treatment, mainly heroin users, report injecting as the 
usual mode of administration. Levels of injecting among 
opioid users vary between countries, from 8 % in the 
Netherlands to 99 % in Latvia and Lithuania (Figure 13), 
which may be explained by factors such as the history 
of heroin use in the country, the type of heroin available 
(white or brown), price and user culture.
Drawing conclusions on time trends in the prevalence 
of injecting drug use based on repeated prevalence 
estimations is difficult because of the lack of data and, in 
some cases, the wide uncertainty ranges of the estimates. 
Available data indicate an overall decrease in opioid 
injection, particularly heroin injection, in Europe. In 
some countries, however, injecting levels appear to have 
remained relatively stable (Greece, Cyprus, Hungary, 
Croatia, Norway), while the Czech Republic reported 
an increase of injectors, mostly methamphetamine users, 
between 2004 and 2009 (100).
Most European countries have reported a decrease of 
the proportion of injectors among primary heroin clients 
between 2004 and 2009. The few countries where this is 
Opioids other than heroin
Increasing illicit use of opioids other than heroin has been 
reported in Australia, Canada, Europe and the United 
States (SAMHSA, 2009). Most of these substances are 
used in medical practice, as pain relievers (morphine, 
fentanyl, codeine, oxycodone, hydrocodone) or as 
substitution drugs in the treatment of heroin dependence 
(methadone, buprenorphine). As with heroin, the non-
medical use of these substances can lead to a range of 
adverse health effects, including dependence, overdose 
and harm associated with injection.
In Europe, about 5 % (around 20 000 patients) of all 
treatment entrants declare opioids other than heroin as 
their primary drug. This is particularly the case in Estonia, 
where 75 % report fentanyl as their primary drug, and in 
Finland, where buprenorphine is reported as the primary 
drug of 58 % of treatment entrants. Other countries with 
significant proportions of clients reporting methadone, 
morphine and other opioids as primary drug include 
Denmark, France, Austria, Slovakia and Sweden, where 
non-heroin opioid users account for between 7 % and 
17 % of all drug clients (1). The Czech Republic also reports 
that buprenorphine users accounted for more than 40 % of 
all problem opioid users between 2006 and 2009.
Levels of illicit use of opioids may be linked with a mixture 
of factors including the drug market and prescription 
practices. For example, a decrease in heroin availability 
and an increase in its price may lead to the use of other 
opioids, as was observed in Estonia with fentanyl (Talu et 
al., 2010) and in Finland with buprenorphine (Aalto et al., 
2007). Inappropriate prescription practices can also lead 
to illicit use of opioid drugs. The expansion of substitution 
treatment accompanied by a lack of supervision can 
create an illicit market, while limited availability of this 
treatment and the prescription of substitution doses that 
are too low can lead users to take other substances as a 
self-medication (Bell, 2010; Roche et al., 2011; Romelsjo et 
al., 2010).
(1) See Table TDI-113 in the 2011 statistical bulletin.
Figure 13: Injecting as usual mode of administration among 
primary opioid users entering treatment in 2009
80.01+
60.01–80.00
40.01–60.00
20.01–40.00
  0.00–20.00
Missing or excluded
NB: Data are expressed as a percentage of reported clients for 
whom the route of administration is known. Data are for 2009 
or most recent year available. See Table TDI-5 (part iii) and 
(part iv) in the 2011 statistical bulletin.
Sources: Reitox national focal points.
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(101) See Table TDI-24 in the 2011 statistical bulletin.
(102) See Table HSR-3 in the 2011 statistical bulletin.
not the case report the highest proportions of heroin users 
among clients entering treatment.
Treatment of problem opioid use
Provision and coverage
Both drug-free and substitution treatment for opioid users 
are available in all EU Member States, Croatia, Turkey 
and Norway. In most countries, treatment is conducted in 
outpatient settings, which can include specialised centres, 
general practitioners’ surgeries and low-threshold facilities. 
In a few countries, specialist inpatient centres play an 
important role in the treatment of opioid dependence (101). 
A small number of countries offer heroin-assisted treatment 
for a selected group of chronic heroin users.
For opioid users, drug-free treatment is generally preceded 
by a detoxification programme, which provides them 
with pharmaceutical assistance to manage the physical 
withdrawal symptoms. This therapeutic approach generally 
requires individuals to abstain from all substances, 
including substitution medication. Patients participate 
in daily activities and receive intensive psychological 
support. While treatment can take place in both outpatient 
and inpatient settings, the types most commonly reported 
are residential (or rehabilitation) programmes, many of 
which apply therapeutic community principles or the 
Minnesota model.
Substitution treatment, generally integrated with 
psychosocial care, is typically provided at specialist 
outpatient centres. Fourteen countries report that it is also 
provided by general practitioners, usually under shared-
care arrangements with specialist treatment centres. 
The total number of opioid users receiving substitution 
treatment in the European Union, Croatia and Norway is 
estimated at 700 000 (690 000 for EU Member States) in 
2009, up from 650 000 in 2007, and about half a million 
in 2003 (102). The vast majority of substitution treatments 
continue to be provided in the 15 pre-2004 EU Member 
States (about 95 % of the total), and numbers in these 
countries continued to increase between 2003 and 2009 
(Figure 14). Among these countries, the highest increases 
were observed in Finland, with a three-fold increase, and 
Austria and Greece, where treatment numbers doubled.
In the 12 countries that joined the EU more recently, the 
number of substitution clients nearly tripled between 
2003 and 2009, from 6 400 to 18 000. Relative to the 
index year 2003, a steep increase can be noted during 
2005–07, but from this date onwards there has been 
little further increase. Proportionally, the expansion of 
substitution treatment in these countries over the six-year 
period was highest in Estonia (16-fold from 60 to over 
1 000 clients, though still reaching only 5 % of opioid 
injectors) and Bulgaria (eight-fold), while there was a 
three-fold increase in Latvia. The smallest increases 
were reported from Slovakia and Hungary, and client 
numbers in Romania remained practically unchanged. 
Increased provision of substitution treatment might be 
linked to several factors, including: responding to high 
levels of injecting drug use and related HIV-transmission; 
alignment with the EU drugs strategy; and the funding of 
pilot projects by international organisations, such as the 
Global Fund and UNODC.
A comparison of the number of clients in substitution 
treatment with the estimated number of problem opioid 
Heroin drought in Europe?
The availability of heroin is reported to have dropped 
sharply in the United Kingdom and Ireland in late 2010 
to early 2011. This is supported by figures showing a 
considerable drop in the purity of heroin seized in the 
United Kingdom between the third quarter of 2009 and the 
third quarter of 2010 (UNODC, 2011).
The extent of the shortage in other European countries is 
less clear, although reports suggest that Italy and Slovenia 
have experienced heroin shortages. Other EU Member 
States, including Germany, France and Scandinavian 
countries, report little or no reduction in heroin availability.
A number of reasons have been put forward to explain 
the apparent heroin drought. First, it has been suggested 
that reduced production of opium in Afghanistan, due to 
poppy blight in the spring of 2010, may be responsible. 
However, this is debatable, as police reports suggest 
that heroin made from Afghan opium may not appear on 
the European drug markets until about 18 months after 
harvest. A second argument is that heroin destined for 
western Europe has been diverted to the Russian market, 
but Russia also appears to be undergoing a heroin 
shortage. It has also been suggested that law enforcement 
efforts have disrupted trafficking, in particular through the 
dismantling of wholesale heroin networks between Turkey 
and the United Kingdom. Also, recent years (2007, 2008) 
have seen record seizures of the heroin precursor acetic 
anhydride in Europe, and these confiscations may have 
affected the drug market over a longer period. Finally, 
other developments in Afghanistan, such as heavy fighting 
in the south of the country, and law enforcement actions 
against heroin laboratories and opium stockpiles, may also 
be influencing heroin supply to Europe.
It is likely that a combination of some of these factors has 
played a role in disrupting the supply of heroin to Europe, 
causing severe shortages in some markets.
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(103) See Figure HSR-1 in the 2011 statistical bulletin.
(104) See Table HSR-3 in the 2011 statistical bulletin.
(105) See the box ‘Heroin-assisted treatment’.
users suggests varying coverage levels in Europe. Of the 
16 countries for which reliable estimates of the number 
of problem opioid users are available, eight report a 
number of substitution treatments corresponding to 40 % 
or more of the target population. Seven of those countries 
are pre-2004 EU Member States, and the remaining 
high-coverage country is Malta. Coverage reaches 37 % 
in the Netherlands and 32 % in the Czech Republic and 
Hungary. Of the five countries with coverage levels below 
30 %, four are newer Member States. The exception in this 
group is Greece, with an estimated coverage of 23 % (103).
Countries in central and eastern Europe report efforts 
to improve access, quality and provision of substitution 
treatment. In 2010, clinical guidelines for the treatment of 
opioid dependence with methadone and buprenorphine 
were issued in Lithuania. Geographical availability of 
substitution treatment in Latvia is expanding, with new 
treatment providers outside of the capital Riga. Regulations 
for the financing of opioid substitution treatment under 
national health insurance have been adopted in the Czech 
Republic. Lack of funding for substitution treatment is, 
however, reported as limiting the geographical coverage 
in Poland and reducing significantly the number of 
treatment slots available among the main providers of 
substitution treatment in Bulgaria, which are non-publicly 
funded organisations.
Overall, it is estimated that about half of the European 
Union’s problem opioid users have access to substitution 
treatment, a level that is comparable to those reported for 
Australia and the United States, though higher than that 
reported for Canada. China reports much lower levels, 
while Russia, despite having the highest estimated number 
of problem opioid users, has not introduced this type of 
treatment (see Table 11).
In Europe, methadone is the most commonly prescribed 
substitution medication, received by up to three 
quarters of clients. Buprenorphine is prescribed to up 
to a quarter of European substitution clients, and is 
the principal substitution drug in the Czech Republic, 
France, Cyprus, Finland, Sweden and Croatia (104). 
The combination buprenorphine/naloxone is available 
in 15 countries. Treatments with slow-release oral 
morphine (see below), codeine (Germany, Cyprus) and 
diacetylmorphine (105) (Belgium, Denmark, Germany, 
Spain, Netherlands, United Kingdom) represent a small 
proportion of all treatments.
In addition to the more commonly used substitution 
medications, slow-release oral morphine, which was 
originally licensed to treat pain in cancer patients, is 
currently provided as an alternative drug for substitution 
treatment for opioid dependence in Bulgaria, Austria, 
Slovenia and Slovakia. A recent review (Jegu et al., 
2011) of 13 studies concluded that levels of retention in 
treatment appeared sufficiently high with this substance 
Figure 14: Clients in opioid substitution treatment in the 15 pre-
2004 and the 12 newer EU Member States — estimated numbers 
and indexed trends
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Table 11: International comparison of estimates 
of problem opioid users and numbers of clients 
in opioid substitution treatment
Problem opioid 
users
Clients in opioid 
substitution 
treatment
European Union and Norway 1 300 000 695 000
Australia 90 000 43 000
Canada 80 000 22 000
China 2 500 000 242 000
Russia 1 600 000 0
USA 1 200 000 660 000
NB: Year: 2009, except for Canada (reference year is 2003).
Sources: Arfken et al. (2010), Chalmers et al. (2009), Popova et al. (2006), 
UNODC (2010), Yin et al. (2010).
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(80.6 % to 95 %), and no different from those reported 
for methadone. Most studies showed that quality of life, 
withdrawal symptoms, craving and illicit drug consumption 
improved with morphine, but there was no comparison 
with other substitution drugs. More information might be 
provided by a forthcoming Cochrane systematic review.
Opioid treatment: effectiveness and outcomes
Opioid substitution treatment, combined with psychosocial 
interventions, is considered to be the most effective 
treatment option for opioid dependence. In comparison 
with detoxification or no treatment at all, both methadone 
and high dosage buprenorphine treatments show better 
rates of retention in treatment and significantly better 
outcomes for drug use, criminal activity, risk behaviours 
and HIV-transmission, overdoses and overall mortality 
(WHO, 2009).
A number of recent studies focus on medication that may 
complement substitution treatment. Two systematic reviews 
have explored whether antidepressants reduced dropout 
among methadone or buprenorphine patients, but did not 
find evidence of effectiveness (Pani et al., 2010b; Stein et 
al., 2010). Another study showed that a single additional 
methadone dose could help reduce craving-induced mood 
problems among stabilised methadone patients (Strasser et 
al., 2010).
The opioid receptor antagonist naltrexone is used to prevent 
relapse to opioid use. In a small-scale trial, naltrexone 
implants were found to be more effective than oral 
naltrexone in reducing both craving and relapse (Hulse et 
al., 2010). A study among released prisoners showed that 
naltrexone implants provided similar reductions in heroin 
and benzodiazepines use to methadone (Lobmaier et al., 
2010). Buprenorphine implants, developed to overcome 
problems of non-compliance and to prevent treatment 
diversion, have also been tested in the United States against 
placebo implants. A preliminary study showed a minor 
difference regarding abstinence in favour of the active 
implants (Ling et al., 2010), and the next step will be to 
compare these implants against other treatments (O’Connor, 
2010). In Europe, a Finnish study is testing whether providing 
suboxone in an electronic device that registers use improves 
compliance and limits the diversion of take-home drugs.
Treatment outcome research documents some encouraging 
results. The Drug Treatment Outcome Research Study 
used a 12-month window to assess treatment outcomes of 
1 796 drug users recruited from 342 agencies (106) across 
England (Jones, A., et al., 2009). Among heroin users 
involved in the baseline interviews, 44 % had stopped 
using at first follow-up and 49 % at second follow-up, and 
there were also consistent reductions for all of the other 
major substances assessed.
(106) Community-based treatment (mainly oral methadone maintenance) and residential treatment.
Heroin-assisted treatment
Heroin-assisted treatment is provided to a total of about 
1 100 problem opioid users in five EU Member States 
(Denmark, Germany, Spain, Netherlands, United Kingdom) 
and 1 360 problem opioid users in Switzerland. This treatment 
is not proposed as a first-line option, but is reserved for 
patients who have not responded to other approaches, such 
as methadone maintenance treatment. All injectable doses 
(typically about 200 mg diamorphine per injection) are taken 
under direct supervision, in order to ensure compliance, safety 
and prevention of any possible diversion to the illicit market: 
this requires the clinics to be open for several sessions per day, 
every day of the year.
Six randomised clinical trials examining the outcomes and 
the cost-effectiveness of this type of treatment have been 
conducted over the last 15 years (see EMCDDA, 2011a). 
All trials included chronic heroin-dependent individuals who 
have repeatedly failed other treatment approaches, and who 
were randomly attributed to heroin-assisted treatment or to 
oral methadone treatment. The studies used different methods 
and outcome variables, and their results are therefore only 
moderately consistent. Overall, they indicate an added value 
of supervised injectable heroin alongside supplementary 
doses of methadone for long-term opioid users for whom other 
approaches have not succeeded. Patients use less street drugs 
and appear to achieve some gains in physical and mental 
health functioning.
Heroin-assisted treatment is estimated to cost EUR 19 020 
per patient per year in Germany and EUR 20 410 in the 
Netherlands (adjusted to 2009 prices). This is substantially 
higher than the cost of providing a patient with one 
year’s oral methadone treatment, which is estimated to be 
EUR 3 490 in Germany and EUR 1 634 in the Netherlands. 
The cost difference between heroin-assisted and methadone 
treatment is largely due to the higher staffing requirements 
for specialist clinics. Despite its higher costs, heroin-
assisted treatment has been shown to be a cost-effective 
intervention for a selected group of chronic heroin users 
(EMCDDA, 2011a).
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Oral substitution treatment in pregnancy
Opioid-dependent expectant mothers are recommended 
to take methadone substitution treatment for the duration 
of their pregnancy. While many women will want to stop 
using opioids on finding out that they are pregnant, opioid 
withdrawal during pregnancy should be avoided because 
of the high risk of relapse to heroin use and the danger of 
withdrawal symptoms inducing miscarriage or premature 
labour (WHO, 2009). Prenatal exposure to methadone is, 
however, also associated with neonatal abstinence syndrome 
which requires medication and hospitalisation.
Buprenorphine is an alternative to methadone in maintenance 
treatment, and it has recently been studied in a sample 
of 175 opioid-dependent pregnant women enrolled in an 
international randomised controlled trial (Jones, H., et al., 
2009a) carried out at six locations in the USA, one in Canada 
and one in Vienna. The women, who enrolled at between 
13 and 30 weeks of pregnancy, were randomly assigned to 
receive methadone or buprenorphine, and were followed up 
with their newborn children until six months post-partum. As 
in other studies, buprenorphine was associated with a higher 
dropout rate (33 %) than methadone (18 %), but the children 
in the buprenorphine group appeared to need less morphine 
to treat neonatal abstinence syndrome and fewer days of 
hospitalisation. The study concluded that, when retained in 
treatment, pregnant women can be offered buprenorphine 
or methadone for treating opioid dependence in pregnancy 
(Jones, H., et al., 2009b).
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Introduction
Drug use can produce a wide range of negative 
consequences, such as accidents, mental health 
disorders, pulmonary diseases, cardiovascular problems, 
unemployment or homelessness. Harmful consequences 
are particularly prevalent among problem drug users, 
whose general health and socioeconomic situation can be 
far below those in the general population.
Opioid use and injecting drug use are two forms of drug 
use closely associated with such harm, notably overdoses 
and the transmission of infectious diseases. The number 
of fatal overdoses reported in the European Union in the 
last two decades is equivalent to about one overdose 
death every hour. Research also shows that, in the last two 
decades, a large number of drug users have died from 
other causes, such as AIDS or suicide (Bargagli et al., 
2006; Degenhardt et al., 2009).
Reducing the mortality and morbidity related to drug use 
is central to European drug policies. The main efforts in 
this area are through interventions that are directed at the 
groups that are most at risk, and targeting the types of 
behaviour directly associated with drug-related harm.
Drug-related infectious diseases
The EMCDDA is systematically monitoring infection with 
HIV and hepatitis B and C viruses among injecting drug 
users (107). The infectious diseases caused by these viruses 
are among the most serious health consequences of drug 
use. Other infectious diseases, including hepatitis A and 
D, sexually transmitted diseases, tuberculosis, tetanus, 
botulism, anthrax and human T-lymphotropic virus, may 
also disproportionately affect drug users.
HIV and AIDS
By the end of 2009, the rate of reported new HIV 
diagnoses among injecting drug users has remained 
low in most countries of the European Union, and 
the overall EU situation compares positively, both in 
a global and in a wider European context (ECDC and 
WHO-Europe, 2010; Wiessing et al., 2009) (Figure 15). 
This may, at least partly, follow from the increased 
availability of prevention, treatment and harm-reduction 
measures, including substitution treatment and needle 
and syringe programmes. Other factors, such as the 
decline in injecting drug use that has been reported in 
several countries, may also have played an important 
role (EMCDDA, 2010g). The average rate of newly 
diagnosed cases in the 26 EU Member States able to 
provide data for 2009 reached a new low of 2.85 per 
million population, or 1 299 newly reported cases (108). 
Nonetheless, in some parts of Europe, data suggest that 
HIV transmission related to injecting drug use continued 
in 2009, underlining the need to ensure the coverage 
and effectiveness of local prevention practice.
The available data on prevalence of HIV in samples of 
injecting drug users in the EU compare again positively 
with prevalence in neighbouring countries in the east (109), 
although comparisons between countries should be 
undertaken with caution due to differences in study 
methods and coverage.
Trends in HIV infection
Data on reported newly diagnosed cases related to 
injecting drug use for 2009 suggest that infection rates are 
still generally falling in the European Union following the 
peak in 2001–02, which was due to outbreaks in Estonia, 
Latvia and Lithuania. Of the five countries reporting 
the highest rates of newly diagnosed infections among 
injecting drug users between 2004 and 2009 (Estonia, 
Spain, Latvia, Lithuania, Portugal), three continued their 
downward trend, but the rate in Estonia and Lithuania 
increased again from 2008 levels (Figure 16) (110). In 
Estonia, the increase was from 26.8 cases per million in 
2008 to 63.4 per million in 2009, and in Lithuania from 
12.5 cases per million in 2008 to 34.9 per million in 
2009. Over the same period, the rate of new infections 
(107) For details on methods and definitions, see the 2011 statistical bulletin.
(108) Data for Austria are missing. The average rate is 2.44 cases per million population for the EU Member States, Croatia, Turkey and Norway.
(109) See Table INF-1 in the 2011 statistical bulletin.
(110) Data for Spain do not have national coverage.
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(111) Trend data are not available from Estonia, Ireland and Turkey. See Table INF-108 in the 2011 statistical bulletin.
(112) Data for Italy are for drug users in treatment where injection status is unknown, therefore a decline in HIV prevalence could also be due to a decline 
in injecting drug use among the tested population.
(113) See Table INF-104 in the 2011 statistical bulletin. 
(114) See Table INF-109 in the 2011 statistical bulletin.
among injectors in Bulgaria also increased from 0.9 new 
cases per million population in 2004 to 9.7 per million 
in 2009, whereas in Sweden the rate peaked at 6.7 new 
cases per million (61 new diagnoses) in 2007. These data 
indicate that a continued potential for HIV outbreaks 
among injecting drug users exists in some countries.
Trend data from HIV prevalence monitoring in samples 
of injecting drug users are an important complement to 
data from HIV-case reporting. Prevalence trend data 
are available from 27 European countries within the 
period 2004–09 (111). In 19 countries, HIV prevalence 
estimates remained unchanged. In five countries (France, 
Italy, Austria, Poland, Portugal), HIV prevalence data 
showed a decrease; in three this is based on national 
samples, while in France the trend is based on data 
from five cities. In Austria, the national sample shows 
no change, but a decrease is observed in Vienna. Two 
countries report increasing HIV prevalence: Slovakia 
(national data) and Latvia (self-reported test results from 
seven cities). In Bulgaria, a decrease at national level 
is not reflected in the capital city (Sofia), where the 
trend is upward. In Italy, there is a nationally declining 
trend, with only one out of the 21 regions reporting an 
increase (112).
The comparison of trends in newly reported infections 
related to injecting drug use with trends in HIV prevalence 
among injecting drug users suggests that the incidence of 
HIV infection among injecting drug users is declining in 
most countries at national level.
Despite mostly declining trends since 2004, the rate of 
reported new HIV diagnoses (per million population) in 
2009 related to injecting drug use is still relatively high 
in Estonia (63.4), Lithuania (34.9), Latvia (32.7), Portugal 
(13.4) and Bulgaria (9.7), indicating that considerable 
numbers of new infections continue to occur among 
injecting drug users in these countries (113).
Further indications of ongoing HIV transmission are 
observed in six countries (Estonia, Spain, France, Latvia, 
Lithuania, Poland) with prevalence levels above 5 % 
among samples of young (under age 25) injecting drug 
users in 2005–07 (114), and two countries (Bulgaria, 
Cyprus) where prevalence in young injecting drug users 
increased in 2004–09.
Figure 15: HIV infections newly diagnosed in injecting drug users in 2009 in Europe and central Asia
     > 50
10 < 50
  5 < 10
  0 < 5
Not known
Reported cases 
per million population
NB: Colour indicates the rate per million population of reported newly diagnosed HIV cases attributed to the injecting drug use risk group that were 
diagnosed in 2009.
Sources: ECDC and WHO-Europe, 2010. Russian data are from the Federal Research and Methodological Centre for AIDS Prevention and Control. HIV 
infection. Information bulletin No 34, p.35, Moscow, 2010 (in Russian).
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(115) See Figure INF-1 and Table INF-104 (part ii) in the 2011 statistical bulletin.
(116) See Tables INF-2 and INF-111 in the 2011 statistical bulletin.
(117) See Tables INF-112 and INF-113 and Figure INF-6 (part ii) and (part iii) in the 2011 statistical bulletin.
(118) See Table INF-111 in the 2011 statistical bulletin.
(119) See Tables INF-112 and INF-113 in the 2011 statistical bulletin.
(120) See Table INF-114 in the 2011 statistical bulletin.
AIDS incidence and access to HAART
Information on the incidence of AIDS, though a poor 
indicator of HIV transmission, can be important for 
showing the new occurrence of symptomatic disease. High 
incidence rates of AIDS may indicate that many injecting 
drug users infected with HIV do not receive highly active 
antiretroviral treatment at a sufficiently early stage in their 
infection to obtain maximum benefit from the treatment. 
A recent global review suggests that this may still be the 
case in some European countries (Mathers et al., 2010).
Latvia is now the country with the highest incidence of 
AIDS related to injecting drug use, with an estimated 20.8 
new cases per million population in 2009, down from 
26.4 per million in 2008. Relatively high AIDS incidence 
among injecting drug users is also reported for Estonia, 
Spain, Portugal and Lithuania, with 19.4, 7.3, 6.6 and 6.0 
new cases per million population, respectively. Among 
these countries, the trend 2004–09 was downward in 
Spain and Portugal, but not in Estonia and Lithuania (115).
Hepatitis B and C
Viral hepatitis in particular, an infection caused by the 
hepatitis C virus (HCV), is highly prevalent in injecting 
drug users across Europe. HCV antibody levels among 
national samples of injecting drug users in 2008–09 
varied from 22 % to 83 %, with eight out of the 12 
countries reporting findings in excess of 40 % (116). Three 
countries (Czech Republic, Hungary, Slovenia) report 
prevalences of under 25 %; though infection rates at this 
level still constitute a significant public health problem.
Within countries, HCV prevalence levels can vary 
considerably, reflecting both regional differences and the 
characteristics of the sampled population. For example, 
in Italy, regional estimates range from 37 % to 81 % 
(Figure 17).
Recent studies (2008–09) show a wide range of HCV 
prevalence levels among injecting drug users under 
25 years and those injecting for less than two years, 
suggesting different levels of HCV incidence in those 
populations across Europe (117). Nonetheless, these studies 
also show that many injectors contract the virus early 
in their injecting career. This implies that there may be 
only a small time window for initiating HCV prevention 
measures.
Over the period 2004–09, declining HCV prevalence 
in injecting drug users is reported from eight countries 
and increasing prevalence from one (Cyprus), while 
a further four countries report diverging trends in different 
datasets. Nonetheless, caution is warranted given the 
limited geographical coverage and/or sample size of the 
studies in some instances (118). Studies on young injectors 
(under age 25) again suggest that some countries may 
be experiencing declines in prevalence in this group at 
national (Bulgaria, Slovenia, United Kingdom) or sub-
national level (Crete in Greece, Vorarlberg in Austria), 
which may indicate declining transmission rates. However, 
some increases are reported as well (Cyprus, Graz in 
Austria). Some of these trends are confirmed in data for 
new injectors (injecting less than two years). Increasing 
HCV prevalence among new injectors is reported in 
Greece (Attica), whereas declines are reported from 
Austria (Vorarlberg) and Sweden (Stockholm) (119).
The prevalence of antibodies to hepatitis B virus (HBV) 
also varies to a great extent, possibly partly due to 
differences in vaccination levels, although other factors 
may play a role. The most informative serological marker 
of HBV infection is HBsAg (hepatitis B virus surface 
antigen), which indicates current infection. For 2004–09, 
four of the 14 countries providing data on this virus 
among injecting drug users report studies with HBsAg 
prevalence levels of over 5 % (Bulgaria, Greece, Lithuania, 
Romania) (120).
Figure 16: Trends in newly reported HIV infections in injecting drug 
users in the five EU Member States reporting the highest rates
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NB: Data reported by end of October 2010, see Figure INF-2 in the 
2011 statistical bulletin.
Sources: ECDC and WHO-Europe, 2010.
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(121) See Tables INF-105 and INF-106 in the 2011 statistical bulletin.
(122) See the box ‘Tuberculosis among drug users’. 
Trends in notified cases of hepatitis B and C show different 
pictures, but these are difficult to interpret as data quality 
is low. However, some insight into the epidemiology of 
these infections may be provided by the proportion of 
injecting drug users among all notified cases where risk 
factors are known (Wiessing et al., 2008). Averaged 
across the 20 countries for which data are available for 
the period 2004–09, injecting drug use accounts for 
63 % of all HCV cases and for 38 % of acute HCV cases 
notified where the risk category is known. For hepatitis B, 
injecting drug users represent 20 % of all notified cases 
and 26 % of acute cases. These data confirm that injecting 
drug users continue to form an important at-risk group for 
viral hepatitis infection in Europe (121).
Other infections
In addition to viral infections, injecting drug users are 
vulnerable to bacterial diseases (122). The outbreak 
of anthrax among injecting drug users in Europe (see 
EMCDDA, 2010a) has highlighted an ongoing problem 
with severe illness due to spore-forming bacteria among 
injectors. A European study collated data on reported 
cases of four bacterial infections (botulism, tetanus, 
Clostridium novyi, anthrax) in injecting drug users in the 
past decade. During the period 2000–09, six countries 
reported 367 cases, with population rates varying from 
0.03 to 7.54 per million population. Most cases of 
infection (92 %) were reported from three countries in the 
north-west of Europe: Ireland, the United Kingdom and 
Norway. This geographical variation is not understood 
and needs further investigation (Hope et al., 2011).
Preventing and responding to infectious 
diseases
The prevention of infectious diseases among drug users 
is an important public health goal of the European Union 
and a component of most Member States’ drug policies. 
Countries aim to prevent and control the spread of 
infectious diseases among drug users by a combination 
of approaches, including surveillance, vaccination and 
treatment of infections; drug treatment, particularly opioid 
substitution treatment; and the provision of sterile injection 
equipment. In addition, community-based activities provide 
information, education and behavioural interventions, 
often implemented through outreach or low-threshold 
agencies. These measures, together with antiretroviral 
Figure 17: Prevalence of HCV antibodies among injecting drug users
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(123) See Table HSR-5 in the 2011 statistical bulletin. For 2007–09, data on the number of syringes were not available for Denmark, Germany and Italy. 
Data on the Netherlands cover only Amsterdam and Rotterdam and data on the United Kingdom do not include England.
(124) See Figure HSR-3 in the 2011 statistical bulletin.
(125) These figures do not include pharmacy sales, which may represent an important source of sterile syringes for drug users in several countries.
therapy and tuberculosis diagnosis and treatment, have 
been promoted by UN agencies as the core interventions 
for HIV prevention, treatment and care for injecting drug 
users (WHO, UNODC and UNAIDS, 2009).
Interventions
The effectiveness of opioid substitution treatment in 
reducing HIV transmission and self-reported injecting 
risk behaviour has been confirmed in several studies and 
reviews. There is growing evidence that the combination 
of opioid substitution treatment and needle and syringe 
programmes is more effective in reducing HIV or HCV 
incidence and injecting risk behaviour than either 
approach alone (ECDC and EMCDDA, 2011).
Building on improvements in the treatment of hepatitis 
C, many countries are increasing their efforts to prevent, 
detect and treat hepatitis among drug users. The European 
Union is supporting several initiatives to improve hepatitis 
C prevention among drug users. These initiatives include: 
mapping national standards and guidelines for HCV 
prevention in the EU (Zurhold, 2011); compilation of 
examples of awareness-raising, prevention, treatment 
and care interventions (Correlation Project and EHRN, 
2010); development of training materials for policymakers, 
medical professionals and local service providers (e.g. 
Hunt and Morris, 2011).
Provision of free, clean syringes organised through 
specialised facilities or pharmacies exists in all countries 
except Turkey, but despite considerable expansion in the 
past two decades, information on geographical coverage 
shows imbalances, with several countries in central and 
eastern Europe and Sweden reporting lack of availability 
in some areas (see Figure 18).
Recent data on syringe provision through specialised 
needle and syringe programmes are available for all but 
three countries and are incomplete in another two (123). 
They show that nearly 50 million syringes per year are 
distributed through these programmes. This is equivalent 
to an average of 94 syringes per estimated injecting drug 
user in the countries providing syringe data.
For 13 countries, the average number of syringes 
distributed in a year per injecting drug user can be 
estimated (124). In seven of these countries, the average 
number of syringes given out by specialised programmes 
is equivalent to less than 100 per injector, four 
countries give out between 100 and 200 syringes, and 
Luxembourg and Norway report the distribution of more 
than 200 syringes per injector (125). For the prevention 
of HIV, UN agencies judge the annual distribution 
of 100 syringes per injecting drug user as low, and 
Tuberculosis among drug users
Tuberculosis (TB) is a bacterial disease, usually attacking 
the lungs, which can be fatal. In 2008, a total of 82 605 
cases were identified in 26 EU Member States and Norway, 
with rates higher than 20 per 100 000 in Romania (114.1), 
Lithuania (66.8), Latvia (47.1), Bulgaria (41.2), Estonia (33.1) 
and Portugal (28.7) (ECDC, 2010). In Europe, the disease 
is predominantly concentrated in high-risk groups, such as 
migrants, homeless people, drug users and prisoners. Due to 
marginalisation and lifestyle, drug users can face higher risks 
of contracting TB than the general population. HIV-positive 
status poses an additional risk of developing TB, which 
is estimated to be between 20 and 30 times greater than 
among those who do not have HIV infection (WHO, 2010a).
Data on TB prevalence among drug-using populations are 
scarce. In Europe, high rates of active (symptomatic) TB are 
reported among drug users in treatment in Greece (1.7 %), 
Lithuania (3 %) and Portugal (1 % to 2 %), while systematic 
testing in drug treatment facilities in Austria, Slovakia and 
Norway did not identify any cases.
Tuberculosis in drug users can be effectively treated, 
although this requires a complex curative regimen of at 
least six months. Completion of treatment is essential, as the 
disease organism quickly becomes tolerant to medicines and 
develops resistance to treatment. For problem drug users, 
especially those with chaotic lifestyles, achieving adherence 
to treatment may be difficult. New approaches that aim 
to shorten the duration of treatment have the potential to 
increase the likelihood of successful completion.
Prevention of infections among injecting drug 
users: ECDC–EMCDDA joint guidelines
In 2011, the European Centre for Disease Prevention 
and Control (ECDC) and the EMCDDA issued joint 
guidance on the prevention and control of infectious 
disease among injecting drug users. The guidance 
provides a comprehensive overview of the effectiveness 
of interventions, including measures such as the provision 
of clean syringes and other injecting equipment; 
drug treatment, including opioid substitution therapy; 
vaccination; testing; and the treatment of infections among 
drug users. The guidance examines models of service 
delivery, and the most appropriate information and 
education messages for this population.
This publication is available in print and on the EMCDDA 
website in English only.
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(126) See ‘Drug-related mortality: a complex concept’, in the 2008 annual report.
(127) The European estimate is based on 2009 data for 17 of the 27 Member States and Norway, 2008 data for nine countries and projected data for 
one country. Belgium is excluded as no data are available. For more information, see Table DRD-2 (part i) in the 2011 statistical bulletin. 
(128) See Figure DRD-7 (part i) and Tables DRD-5 (part ii) and DRD-107 (part i) in the 2011 statistical bulletin.
(129) For detailed methodological information, see the 2011 statistical bulletin and drug-related death key indicator pages.
200 syringes per injector as high (WHO, UNODC and 
UNAIDS, 2009).
Over the last four reporting years (2005–09) the total 
number of syringes given out by syringe programmes 
has increased 32 %. A sub-regional analysis of syringe 
provision trends shows a flattening of the increase among 
the pre-2004 EU Member States and a rise in the newer 
Member States.
Drug-related deaths and mortality
Drug use is one of the major causes of health problems 
and mortality among young people in Europe, and can 
account for a considerable proportion of all deaths 
among adults. Studies have found that between 10 % 
and 23 % of mortality among those aged 15–49 could 
be attributed to opioid use (Bargagli et al., 2006; Bloor 
et al., 2008).
Mortality related to drug use comprises the deaths 
caused directly or indirectly by the use of drugs. This 
includes deaths from drug overdoses (drug-induced 
deaths), HIV/AIDS, traffic accidents (in particular when 
combined with alcohol), violence, suicide and chronic 
health problems caused by repeated use of drugs (e.g. 
cardiovascular problems in cocaine users) (126).
Drug-induced deaths
The most recent estimates suggest that there were about 
7 630 drug-induced deaths in 2009 in the EU Member 
States and Norway, indicating a stable situation when 
compared with the 7 730 cases reported in 2008 (127). 
The numbers are likely to be conservative, as national data 
may be affected by under-reporting or under-ascertainment 
of drug-induced deaths. Few countries have assessed the 
magnitude of underestimation in their national data.
During the period 1995–2008, between 6 300 and 
8 400 drug-induced deaths were reported each year by 
EU Member States and Norway. In 2008, the most recent 
year for which data are available for almost all countries, 
more than half of all reported drug-induced deaths were 
accounted for by two countries, Germany and the United 
Kingdom, who together with Spain and Italy registered 
two thirds of all reported cases (5 075).
For 2009, the average EU mortality rate due to overdoses 
is estimated at 21 deaths per million population aged 
15–64 years, with most countries reporting rates of 
between 4 and 59 deaths per million (Figure 19). Rates 
of over 20 deaths per million are found in 13 out of 
28 European countries, and rates of over 40 deaths 
per million in seven countries. Among Europeans aged 
15–39 years, drug overdoses accounted for 4 % of all 
deaths (128).
The number of reported drug-induced deaths can be 
influenced by the prevalence and patterns of drug use 
(injection, polydrug use), the age and the co-morbidities 
of drug users and the availability of treatment and 
emergency services, as well as by the quality of data 
collection and reporting. Improvements in the reliability of 
European data have allowed better descriptions of trends, 
and most countries have now adopted a case definition 
endorsed by the EMCDDA (129). Nevertheless, caution must 
be exercised when comparing countries because there 
are still differences in reporting methodology and data 
sources.
Deaths related to opioids
Heroin
Opioids, mainly heroin or its metabolites, are present in 
the majority of drug-induced deaths reported in Europe. 
Figure 18: Geographical availability of needle and syringe 
programmes at regional level
At least one NSP
available
No NSP available
No information 
MT00
NB: Regions defined according to the nomenclature of territorial 
units for statistics (NUTS) level 2; for further information see the 
Eurostat website.
Source: See Table HSR-4 in the 2011 statistical bulletin.
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(130) As most of the drug-induced deaths reported to the EMCDDA are opioid overdoses (mainly heroin), the general characteristics of the reported deaths 
are presented here to describe and analyse deaths related to heroin use.  
See Figure DRD-1 in the 2011 statistical bulletin.
(131) See Figures DRD-2 and DRD-3 and Table DRD-1 (part i) in the 2011 statistical bulletin.
In the 22 countries providing data for 2008 or 2009, 
opioids accounted for the large majority of all cases: over 
90 % in five countries, and between 80 % and 90 % in 
a further 12. Substances often found in addition to heroin 
include alcohol, benzodiazepines, other opioids and, in 
some countries, cocaine. This suggests that a substantial 
proportion of all drug-induced fatalities occur in a context 
of polydrug use, as illustrated by a review of toxicology 
of drug-related deaths in Scotland in 2000–07. It showed 
that the presence of heroin and alcohol were positively 
associated, particularly among older males. Among men 
whose deaths were related to heroin, alcohol was present 
in 53 % of those aged 35 and more, compared to 36 % in 
cases under 35 years (Bird and Robertson, 2011; see also 
GROS, 2010).
Men account for most overdose deaths reported in 
Europe (81 %). Overall, there are around four males for 
each female case (with the ratio ranging from 1.4:1 in 
Poland to 31:1 in Romania) (130). In the Member States 
that joined the EU more recently, reported drug-induced 
deaths are more likely in males and in younger people 
compared to the pre-2004 Member States and Norway. 
Patterns differ across Europe, with higher proportions 
of males reported in southern countries (Greece, Italy, 
Romania, Cyprus, Hungary, Croatia) and in Estonia, Latvia 
and Lithuania. Denmark, the Netherlands, Sweden and 
Norway report higher proportions of older cases. In the 
majority of countries, the average age of those dying of 
heroin overdoses is in the mid-30s, and in many countries 
it is increasing. This suggests a possible stabilisation or 
decrease in the number of young heroin users, and an 
ageing cohort of problem opioid users. Overall, 12 % of 
overdose deaths reported in Europe occur among those 
aged under 25 years (131).
A number of factors are associated with fatal and non-
fatal heroin overdoses. These include injection and 
simultaneous use of other substances, in particular alcohol, 
benzodiazepines and some antidepressants. Other factors 
linked with overdoses are binge drug use, co-morbidity, 
homelessness, poor mental health (e.g. depression and 
intentional poisoning), not being in drug treatment, 
previous experience of overdose and being alone at the 
Figure 19: Estimated mortality rates among all adults (15–64 years) due to drug-induced deaths
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NB: For more information, see Figure DRD-7 in the 2011 statistical bulletin.
Sources: Reitox national focal points.
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(132) See the box ‘Methadone and mortality’.
(133) For data on deaths related to drugs other than heroin, see Table DRD-108 in the 2011 statistical bulletin.
(134) See Figures DRD-8 and DRD-11 in the 2011 statistical bulletin.
time of overdose (Rome et al., 2008). The time immediately 
after release from prison (WHO, 2010a) or discharge from 
drug treatment is a particularly risky period for overdoses, 
as illustrated by a number of longitudinal studies.
Other opioids
Besides heroin, a range of other opioids are found in 
toxicological reports, including methadone (132) and 
buprenorphine. Deaths due to buprenorphine poisoning are 
infrequent and mentioned by very few countries, despite 
its increasing use in substitution treatment in Europe. In 
Finland, however, buprenorphine remains the most common 
opioid detected in forensic autopsies, but usually in 
combination with other substances. This was illustrated by 
a recent Finnish report investigating drug findings in cases 
of accidental poisoning, which reported the presence of 
benzodiazepines in almost all (38 out of 40) cases where 
buprenorphine was identified as the primary cause of 
death. Alcohol was also a significant contributory factor 
identified in 22 out of 40 cases (Salasuo et al., 2009). In 
Estonia, most drug-induced deaths reported in 2009 were, 
as in previous years, due to 3-methylfentanyl.
Deaths related to other drugs
Deaths caused by acute cocaine poisoning seem to be 
relatively uncommon (EMCDDA, 2010a). But, as cocaine 
overdoses are more difficult to define and identify than 
those related to opioids, they may be under-reported (see 
Chapter 5).
In 2009, about 900 deaths related to cocaine were 
reported in 21 countries. Due to the lack of comparability 
in the available data, it is difficult to describe the 
European trend. The most recent data for Spain and the 
United Kingdom, the two countries with the highest levels 
of cocaine prevalence, indicate a decrease in deaths 
related to the drug: in Spain, from 25.1 % of the reported 
cases with cocaine (and no opiates) in 2007 to 19.3 % in 
2008; and in the United Kingdom, from 12.7 % in 2008 
to 9.6 % in 2009. Cocaine is very rarely identified as the 
only substance contributing to a drug-induced death.
A recent international review on mortality among 
cocaine users concluded that there are limited data on 
the extent of elevated mortality among problematic or 
dependent cocaine users (Degenhardt et al., 2011). The 
review included findings from three European follow-up 
studies: a French study following individuals arrested for 
cocaine offences; a Dutch study with cocaine injectors 
recruited via low-threshold services; and an Italian study 
with dependent cocaine users receiving treatment. Crude 
mortality rates in these studies ranged from 0.54 to 4.6 
per 100 person-years. A recent Danish cohort study, with 
individuals in treatment for cocaine use, showed an excess 
mortality risk of 6.4 compared to same age and sex peers 
in the general population (Arendt et al., 2011).
Deaths in which ecstasy (MDMA) is present are 
infrequently reported and, in many of these cases, the 
drug has not been identified as the direct cause of 
death (133). In 2009, deaths possibly related to cathinones 
were reported in England (mephedrone) and Finland 
(MDPV) (see Chapter 8).
Trends in drug-induced deaths
Drug-induced deaths increased sharply in Europe during 
the 1980s and early 1990s, paralleling the increase in 
heroin use and drug injection, and thereafter remained 
at high levels (134). Between 2000 and 2003, most 
EU Member States reported a decrease, followed by 
Methadone and mortality
With an estimated 700 000 opioid users undergoing 
substitution treatment, drugs such as methadone have 
recently come under the spotlight with regard to drug-
induced deaths. Methadone is often mentioned in the 
toxicology reports for deaths related to drug use, and 
is sometimes identified as the cause of death. In spite 
of this, the current available evidence strongly supports 
the benefits of well-regulated and supervised opioid 
substitution treatment, combined with psychosocial 
assistance interventions, for keeping patients in treatment 
and reducing illicit opioid use and mortality.
Observational studies report the mortality rate for opioid 
users in methadone treatment to be approximately one 
third the rate of those out of treatment. Treatment duration 
is an important factor, with recent studies showing that 
opioid substitution treatment has a greater than 85 % 
chance of reducing overall mortality among opioid 
users, if they remain in treatment for 12 months or more 
(Cornish et al., 2010). Survival benefits increase with 
cumulative exposure to treatment (Kimber et al., 2010). 
Furthermore, methadone appears to reduce the risk 
of HIV infection by approximately 50 % compared to 
withdrawal or no treatment (Mattick et al., 2009). With 
regard to methadone-related deaths in a population, a 
recent study in Scotland and England concluded that the 
introduction of supervised methadone dosing was followed 
by a substantial decline in deaths where methadone was 
involved. Between 1993 and 2008, there was at least a 
four-fold reduction in deaths due to methadone-related 
overdose per amount of methadone prescribed, against a 
background of treatment expansion (Strang et al., 2010).
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a subsequent increase from 2003 until 2008. Preliminary 
data available for 2009 suggest an overall figure equal 
to or slightly below that for 2008. Where a comparison is 
possible, the numbers of deaths reported have decreased 
in some of the largest countries, including Germany, Italy 
and the United Kingdom.
The reasons for the sustained or increasing numbers 
of reported drug-induced deaths in some countries are 
difficult to explain, especially given the indications of 
decreases in injecting drug use and increases in the 
numbers of opioid users in contact with treatment and 
harm-reduction services. Possible explanations include: 
increased levels of polydrug use (EMCDDA, 2009b) or 
high-risk behaviour; increases in the numbers of relapsing 
opioid users leaving prison or treatment; and an ageing 
cohort of more vulnerable drug users.
Overall mortality related to drug use
Overall mortality related to drug use comprises drug-
induced deaths and those caused indirectly through the 
use of drugs, such as through the transmission of infectious 
diseases, cardiovascular problems and accidents. Deaths 
indirectly related to drug use are difficult to quantify, but 
their impact on public health can be considerable. Such 
deaths are mainly concentrated among problem drug 
users, although some (e.g. traffic accidents) occur among 
occasional users.
Estimates of overall drug-related mortality can be derived 
in various ways, for example by combining information 
from mortality cohort studies with estimates of drug use 
prevalence. Another approach is to use existing general 
mortality statistics and estimate the proportion related to 
drug use.
Mortality cohort studies
Mortality cohort studies track the same groups of problem 
drug users over time and, through linkage with mortality 
registries, try to identify the causes of all deaths occurring 
in the group. This type of study can determine overall 
and cause-specific mortality rates for the cohort, and can 
estimate the group’s excess mortality compared to the 
general population (135).
Depending on recruitment settings (e.g. drug treatment 
facilities) and enrolment criteria (e.g. injecting drug users, 
heroin users), most cohort studies show mortality rates in 
the range of 1 % to 2 % per year among problem drug 
users. These mortality rates are roughly 10 to 20 times 
higher than those of the same age group in the general 
population. The relative importance of the different causes 
of death varies across populations, between countries 
and over time. Generally, though, the main cause of death 
among problem drug users in Europe is drug overdose, 
accounting for up to 50 % to 60 % of deaths among 
injectors in countries with low prevalence of HIV/AIDS. 
In addition to HIV/AIDS and other diseases, frequently 
reported causes of deaths include suicide, accidents and 
alcohol abuse.
Deaths indirectly related to drug use
By combining existing data from Eurostat and HIV/AIDS 
surveillance, the EMCDDA has estimated that about 
2 100 people died of HIV/AIDS attributable to drug use 
in the European Union in 2007 (136), with 90 % of these 
deaths occurring in Spain, France, Italy and Portugal.
Other diseases that also account for a proportion of 
deaths among drug users include chronic conditions 
such as liver diseases, mainly due to infection with the 
hepatitis C virus (HCV) and often worsened by heavy 
alcohol use and HIV co-infection. Deaths caused by other 
infectious diseases are rarer. Causes of death among drug 
users such as suicide and trauma as well as homicide 
have received much less attention, despite indications of 
a considerable impact on mortality.
Reducing drug-related deaths
Fifteen European countries report that their national drug 
strategy has a focus on the reduction of drug-related 
deaths, that such policies exist at regional level, or 
that they have a specific action plan for the prevention 
of drug-related deaths. In some of the other countries 
(Estonia, France, Austria), recent increases in drug-
related deaths (partly among younger age groups and 
integrated users) have raised awareness of the need for 
improved responses.
(135) For information on mortality cohort studies, see the ‘Key indicators’ on the EMCDDA website.
(136) See Table DRD-5 (part iii) in the 2011 statistical bulletin.
‘Selected issue’: Mortality related to drug use 
— a comprehensive approach and public health 
implications
An EMCDDA ‘Selected issue’, published this year, 
presents the findings on drug-related mortality from recent 
longitudinal studies among problem drug users in Europe. 
It examines the overall and cause-specific mortality, and 
describes the risk and protective factors identified through 
research. The public health implications are also reviewed.
This publication is available in print and on the EMCDDA 
website in English only.
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Treatment can significantly reduce the mortality risk of 
drug users, although risks related to drug tolerance arise 
when entering or leaving treatment. Studies show that 
the risk of drug-induced death on relapse after treatment 
or in the weeks after release from prison is substantially 
elevated.
Due to its pharmacological safety profile, buprenorphine 
is recommended for opioid maintenance in some 
countries (137), and a buprenorphine/naloxone 
combination has obtained marketing authorisation in at 
least half of the countries (138).
While progress has been made in some European 
countries towards closing the treatment gap between 
community and prison (139), disruption of drug treatment, 
whether due to arrest, imprisonment or discharge, has 
been identified as increasing overdose risk (Dolan et 
al., 2005). This has led to the European regional office 
of the World Health Organisation (2010c) issuing 
recommendations on overdose prevention in prison and 
improved continuity of care after release.
Alongside improving access to drug treatment, other 
interventions to reduce overdose risks in drug users have 
been studied. These interventions address personal, 
situational and drug-use related factors. Overdose 
risk information materials, often produced in several 
languages to reach migrant drug users, are distributed 
in the majority of countries through specialised drugs 
agencies and websites, and more recently also through 
telephone messaging and e-mail. Counselling and safer-
use training for drug users, delivered by drug workers 
or through peer educators, exist in 27 countries but 
provision of these interventions is often sporadic and 
limited (140).
Additional responses reported by small numbers 
of countries include: follow-up of those who have 
suffered a drug-related emergency (Belgium, Denmark, 
Luxembourg, Netherlands, Austria); ‘early-warning 
systems’ to alert users to dangerous substances 
(Belgium, Czech Republic, France, Hungary, Portugal, 
Croatia); and improved controls to prevent multiple drug 
prescriptions (Luxembourg, United Kingdom). Supervised 
drug consumption facilities, such as those available in 
Germany, Spain, Luxembourg, the Netherlands and 
Norway, provide opportunities for immediate intervention 
by professionals in cases of overdose, and reduce the 
health impact of non-fatal overdoses. Evidence for the 
effect of supervised drug consumption rooms on drug-
induced deaths in the community include a recent 
study carried out in Vancouver, which reported a 35 % 
reduction in overdose fatalities in the affected community 
after a supervised injecting facility was opened (Marshall, 
B., et al., 2011). This result points in the same direction 
as earlier studies reviewed in a monograph on harm 
reduction (EMCDDA, 2010b).
Overdose training combined with a take-home dose of 
naloxone — which reverses the effects of opioids, and 
is widely used in hospitals and emergency medicine — 
is an intervention that can prevent deaths from opioid 
overdose. Some European countries report the existence 
of community-based programmes that prescribe naloxone 
to drug users at risk of opioid overdose. Naloxone 
prescribing is accompanied by compulsory training 
in recognising overdoses, providing basic life-support 
techniques (e.g. rescue breathing, recovery position) and 
how to administer naloxone. This intervention targets drug 
users, their families and peers, and aims to help them to 
take effective action in overdose situations, while awaiting 
the arrival of emergency services.
The distribution of naloxone to drug users is reported 
by Italy (where 40 % of drugs agencies provide the 
substance), Germany and the United Kingdom (England 
and Wales). New initiatives are reported by Bulgaria, 
Denmark and Portugal. In Scotland, provision of ‘take-
home naloxone’ to all at-risk individuals leaving prison 
was introduced nationally in 2010, and the government 
is supporting a national take-home naloxone programme 
for those deemed to be at risk of opioid overdose 
and those who may come into contact with them. 
The effectiveness of naloxone-on-release in reducing 
overdose deaths in the weeks after release from prison is 
being evaluated in England by the N-Alive project study, 
which will perform a randomised controlled trial among 
5 600 prisoners.
 
(137) See treatment guidelines on the ‘Best practice’ portal.
(138) See Table HSR-1 in the 2011 statistical bulletin.
(139) See Chapter 2 and Table HSR-9 in the 2011 statistical bulletin.
(140) See Table HSR-8 in the 2011 statistical bulletin.
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Introduction
The provision of timely and objective information on new 
drugs and emerging trends is of growing importance, 
given the increasingly dynamic and fast-moving nature 
of the European drugs problem. The new drugs market 
is distinguished by the speed at which suppliers respond 
to the imposition of control measures by offering new 
alternatives to restricted products. A range of information 
sources and leading-edge indicators, including Internet 
monitoring and wastewater analysis, can assist in providing 
a better picture of emerging drug trends in Europe. This 
chapter details the new psychoactive substances detected 
through the early-warning system, and follows up on the risk 
assessment of mephedrone. The ‘legal highs’ phenomenon 
is examined, along with a number of national responses to 
the open sale of new substances.
Action on new drugs
The European Union’s early-warning system has been 
developed as a rapid-response mechanism to the 
emergence of new psychoactive substances on the 
drug scene. The system is currently under review in the 
framework of the European Commission’s assessment of 
the functioning of Council Decision 2005/387/JHA (141).
New psychoactive substances
Between 1997 and 2010, more than 150 new 
psychoactive substances were formally notified through 
the early-warning system, and are now being monitored. 
Over this period, the rate at which new substances 
appear on the market has increased, with record numbers 
of new substances being reported in the last two years 
— 24 in 2009 and 41 in 2010 (142). Many of these new 
substances have been detected through testing products 
sold on the Internet and in specialist shops (e.g. smart 
shops, head shops).
Most of the 41 new psychoactive substances 
identified in 2010 are synthetic cathinones or 
synthetic cannabinoids. With 15 new derivatives 
detected in 2010, synthetic cathinones are now, after 
the phenethylamines, the second-largest drug family 
monitored by the early-warning system. The list of newly 
notified substances also contains a diverse group of 
chemicals, including a synthetic cocaine derivative, 
a natural precursor and various synthetic psychoactive 
substances. Derivatives of phencyclidine (PCP) and 
ketamine, two established drugs used now or in the past 
in human or veterinary medicine, were reported for the 
first time in 2010.
The emergence of new drugs based on medicines with 
known abuse potential is an example of how innovation 
in the illicit market requires a joined-up response from 
medicines and drug control regulators. This issue is more 
of a potential threat than an immediate problem, but given 
the speed at which new developments occur in this area, 
anticipating future challenges may be important.
Risk assessment
In 2010, mephedrone (4-methylmethcathinone) became 
the first cathinone derivative to be formally risk assessed. 
It was also the first substance to be risk assessed under 
new operating guidelines (143). The risk assessment faced 
challenges related to limited availability of data, and 
also mephedrone’s dissimilarity to previously assessed 
compounds. However, for the first time, toxicological 
screening data from an exploratory study with a group 
of mephedrone users was incorporated, allowing the 
findings to be better grounded in evidence than in earlier 
risk assessments.
Based on the findings of the risk assessment report 
(EMCDDA, 2010e), in December 2010 the European 
Council decided to submit mephedrone to control 
measures and criminal penalties throughout Europe (144). 
(141) Council Decision 2005/387/JHA of 10 May 2005 on the information exchange, risk assessment and control of new psychoactive substances 
(OJ L 127, 20.5.2005, p. 32).
(142) See the box ‘Main groups of new psychoactive substances monitored by the early-warning system’. 
(143) See the box ‘Risk assessment guidelines’.
(144) Council Decision 2010/759/EU of 2 December 2010 on submitting 4-methylmethcathinone (mephedrone) to control measures (OJ L 322, 8.12.2010, 
p. 44).
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(145) Belgium, Denmark, Germany, Estonia, Ireland, France, Italy, Latvia, Lithuania, Luxembourg, Malta, Austria, Poland, Romania, Sweden, United 
Kingdom, Croatia, Norway. 
By that time, 18 European countries had already 
introduced control measures on mephedrone (145). The 
remaining EU Member States have one year to take the 
necessary measures.
Follow-up on mephedrone
A small number of sources allow some ongoing monitoring 
of mephedrone use and availability in Europe, primarily 
Internet surveys with clubbers and studies of online 
sales. Internet surveys among readers of a UK clubbers’ 
magazine placed lifetime use of mephedrone at around 
40 % in 2010 (2 295 respondents, Dick and Torrance, 
2010), and 61 % in 2011 (2 560 respondents, Winstock, 
2011), though last month use fell from 33 % to 25 % over 
the same period. These surveys cannot be considered as 
representative of the wider population of club-goers.
The online availability of mephedrone has been assessed 
through six EMCDDA Internet studies (snapshots) between 
December 2009 and February 2011. In the first half of 
2010, mephedrone was widely and legally available from 
suppliers on the Internet, where it was sold both in retail 
and bulk quantities. EMCDDA snapshots of online drug 
shops carried out in English showed a peak in mephedrone 
online availability in March 2010, with 77 retailers 
offering it for sale. Since then, the total number of online 
shops selling mephedrone has been falling as, from April 
2010, European countries started to place control measures 
on the substance. Despite mephedrone being controlled in 
the majority of Member States by early 2011, an EMCDDA 
multilingual snapshot showed that the drug continued to 
be available online at this time, with 23 sites identified 
to be offering mephedrone to buyers in the European 
Union. Of the original 77 online shops identified in March 
2010, only 15 were still in operation a year later and 
Main groups of new psychoactive substances 
monitored by the early-warning system
New psychoactive substances appearing on the drugs market 
in Europe have historically belonged to a small number of 
chemical families, with the phenethylamines and tryptamines 
accounting for the majority of reports to the early-warning 
system. In the past five years, however, increasing numbers of 
new substances from an expanding range of chemical families 
have been reported (see Figure).
Phenethylamines encompass a wide range of substances that 
may exhibit stimulant, entactogenic or hallucinogenic effects. 
Examples include the synthetic substances amphetamine, 
methamphetamine and MDMA (3,4-methylenedioxy-
methamphetamine) and mescaline, which occurs naturally.
Tryptamines include a number of substances that 
have predominantly hallucinogenic effects. The main 
representatives are the naturally occurring compounds 
dimethyltryptamine (DMT), psilocin and psilocybin (found 
in hallucinogenic mushrooms) as well as the semi-synthetic 
lysergic acid diethylamide (LSD).
Piperazines are represented by mCPP (1-(3-chlorophenyl)
piperazine) and BZP (1-benzylpiperazine), both of which are 
central nervous system stimulants.
Cathinones have stimulant effects. The main cathinone 
derivatives are the semi-synthetic methcathinone and the 
synthetic compounds mephedrone, methylone and MDPV 
(3,4-methylenedioxypyrovalerone).
Synthetic cannabinoids are functionally similar to delta-
9-tetrahydrocannabinol (THC), the active principle of 
cannabis. Like THC, they can have hallucinogenic, sedative 
and depressant effects. They have been detected in herbal 
smoking mixtures such as ‘Spice’ (see EMCDDA, 2009d).
Other substances reported to the early-warning system include 
various plant-derived and synthetic psychoactive substances 
(e.g. indanes, benzodifuranyls, narcotic analgesics, synthetic 
cocaine derivatives, ketamine and phencyclidine derivatives), 
which do not strictly belong to any of the previous families. 
Also included here are a small number of medicinal products 
and derivatives.
For more information on selected new psychoactive 
substances, see the EMCDDA ‘Drug profiles’.
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(146) Such products included MDAI (5,6-methylenedioxy-2-aminoindane), 5-IAI (5-iodo-2-aminoindane), MDAT (6,7-methylenedioxy-2-aminotetralin), 5-APB 
(5-(2-aminopropyl)benzofuran, sold as ‘Benzo fury’), 6-APB (6-(2-aminopropyl)benzofuran), naphyrone (naphthylpyrovalerone, sold as NRG-1), 4-MEC 
(4-methylethcathinone, sold as NRG-2) and methoxetamine (2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone). 
(147) 3,4-Methylenedioxypyrovalerone, a derivative of pyrovalerone, which is controlled under Schedule IV of the 1971 UN Convention.
(148) PMA (para-methoxyamphetamine) has been listed in Schedule I of the 1971 UN Convention since 1986 and PMMA (para-methoxymethylamphetamine) 
has been controlled at EU level since 2002; see EMCDDA (2003). 
(149) See the box ‘Not so ‘legal highs’’.
only two of these still sold mephedrone. The 13 remaining 
shops continued to sell other products, often presented as 
‘research chemicals’ and marketed as ‘legal alternatives 
to mephedrone’ (146). The 2011 EMCDDA snapshot also 
identified a major decrease since 2010 in the number 
of online shops offering mephedrone that appear to be 
based in the United Kingdom. In 2011, the country with the 
highest number of online shops selling mephedrone was 
the United States (six), followed by the Czech Republic and 
the United Kingdom (three each). Over the same period, 
the price of mephedrone increased, from between EUR 10 
and EUR 12 per gram in 2010, to between EUR 20 and 
EUR 25 per gram in 2011.
Intoxications and deaths related to mephedrone continue to 
be closely monitored by the early-warning system. Non-fatal 
adverse health effects of mephedrone consumption have 
been reported in Ireland and the United Kingdom. In 2010, 
reports were received of 65 suspected mephedrone-related 
deaths in England, of which tests showed the drug to be 
present in 46 cases. However, identification of a substance 
in a toxicology sample does not necessarily mean that it 
caused or contributed to death, and reports of fatalities 
linked to mephedrone need to be interpreted with caution.
Follow-up on other substances
There is no routine monitoring in Europe of substances 
that have been risk-assessed, including those subsequently 
controlled. The available information on such substances 
comes mainly from drug seizures and from reports of 
adverse health effects of controlled substances reported 
to the early-warning system. A number of Member 
States report that the piperazines BZP and mCPP were 
still available in 2009 and 2010. mCPP was often 
found in tablets sold as ecstasy, identified by pill-testing 
programmes, for example in the Netherlands. Also in 2010, 
Finland reported the presence of MDPV (147) in 13 post-
mortem toxicology samples, while the reappearance of 
two phenethylamines, PMA and PMMA (148), was reported 
by three countries. In the Netherlands, powders sold as 
amphetamine were found to contain up to 10 % PMA, and 
tablets sold as ecstasy had a high content of PMMA; in 
Norway, a considerable amount of PMMA was seized; 
and, in Austria, a mixture sold as amphetamine contained 
50 % PMMA. All countries reported health incidents and 
fatalities related to PMA and PMMA, two substances that 
are known to have considerable toxicity and that have 
been responsible for fatal overdoses in the past.
‘Legal highs’
Since the 1980s, new psychoactive substances have been 
referred to as ‘designer drugs’, though in recent years 
the term ‘legal highs’ has become popular. ‘Legal highs’ 
refers to a broad category of unregulated psychoactive 
compounds or products containing them that are marketed 
as legal alternatives to well-known controlled drugs, 
usually sold via the Internet or in smart shops or head 
shops. This term is applied to a wide range of synthetic 
and plant-derived substances and products, including 
‘herbal highs’, ‘party pills’ and ‘research chemicals’, many 
of which may be specifically designed to circumvent 
existing drug controls. The term itself, though in common 
usage, remains problematic (149).
Risk assessment guidelines
The current operating guidelines for the risk assessment of new 
psychoactive substances, adopted in 2008, were implemented 
for the first time in 2010 with mephedrone (EMCDDA, 2010c). 
The guidelines provide a conceptual framework for conducting 
a scientifically sound, evidence-based assessment in a timely 
fashion and where information sources are limited. The 
main areas under consideration are health and social risks, 
manufacture and trafficking, involvement of organised crime 
and the possible consequences of control measures.
The guidelines consider all factors that, according to the 
1961 and 1971 UN Conventions, would warrant placing 
a substance under international control. They also introduce 
a novel semi-quantitative scoring system based on expert 
judgment. The guidelines take into account a dual definition 
of risk, namely the probability that some harm may occur 
(usually defined as ‘risk’), and the degree of seriousness 
of such harm (usually defined as ‘hazard’). In addition, 
there is a review of the prevalence of use, the potential 
benefits and the risks of the substance independent of its 
legal status in the Member States and comparison with 
better known drugs.
In 2010, the World Health Organisation also adopted 
a revision of their guidelines for the review of psychoactive 
substances for international control (WHO, 2010b).
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(150) Bulgarian, Czech, Danish, German, Greek, English, Spanish, French, Italian, Latvian, Hungarian, Maltese, Dutch, Polish, Portuguese, Romanian, 
Slovak and Swedish.
Prevalence and Internet availability
In Europe, there are few studies on the prevalence of 
‘legal highs’, as a collective term or referring to individual 
substances. A 2008 Polish study among 1 400 18-year-
old students found that 3.5 % had used ‘legal highs’ at 
least once in their life, while a follow-up study on 1 260 
students in 2010 reported an increase to 11.4 %. The use 
of ‘legal highs’ during the last 12 months was reported 
by 2.6 % of students in 2008, and increased to 7.2 % in 
2010. Last month use, however, dropped from 1.5 % in 
2008 to 1.1 % in 2010. Further studies on the prevalence 
of ‘legal highs’ are expected from the Czech Republic, 
Ireland and Spain in 2011.
The EMCDDA monitors the online availability of ‘legal 
highs’ through regular targeted Internet snapshots, 
the most recent one using 18 of the 23 official EU 
languages (150), spoken as mother tongue by 97 % of 
the EU population, as well as Russian and Ukranian. 
In addition to searching for the term ‘legal highs’, the 
substances covered in these studies include ‘herbal 
highs’ (‘Spice’, kratom and salvia), GBL (gamma-
butyrolactone) and hallucinogenic mushrooms. 
The 2011 Internet snapshot identified 314 online shops 
selling ‘legal highs’ that would dispatch products 
to at least one EU Member State. Establishing the 
country of origin of online shops is difficult, but based 
on attributes such as contact information, country code 
domain, currency and shipping information, the United 
Kingdom appeared to be the most common (Figure 20). 
English was the most common interface language, 
accounting for 83 % of the online shops surveyed in 
2011. Kratom and salvia were the two most frequently 
offered ‘legal highs’, available in 92 and 72 online 
shops, respectively.
The availability of ‘Spice’-like products on the Internet 
continued to fall in 2011, with 12 of the surveyed online 
retailers offering the substances, down from 21 shops in 
2010 and 55 in 2009. In 2011, the price of a 3-gram 
packet of ‘Spice’-like product was between EUR 12 
and EUR 18, compared to around EUR 20 to EUR 30 in 
2009. This parallel drop in availability and price may 
suggest competition from other new drugs.
Figure 20: Apparent country of origin of online shops offering 
‘legal highs’ detected in the 2010 and 2011 Internet snapshots
0
10
20
30
40
50
60
70
80
U
ni
te
d 
Ki
ng
do
m
U
ni
te
d 
St
at
es
N
et
he
rla
nd
s
G
er
m
an
y
C
ze
ch
 R
ep
ub
lic
H
un
ga
ry
N
ew
 Z
ea
la
nd
Po
la
nd
A
us
tri
a
Sp
ai
n
Sl
ov
ak
ia
N
um
be
r 
of
 o
nl
in
e 
sh
op
s
2010 2011
NB: Only Member States with at least two online shops in both 2010 
and 2011 have been included in the figure. In 2011, a search 
conducted in Romanian for the first time identified 13 online 
shops based in Romania.
Not so ‘legal highs’
The term ‘legal highs’ is used as an umbrella term for 
psychoactive substances not controlled by drug laws. 
Describing these substances as ‘legal’ can be incorrect or 
misleading to customers, as many of them may be covered 
by medicines or food safety law.
Under the European product safety directive, producers 
are obliged to put only safe products on the market. Under 
reasonably foreseeable conditions of use, a product should 
not ‘present any risk or only the minimum risks compatible 
with the product’s use, considered to be acceptable and 
consistent with a high level of protection for the safety and 
health of persons’, taking into account its characteristics, 
the labelling, any warnings and instructions for its use. 
Perhaps in response to this, online shops are increasingly 
displaying health warnings about their products. Under 
the directive, distributors must also inform the competent 
authorities of serious risks, and the distributors’ actions 
for their prevention. Offences can be punishable by 
imprisonment.
In Europe, selling a new drug is no more ‘legal’ than 
selling any other untested, mislabelled product. Examples 
of measures against the sale of ‘legal highs’ based on 
consumer protection regulations include the confiscation 
of ‘Spice’ and mephedrone from suppliers in Italy and the 
United Kingdom on the basis of inappropriate labelling. 
Also, in 2010 in Poland, 1 200 ‘head shops’ were closed 
down by the health inspectorate.
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Controlling and policing the open sale 
of new drugs
The rapid spread of new substances is pushing Member 
States to rethink and revise some of their standard 
responses to the drug problem. In 2010, both Ireland and 
Poland rapidly passed legislation to limit the open sale of 
psychoactive substances not controlled under drug laws. 
This required both countries to work on a careful legal 
definition of such substances. The Irish law defines them 
as psychoactive substances, not specifically controlled 
under existing legislation, that have the capacity to 
stimulate or depress the central nervous system, resulting 
in hallucinations, dependence or significant changes to 
motor function, thinking or behaviour. Medicinal and 
food products, animal remedies, intoxicating liquor and 
tobacco are excluded. The Polish law refers to ‘substitute 
drugs’, defined as a substance or plant used instead of, or 
for the same purposes as, a controlled drug, and whose 
manufacture or placing on the market is not regulated 
by separate provisions. It makes no specific reference to 
whether the drug should be considered as harmful.
The Irish law is enforced by the police. High-level police 
officers can serve a ‘prohibition notice’ on a seller; if 
the offender does not comply with this, the courts can 
issue a ‘prohibition order’. Selling, advertising and non-
compliance with a ‘prohibition order’ are punishable 
by up to five years in prison. By contrast, in Poland, the 
law is enforced by the state sanitary inspectorate. The 
penalty for manufacturing substitute drugs or introducing 
them into circulation is a severe fine, while the penalty 
for advertising them is up to one year in prison. The state 
sanitary inspectors may prohibit trade of a ‘substitute drug’ 
for up to 18 months in order to assess its safety, if there 
is a justified suspicion that it might pose a threat to life or 
health. If the drug is found to be harmful, the distributor is 
obliged to meet the costs of the assessment. The inspectors 
also have the right to close premises for up to three 
months. In both countries, no offence or punishment is set 
out for the users of these substances.
Policing newly controlled psychoactive 
substances
Detailed guidance on policing newly controlled 
psychoactive substances, in particular, synthetic 
cannabinoids, piperazines and cathinones as well as GBL 
and 1,4-butanediol, was issued to police forces in the United 
Kingdom in 2010 (ACPO, 2010). The guidance provides 
information on the appearance, use patterns, effects and 
risks of the drugs and their manual handling. The guidance 
recommends a consistent national approach to policing the 
possession and distribution of such substances. The need 
for forensic analysis for the correct identification and the 
required standard of evidence is recognised. Emphasis is 
placed on the importance of a joint approach between the 
police and local authorities in policing head shops. Police 
visits to head shops are encouraged, in order to gather 
information and to provide information to the proprietors 
and to give them the opportunity to hand over controlled 
substances. For this purpose, a standardised letter is 
suggested, urging the shop owner to review the measures 
in place and to ensure that they comply with the law.
Wastewater analysis
Wastewater analysis or sewage epidemiology is a rapidly 
developing scientific discipline with the potential for 
monitoring population level trends in illicit drug consumption.
Advances in analytical chemistry have made it possible 
to identify urinary excretion of illicit drugs and their main 
metabolites in wastewater at very low concentrations. This 
is comparable to taking a much diluted urine sample from 
an entire community (rather than from an individual user). 
With certain assumptions, it is possible to back-calculate 
from the amount of the metabolite in the wastewater to an 
estimate of the amount of a drug consumed in a community.
While early research focused on identifying cocaine 
and its metabolites in wastewater, recent studies have 
produced estimates on levels of cannabis, amphetamine, 
methamphetamine, heroin and methadone. The identification 
of less commonly used drugs, such as ketamine and 
new psychoactive substances, looks promising.
This area of work is developing in a multidisciplinary 
fashion, with important contributions from a number 
of disciplines, including analytical chemistry, 
physiology, biochemistry, sewage engineering and 
conventional drug epidemiology. A 2011 EMCDDA 
expert meeting on wastewater analysis identified at 
least 18 research groups operating in 13 European 
countries working in this area. At the top of the current 
research agenda is the development of a consensus 
on sampling methods and tools, as well as the 
establishment of a code of good practice for the field.
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(151) Hyperlinks to online sources can be found in the PDF version of the annual report, available on the EMCDDA website (http://www.emcdda.europa.eu/
publications/annual-report/2011).
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